


Case 23919

NOVEL 2-AMINOXAZOLINES AS TAAR1 LIGANDS

The invention relates to the use of compounds of formula



wherein

- R^1 is hydrogen, deuterium, tritium, lower alkyl, lower alkoxy, lower alkyl substituted
 5 by halogen, lower alkoxy substituted by halogen, halogen, phenyl optionally substituted by halogen, or is phenoxy, benzyl, benzyloxy, -COO-lower alkyl, -O-(CH₂)_o-O-lower alkyl, NH-cycloalkyl, cycloalkyl or tetrahydropyran-4-yloxy, wherein the substituents for $n > 1$ may be the same or different;
- X is a bond, -CHR-, -CHRCHR'-, -OCH₂-, -CH₂OCHR-, -CH₂CH₂CH₂-, -SCH₂-,
 10 -S(O)₂CH₂-, -CH₂SCH₂-, -CH₂N(R)CH₂-, -cycloalkyl-CH₂- or SiRR'-CH₂-;
- R/R' may be independently from each other hydrogen, lower alkyl or lower alkyl substituted by halogen;
- R^2 is hydrogen, phenyl or lower alkyl;
- Y is phenyl, naphthyl, thiophenyl, pyridinyl, cycloalkyl, 1,2,3,4-tetrahydro-
 15 naphthalen-2-yl, 2,3-dihydrobenzo[1,4]dioxin-6-yl or benzo[1,3]dioxol-5-yl;
- n is 0, 1, 2 or 3;
- o is 2 or 3;

or to a pharmaceutically suitable acid addition salt for the manufacture of medicaments for the treatment of diseases related to the biological function of the trace
 20 amine associated receptors, which diseases are depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative

disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

The invention includes all racemic mixtures, all their corresponding enantiomers and/or optical isomers.

In addition, all tautomeric forms of compounds of formula I are also encompassed by the present invention.

10

2-Aminooxazolines are described in the literature as hypertensive agents with good affinity to the adrenergic receptor or as intermediates in processes for preparation of pharmaceutical active agents, for example in EP 0 167 459, US 4,311,840, DE 2,253, 555, Tetrahedron (2001), 57(1), 195 – 200 or in Bioorganic and Medicinal Chemistry Letters (2004), 14(2), 313-316.

15

It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

20

Some of the physiological effects (i.e. cardiovascular effects, hypotension, induction of sedation) which have been reported for compounds which may bind to adrenergic receptors (WO02/076950, WO97/12874 or EP 0717 037) may be considered to be undesirable side effects in the case of medicaments aimed at treating diseases of the central nervous system as described above. Therefore it is desirable to obtain medicaments having selectivity for the TAAR1 receptor vs adrenergic receptors. Objects of the present invention show selectivity for TAAR1 receptor over adrenergic receptors,

30

in particular good selectivity vs the human and rat $\alpha 1$ and $\alpha 2$ adrenergic receptors.

The classical biogenic amines (serotonin, norepinephrine, epinephrine, dopamine, histamine) play important roles as neurotransmitters in the central and peripheral nervous system [1]. Their synthesis and storage, as well as their degradation and reuptake after release are tightly regulated. An imbalance in the levels of biogenic amines is known to be responsible for the altered brain function under many pathological conditions [2-5]. A second class of endogenous amine compounds, the so-called trace amines (TAs) significantly overlap with the classical biogenic amines regarding structure, metabolism and subcellular localization. The TAs include p-tyramine, β -phenylethylamine, tryptamine and octopamine, and they are present in the mammalian nervous system at generally lower levels than classical biogenic amines [6].

Their dysregulation has been linked to various psychiatric diseases like schizophrenia and depression [7] and for other conditions like attention deficit hyperactivity disorder, migraine headache, Parkinson's disease, substance abuse and eating disorders [8,9].

For a long time, TA-specific receptors had only been hypothesized based on anatomically discrete high-affinity TA binding sites in the CNS of humans and other mammals [10,11]. Accordingly, the pharmacological effects of TAs were believed to be mediated through the well known machinery of classical biogenic amines, by either triggering their release, inhibiting their reuptake or by "crossreacting" with their receptor systems [9,12,13]. This view changed significantly with the recent identification of several members of a novel family of GPCRs, the trace amine associated receptors (TAARs) [7,14]. There are 9 TAAR genes in human (including 3 pseudogenes) and 16 genes in mouse (including 1 pseudogene). The TAAR genes do not contain introns (with one exception, TAAR2 contains 1 intron) and are located next to each other on the same chromosomal segment. The phylogenetic relationship of the receptor genes, in agreement with an in-depth GPCR pharmacophore similarity comparison and pharmacological data suggest that these receptors form three distinct subfamilies [7,14]. TAAR1 is in the first subclass of four genes (TAAR1-4) highly conserved between human and rodents. TAs activate TAAR1 via $G\alpha_s$. Dysregulation of TAs was shown to contribute to the aetiology of various diseases like depression, psychosis, attention deficit hyperactivity disorder, substance abuse, Parkinson's disease, migraine headache, eating disorders,

metabolic disorders and therefore TAAR1 ligands have a high potential for the treatment of these diseases.

Therefore, there is a broad interest to increase the knowledge about trace amine associated receptors.

5 References used:


- 1 Deutch, A.Y. and Roth, R.H. (1999) Neurotransmitters. In *Fundamental Neuroscience* (2nd edn) (Zigmond, M.J., Bloom, F.E., Landis, S.C., Roberts, J.L. and Squire, L.R., eds.), pp. 193-234, Academic Press;
- 2 Wong, M.L. and Licinio, J. (2001) Research and treatment approaches to
10 depression. *Nat. Rev. Neurosci.* 2, 343-351;
- 3 Carlsson, A. *et al.* (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. *Annu. Rev. Pharmacol. Toxicol.* 41, 237-260;
- 4 Tuite, P. and Riss, J. (2003) Recent developments in the pharmacological treatment of Parkinson's disease. *Expert Opin. Investig. Drugs* 12, 1335-1352,
- 15 5 Castellanos, F.X. and Tannock, R. (2002) Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. *Nat. Rev. Neurosci.* 3, 617-628;
- 6 Usdin, Earl; Sandler, Merton; Editors. *Psychopharmacology Series, Vol. 1: Trace Amines and the Brain*. [Proceedings of a Study Group at the 14th Annual Meeting of
20 the American College of Neuropsychopharmacology, San Juan, Puerto Rico] (1976);
- 7 Lindemann, L. and Hoener, M. (2005) A renaissance in trace amines inspired by a novel GPCR family. *Trends in Pharmacol. Sci.* 26, 274-281;
- 8 Branchek, T.A. and Blackburn, T.P. (2003) Trace amine receptors as targets for novel therapeutics: legend, myth and fact. *Curr. Opin. Pharmacol.* 3, 90-97;
- 25 9 Premont, R.T. *et al.* (2001) Following the trace of elusive amines. *Proc. Natl. Acad. Sci. U. S. A.* 98, 9474-9475;
- 10 Mousseau, D.D. and Butterworth, R.F. (1995) A high-affinity [3H] tryptamine binding site in human brain. *Prog. Brain Res.* 106, 285-291;
- 11 McCormack, J.K. *et al.* (1986) Autoradiographic localization of tryptamine binding
30 sites in the rat and dog central nervous system. *J. Neurosci.* 6, 94-101;
- 12 Dyck, L.E. (1989) Release of some endogenous trace amines from rat striatal slices in the presence and absence of a monoamine oxidase inhibitor. *Life Sci.* 44, 1149-1156;

- 13 Parker, E.M. and Cubeddu, L.X. (1988) Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding. *J. Pharmacol. Exp. Ther.* 245, 199-210;
- 14 Lindemann, L. *et al.* (2005) Trace amine associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. *Genomics* 85, 372-385.

Objects of the embodiments disclosed herein are the use of compounds of formula I and their pharmaceutically acceptable salts for the manufacture of medicaments for the treatment of diseases related to the biological function of the trace amine associated receptors, new specific compounds falling into the scope of formula I, their manufacture and medicaments based on a compound in accordance with the invention in the control or prevention of illnesses such as depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

The preferred indications using the compounds of the present disclosure are depression, psychosis, Parkinson's disease, anxiety and attention deficit hyperactivity disorder (ADHD).

In a first aspect, there is provided the use of a compound of formula



wherein

R^1 is hydrogen, deuterium, tritium, C_{1-7} -alkyl, C_{1-7} -alkoxy, C_{1-7} -alkyl substituted by halogen, C_{1-7} -alkoxy substituted by halogen, halogen, phenyl optionally substituted by halogen, or is phenyloxy, benzyl, benzyloxy, $-COO-C_{1-7}$ -alkyl, $-O-(CH_2)_o-O-C_{1-7}$ -alkyl, $NH-C_{3-6}$ -cycloalkyl,

C₃₋₆-cycloalkyl or tetrahydropyran-4-yloxy, wherein the substituents for n > 1 may be the same or different;

X is a bond, -CHR-, -CHRCHR'-, -OCH₂-, -CH₂OCHR-, -CH₂CH₂CH₂-, -SCH₂-, -S(O)₂CH₂-, -CH₂SCH₂-, -CH₂N(R)CH₂-, -C₃₋₆-cycloalkyl-CH₂- or SiRR'-CH₂-;

R/R' may be independently from each other hydrogen, C₁₋₇-alkyl or C₁₋₇-alkyl substituted by halogen;

R² is hydrogen, phenyl or C₁₋₇-alkyl;


Y is phenyl, naphthyl, thiophenyl, pyridinyl, C₃₋₆-cycloalkyl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydrobenzo[1,4]dioxin-6-yl or benzo[1,3]dioxol-5-yl;

n is 0, 1, 2 or 3;

o is 2 or 3;

or of a pharmaceutically suitable acid addition salt for the manufacture of medicaments for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases are anxiety disorders, bipolar disorder, psychotic disorders, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, and metabolic disorders, diabetes, diabetic complications, dyslipidemia, disorders of energy consumption and assimilation, and disorders and malfunction of body temperature homeostasis.

In a second aspect, there is provided a compound of formula I-A according to formula I as defined above,



wherein


R¹ is halogen, for n > 1 the halogen atom may be the same or different;

R² is hydrogen, phenyl or C₁₋₇-alkyl;

n is 1, 2 or 3;

or a pharmaceutically suitable acid addition salt, with the exception of 4-(4-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine.

In a third aspect, there is provided a compound of formula I-B according to formula I as defined above,




R^1 is CH_3 , CF_3 , OCH_3 , OCF_3 or OCH_2 -phenyl;

R^2 is hydrogen, phenyl or C_{1-7} -alkyl;

n is 1, 2 or 3;

or a pharmaceutically suitable acid addition salt, with the exception of
 4-(4-trifluoromethyl-phenyl)4,5-dihydro-oxazol-2-ylamine,
 4-(4-methoxy-phenyl)4,5-dihydro-oxazol-2-ylamine and
 4-(3,4-dimethoxy-phenyl)4,5-dihydro-oxazol-2-ylamine.

In a fourth aspect, there is provided a compound of formula I-C according to formula I as defined above,




wherein

R^2 is hydrogen, phenyl or C_{1-7} -alkyl;

or a pharmaceutically suitable acid addition salt.

In a fifth aspect, there is provided a compound of formula I-D according to formula I as defined above,



wherein


R^1 is halogen and CF_3 , or halogen and CH_3 , or halogen and C_{3-6} -cycloalkyl, or is halogen and OCH_3 ;

R^2 is hydrogen, phenyl or C_{1-7} -alkyl;

n is 2;

or a pharmaceutically suitable acid addition salt.

In a sixth aspect, there is provided a compound of formula I-E according to formula I as defined above,



wherein

R^1 is halogen, CF_3 or CH_3 ,


R^2 is hydrogen, phenyl or C_{1-7} -alkyl;

R may be C_{1-7} -alkyl or C_{1-7} -alkyl substituted by halogen;

n is 1 or 2;

or a pharmaceutically suitable acid addition salt.

In a seventh aspect, there is provided a compound of formula I-F according to formula I as defined above,



wherein

R^1 is hydrogen, C_{1-7} -alkyl, C_{1-7} -alkoxy, C_{1-7} -alkyl substituted by halogen, C_{1-7} -alkoxy substituted by halogen or is halogen, wherein the substituents for $n > 1$ may be the same or different;

R/R' may be independently from each other hydrogen, C_{1-7} -alkyl or C_{1-7} -alkyl substituted by halogen,

R^2 is hydrogen, phenyl or C_{1-7} -alkyl;

n is 0, 1, 2 or 3;

or a pharmaceutically suitable acid addition salt, which compounds are


(S)-4-[2-(4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine

(S)-4-[2-(4-fluoro-3-methoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine

((S)-4-[2-(2,4-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-o-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-m-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-p-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(R)-4-[2-(3,4-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-2-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-4-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-3-methyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-{2-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-ethyl}-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-3-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,3-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-(1-methyl-2-phenyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine

(S)-4-[2-(4-trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-difluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-dichloro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-dichloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-((S)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-((R)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-6-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,4-dichloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,5-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-4-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-5-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine or
(S)-4-[2-(5-chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine.

In an eighth aspect, there is provided a compound of formula I-H according to formula I as defined above,



wherein

R¹ is halogen;

n is 0 or 1;

or a pharmaceutically suitable acid addition salt.

In a ninth aspect, there is provided a compound of formula I as defined above, wherein X is $-(CH_2)_3-$ and Y is phenyl.

In a tenth aspect, there is provided a compound of formula I as defined above, wherein X is $-SCH_2-$, $-S(O)_2CH_2-$, $-CH_2S(O)_2CH_2-$ or $-CH_2SCH_2-$ and Y is phenyl.

In a eleventh aspect, there is provided a compound of formula I as defined above, wherein X is $-CH_2N(R)CH_2-$, C_{3-6} -cycloalkyl- CH_2- or $SiRR'-CH_2-$ and Y is phenyl.

In a twelfth aspect, there is provided a compound of formula I as defined above, wherein X is described as defined above and Y is naphthyl, pyridyl, cyclohexyl, 2,3-dihydrobenzo[1,4]dioxin or 1,2,3,4-tetrahydronaphthalen.

In a thirteenth aspect, there is provided a medicament containing one of the compounds as defined above

- (S)-4-(2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(4-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(2,3-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(3,4-dichlorophenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(3-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(5-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(3-bromo-2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

(S)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2,3,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,4-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2,3-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-4-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-5-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(5-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(3-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(3,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2,4-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(2,3,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-bromo-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-3-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(2,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(2,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(2-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-5-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(5-chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(4-chloro-2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(-)-(R)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(2,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2,5-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine
(-)-(R)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2-chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,4-dichloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-o-tolyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-trifluoromethoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-o-tolyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-benzyloxy-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-methyl-4-(4-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(S)-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-methyl-4-p-tolyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-methyl-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine
(S)-4-biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4'-chloro-biphenyl-4-yl)-4,5-dihydro-oxazol-2-ylamine.
(RS)-4-(3-chloro-4-methoxyphenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-4-methoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-fluoro-4-trifluoromethyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(5-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(-)-(R)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(5-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(5-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(5-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(5-chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(5-chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(5-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(S)-4-(4-chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine or
(S)-4-(3-chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-3-methoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
((S)-4-[2-(2,4-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-o-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-m-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-p-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(R)-4-[2-(3,4-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-2-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-4-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-3-methyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-3-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,3-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine

(S)-4-(1-methyl-2-phenyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-difluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-dichloro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-dichloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-((S)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-((R)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-6-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,4-dichloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,5-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-4-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-5-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(5-chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine.

(S)-4-(3-Phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine
(R)-4-(3-Phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine.
(R)-4-phenylsulfanylmethyl-4,5-dihydro-oxazol-2-ylamine
(R)-4-benzenesulfonylmethyl-4,5-dihydro-oxazol-2-ylamine
(R)-4-benzylsulfanylmethyl-4,5-dihydro-oxazol-2-ylamine
(R)-4-(4-chloro-phenylsulfanylmethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[1-(4-chloro-phenyl)-cyclopropylmethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[1-(4-chloro-phenyl)-cyclobutylmethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-(1-phenyl-cyclopropylmethyl)-4,5-dihydro-oxazol-2-ylamine
(R)-4-[(dimethyl-phenyl-silanyl)-methyl]-4,5-dihydro-oxazol-2-ylamine.
(RS)-4-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-naphthalen-1-yl-4,5-dihydro-oxazol-2-ylamine
(R)-4-naphthalen-1-ylmethyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-naphthalen-1-ylmethyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-naphthalen-2-ylmethyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(1,2,3,4-tetrahydro-naphthalen-2-yl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-pyridin-4-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(6-trifluoromethyl-pyridin-2-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-methyl-pyridin-4-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine or
(S)-4-(2-cyclohexyl-ethyl)-4,5-dihydro-oxazol-2-ylamine.

and pharmaceutically acceptable excipients.

As used herein, the term "lower alkyl" denotes a saturated straight- or branched-chain group containing from 1 to 7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, 2-butyl, t-butyl and the like. Preferred alkyl groups are groups with 1 - 4 carbon atoms.

As used herein, the term "lower alkoxy" denotes a group wherein the alkyl residue is as defined above and which is attached via an oxygen atom.

As used herein, the term "lower alkyl substituted by halogen" denotes an alkyl group as defined above, wherein at least one hydrogen atom is replaced by halogen, for example CF_3 , CHF_2 , CH_2F , CH_2CF_3 , $\text{CH}_2\text{CH}_2\text{CF}_3$, $\text{CH}_2\text{CF}_2\text{CF}_3$ and the like.

The term "halogen" denotes chlorine, iodine, fluorine and bromine.

The term "cycloalkyl" is an alkylene ring, containing from 3 to 6 carbon ring atoms.


The term "pharmaceutically acceptable acid addition salts" embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid,
 5 citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.

The compounds mentioned below are specific novel and preferred for the uses as described above.

Preferred compounds of formula I are those, wherein X is a bond.

10

Preferred compounds of this group of formula I are those, wherein Y is phenyl, substituted by one or more halogen atoms:



I-A


- R¹ is halogen, for n > 1 the halogen atom may be the same or different;
 15 R² is hydrogen, phenyl or lower alkyl;
 n is 1, 2 or 3;

or a pharmaceutically suitable acid addition salt, for example

- (S)-4-(2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(4-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 20 (RS)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(2,3-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(3,4-dichlorophenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 25 (RS)-4-(3-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(5-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(4-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(3-bromo-2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 30 (S)-4-(3,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine

- (S)-4-(2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
5 (S)-4-(2,3,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,4-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2,3-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
10 (S)-4-(4-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-4-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
15 (S)-4-(3-chloro-5-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
20 (RS)-4-(3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(5-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
25 (+)-(S)-4-(3-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(3,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2,4-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(2,3,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
30 (S)-4-(4-bromo-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-3-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(2,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
35 (RS)-4-(4-bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

- (RS)-4-(2,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (+)-(S)-4-(2-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(3-chloro-5-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-methyl-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 5 (S)-4-(5-chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-methyl-4-(4-chloro-2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(3-chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(4-chloro-2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
 10 (RS)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
 (-)-(R)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (+)-(S)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (+)-(S)-4-(2,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 15 (RS)-4-(2,5-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
 (+)-(S)-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(3-chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(4-chloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine
 20 (-)-(R)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (+)-(S)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(2-chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
 (+)-(S)-4-(4-bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(4-bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 25 (S)-4-(3,4-dichloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine
 (+)-(S)-4-(4-bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(4-bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine or
 (S)-4-(4-bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine.
- 30 Further preferred compounds from this group are those, wherein Y is phenyl substituted by CH₃, CF₃, OCH₃, OCF₃ or OCH₂-phenyl,



I-B


R^1 is CH_3 , CF_3 , OCH_3 , OCF_3 or OCH_2 -phenyl;

R^2 is hydrogen, phenyl or lower alkyl;

n is 1, 2 or 3;

or a pharmaceutically suitable acid addition salt, for example the following compounds

- 5 (RS)-4-(2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - (RS)-4-o-tolyl-4,5-dihydro-oxazol-2-ylamine
 - (RS)-4-(4-trifluoromethoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - (RS)-4-(4-methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - (S)-4-o-tolyl-4,5-dihydro-oxazol-2-ylamine
 - 10 (RS)-4-(4-benzyloxy-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - (S)-4-(2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - (S)-4-(4-methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - (S)-4-methyl-4-(4-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - (S)-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - 15 (S)-4-methyl-4-p-tolyl-4,5-dihydro-oxazol-2-ylamine
 - (S)-4-methyl-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - (RS)-4-(4-methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - (+)-(S)-4-(4-methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
- 20 Further preferred compounds from this group are those, wherein Y is phenyl substituted by phenyl, which is optionally substituted by halogen:




R^2 is hydrogen, phenyl or lower alkyl;

or a pharmaceutically suitable acid addition salt, for example the following compounds

- 25 (RS)-4-biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine
- (S)-4-biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine or
- (RS)-4-(4'-chloro-biphenyl-4-yl)-4,5-dihydro-oxazol-2-ylamine.

Further preferred compounds from this group are those, wherein Y is phenyl substituted
30 by halogen and CF_3 , halogen and CH_3 , halogen and cycloalkyl or by halogen and OCH_3 ,



I-D

R^1 is halogen and CF_3 , or is halogen and CH_3 , or is halogen and cycloalkyl, or is halogen and OCH_3 ;

R^2 is hydrogen, phenyl or lower alkyl;

5 n is 1, 2 or 3;

or a pharmaceutically suitable acid addition salt, for example the following compounds

(RS)-4-(3-chloro-4-methoxyphenyl)-4,5-dihydro-oxazol-2-ylamine

(S)-4-(3-chloro-4-methoxyphenyl)-4,5-dihydro-oxazol-2-ylamine

(S)-4-(2-fluoro-4-trifluoromethyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

10 (RS)-4-(4-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(5-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(4-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(+)-(S)-4-(4-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

15 (+)-(S)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(-)-(R)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(+)-(S)-4-(4-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(5-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(5-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

20 (+)-(S)-4-(5-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(4-chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(5-chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(4-chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

(S)-4-(4-chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

25 (RS)-4-(4-bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(S)-4-(4-chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

(+)-(S)-4-(5-chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(4-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(+)-(S)-4-(4-bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

30 (+)-(S)-4-(5-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine


(RS)-4-(4-chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(+)-(S)-4-(4-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

- (RS)-4-(3-chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(4-chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine.
 (S)-4-(4-chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(3-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 5 (S)-4-(4-chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(3-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine or
 (S)-4-(3-chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine.

- Preferred compounds of formula I are further those, wherein X is CHR.

- 10 Preferred compounds from this group are those, wherein Y is phenyl:



R¹ is halogen, CF₃ or CH₃,

R² is hydrogen, phenyl or lower alkyl;

R may be independently from each other hydrogen, lower alkyl or lower alkyl
 15 substituted by halogen;


n is 1 or 2;

or a pharmaceutically suitable acid addition salt, for example the following compounds

- (S)-4-(2-chloro-benzyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(3-trifluoromethyl-benzyl)-4,5-dihydro-oxazol-2-ylamine or
 20 (RS)-4-(2-fluoro-5-methyl-benzyl)-4,5-dihydro-oxazol-2-ylamine.

- Preferred compounds of formula I are further those, wherein X is CHRCHR'.

Preferred compounds from this group are those, wherein Y is phenyl,



- 25 R¹ is hydrogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or is halogen, wherein the substituents for n > 1 may be the same or different;

R/R' may be independently from each other hydrogen, lower alkyl or lower alkyl substituted by halogen;

R² is hydrogen, phenyl or lower alkyl;


n is 0, 1, 2 or 3;

- 5 or a pharmaceutically suitable acid addition salt, for example the following compounds
- (R)-4-phenethyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-phenethyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-phenethyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-methyl-4-phenethyl-4,5-dihydro-oxazol-2-ylamine
- 10 (S)-4-[2-(4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-3-methoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
((S)-4-[2-(2,4-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- 15 (S)-4-[2-(2-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-o-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-m-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
- 20 (S)-4-(2-p-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(R)-4-[2-(3,4-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- 25 (S)-4-[2-(4-chloro-2-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-4-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- 30 (S)-4-[2-(4-fluoro-3-methyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine

- (S)-4-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-3-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,3-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
5 (S)-4-[2-(3-chloro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-(1-methyl-2-phenyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
10 (S)-4-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
15 (S)-4-[2-(3-trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-difluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
20 (S)-4-[2-(3,4-difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-dichloro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-dichloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
25 (S)-4-[2-(2-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
30 (S)-4-[2-(4-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-((S)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-((R)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine
35 (S)-4-[2-(2-chloro-6-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine


- (S)-4-[2-(2,4-dichloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
 (S)-4-[2-(2-bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
 (S)-4-[2-(2,5-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
 (S)-4-[2-(3-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
 5 (S)-4-[2-(3-chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
 (S)-4-[2-(3-chloro-4-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
 (S)-4-[2-(3-chloro-5-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine or
 (S)-4-[2-(5-chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine.

- 10 - Preferred compounds of formula I are further those, wherein X is OCH₂.
 and Y is phenyl.



- R¹ is lower alkyl, lower alkyl substituted by halogen or halogen, wherein the substituents for n > 1 may be the same or different;
 15 R² is hydrogen, phenyl or lower alkyl;
 n is 0, 1, 2 or 3;
 or a pharmaceutically suitable acid addition salt, for example the following compounds
 (S)-4-(4-fluoro-phenoxyethyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(4-chloro-phenoxyethyl)-4,5-dihydro-oxazol-2-ylamine
 20 (S)-4-(3,4-dichloro-phenoxyethyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(3,5-dichloro-phenoxyethyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(4-bromo-phenoxyethyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(3-chloro-phenoxyethyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(2,4-difluoro-phenoxyethyl)-4,5-dihydro-oxazol-2-ylamine or
 25 (S)-4-(2-fluoro-phenoxyethyl)-4,5-dihydro-oxazol-2-ylamine.

- Preferred compounds of formula I are further those, wherein X is CH₂OCHR.
 Preferred compounds from this group are those, wherein Y is phenyl:



R^1 is hydrogen or halogen;

n is 0 or 1;

or a pharmaceutically suitable acid addition salt, for example the following compound

- 5 (S)-4-benzyloxymethyl-4,5-dihydro-oxazol-2-ylamine.

- Preferred compounds of formula I are further those, wherein X is $-(CH_2)_3-$

Preferred compounds from this group are those, wherein Y is phenyl,

for example the following compounds

- 10 (S)-4-(3-Phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine or
(R)-4-(3-Phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine.

- Preferred compounds of formula I are further those, wherein X is $-SCH_2-$,

$-S(O)_2CH_2-$, or $-CH_2SCH_2-$.

- 15 Preferred compounds from this group are those, wherein Y is phenyl, for example the following compounds

(R)-4-phenylsulfanylmethyl-4,5-dihydro-oxazol-2-ylamine

(R)-4-benzenesulfonylmethyl-4,5-dihydro-oxazol-2-ylamine

(R)-4-benzylsulfanylmethyl-4,5-dihydro-oxazol-2-ylamine or

- 20 (R)-4-(4-chloro-phenylsulfanylmethyl)-4,5-dihydro-oxazol-2-ylamine.

- Preferred compounds of formula I are further those, wherein X is $-CH_2N(R)CH_2-$,

cycloalkyl- CH_2- or $SiRR'-CH_2-$;

Preferred compounds from this group are those, wherein Y is phenyl, for example the

- 25 following compounds

(S)-4-[1-(4-chloro-phenyl)-cyclopropylmethyl]-4,5-dihydro-oxazol-2-ylamine

(S)-4-[1-(4-chloro-phenyl)-cyclobutylmethyl]-4,5-dihydro-oxazol-2-ylamine

(S)-4-(1-phenyl-cyclopropylmethyl)-4,5-dihydro-oxazol-2-ylamine


(S)-4-[(benzyl-ethyl-amino)-methyl]-4,5-dihydro-oxazol-2-ylamine or

- 30 (R)-4-[(dimethyl-phenyl-silanyl)-methyl]-4,5-dihydro-oxazol-2-ylamine.

- Preferred compounds of formula I are further those, wherein X is described above and Y is naphthyl, pyridyl, cyclohexyl, 2,3-dihydrobenzo[1,4]dioxin or 1,2,3,4-tetrahydronaphthalen.

- (RS)-4-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-4,5-dihydro-oxazol-2-ylamine
 5 (RS)-4-naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-naphthalen-1-yl-4,5-dihydro-oxazol-2-ylamine
 (R)-4-naphthalen-1-ylmethyl-4,5-dihydro-oxazol-2-ylamine
 (S)-4-naphthalen-1-ylmethyl-4,5-dihydro-oxazol-2-ylamine
 (S)-4-naphthalen-2-ylmethyl-4,5-dihydro-oxazol-2-ylamine
 10 (RS)-4-(1,2,3,4-tetrahydro-naphthalen-2-yl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine
 (S)-4-[2-(3-fluoro-pyridin-4-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
 (S)-4-[2-(6-trifluoromethyl-pyridin-2-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
 (S)-4-[2-(2-methyl-pyridin-4-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine or
 15 (S)-4-(2-cyclohexyl-ethyl)-4,5-dihydro-oxazol-2-ylamine.

A further embodiment of the invention are compound of formula




wherein

- 20 R¹ is hydrogen, deuterium, tritium, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, halogen, phenyl optionally substituted by halogen, or is phenyloxy, benzyl, benzyloxy, or -COO-lower alkyl;
 X is a bond, -CHR- or -CHRCH₂-;
 R is hydrogen or lower alkyl;
 25 R² is hydrogen or lower alkyl;
 Y is aryl, heteroaryl, 1,2,3,4-tetrahydro-naphthalen-2-yl, 2,3-dihydrobenzo[1,4]dioxin-6-yl or benzo[1,3]dioxol-5-yl;
 n is 0, 1, 2 or 3;
 or pharmaceutically suitable acid addition salt with the exception of
 30 (S)-4-phenyl-4,5-dihydro-oxazol-2-ylamine,
 (R)-4-phenyl-4,5-dihydro-oxazol-2-ylamine,

(S)-4-benzyl-4,5-dihydro-oxazol-2-ylamine and
(RS)-4-phenethyl-4,5-dihydro-oxazol-2-ylamine.


The present compounds of formula I and their pharmaceutically acceptable salts
5 can be prepared by methods known in the art, for example, by processes described below, which process comprises

a) Reacting a compound of formula



with cyanogen bromide

10 to a compound of formula



wherein the definitions are as described above, or

if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.


15 The preparation of compounds of formula I of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses of the compounds of the invention are shown in the following schemes 1-9. The skills required for carrying out the reaction and purification of the resulting products are known to those skilled in the art. The substituents and indices used in the following description of the processes have the
20 significance given herein before unless indicated to the contrary.

In more detail, the compounds of formula I can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art. The reaction sequence is not limited to the one displayed in schemes 1

to 9, however, depending on the starting materials and their respective reactivity the sequence of reaction steps can be freely altered. Starting materials are either commercially available or can be prepared by methods analogous to the methods given below, by methods described in references cited in the description or in the examples, or by methods known in the art.

GENERAL PROCEDURE

Scheme 1



Step A: Reduction of an acid group ($R' = H$) can be effected by treatment with $LiAlH_4$, BH_3 -THF, BH_3 - Me_2S complex in the presence of BF_3 -etherate or Red-Al in a solvent such as 1,2-dimethoxyethane, THF, diethylether or toluene at r.t. $\rightarrow$ reflux for 1 – 24 hrs.

- Alternatively, reduction of an acid group ($R' = H$) can be effected by treatment with
- 5 $LiBH_4$ in the presence of Me_3SiCl in a solvent such as methanol at 0 °C $\rightarrow$ r.t. for 1 – 24 hrs.


Reduction of an ester group ($R' = \text{methyl or ethyl}$) can be effected by treatment with $LiAlH_4$, $LiBH_4$, $NaBH_4$ or Red-Al in a suitable solvent such as 1,2-dimethoxyethane, THF, diethylether, toluene, MeOH or EtOH at -78°C $\rightarrow$ reflux for 1 – 24 hrs.

- 10 Preferred conditions for acids and esters are $LiAlH_4$ in THF at r.t. overnight, or $LiBH_4/Me_3SiCl$ in methanol at 0 °C $\rightarrow$ r.t. overnight.

Step B: Cyclisation of the aminoalcohol to the corresponding 2-aminooxazoline can be accomplished by treatment with cyanogen bromide in THF as solvent and K_2CO_3 as base at r.t. overnight, or by treatment with cyanogen bromide in methanol as solvent and

- 15 sodium acetate as base at 0 °C to r.t. overnight.

Scheme 2



Step A: Wittig reaction between Garner's aldehyde IV and a benzyl-substituted

phosphonic acid diethyl ester V can be accomplished by using a base such as NaH,

- 5 KOtBu, NaOMe, NaOEt, n-BuLi, LiHMDS, NaHMDS, KHMDS, LDA in a solvent such as THF, dioxane, acetonitrile, 1,2-dimethoxyethane, DMF, benzene, toluene or mixtures thereof at temperatures from -78°C – 80°C for 15 min – 8 hrs and if appropriate optional addition of a crown ether for ylide generation and then condensing the ylide with the carbonyl compound in the same solvent at temperature between 0 and 80°C for 1 – 24
- 10 hrs. Alternatively, the base, the carbonyl compound and the base and the optional crown ether can be added to the reaction mixture at the same time without preformation of the ylide at temperatures from -78°C – 80°C.

- Preferred conditions are ylide formation at 0°C using n-buthyl lithium solution in hexane as base and 1,2-dimethoxyethane as solvent, reacting the phosphonic acid ester for 5 min
- 15 at 0°C, and then condensation with the carbonyl component at reflux overnight.

- Step B:** Reduction of the alkene can be effected by hydrogenation with hydrogen under normal or elevated pressure or by transfer hydrogenation using ammonium formate or cyclohexadiene as hydrogen source with a catalyst such as PtO₂, Pd-C or Raney nickel in solvents such as MeOH, EtOH, H₂O, dioxane, THF, HOAc, EtOAc CH₂Cl₂, CHCl₃, DMF
- 20 or mixtures thereof. Alternatively, the reduction of the alkene can be effected by Mg in MeOH or by LiAlH₄ in THF or diethylether.

Preferred conditions are hydrogenation in the presence of Pd/C as catalyst with EtOH as solvent.


Step C: Simultaneous cleavage of the amino alcohol protecting groups can be effected with a mineral acid such as HCl, H₂SO₄ or H₃PO₄ or an organic acid such as CF₃COOH, CHCl₂COOH, HOAc or p-toluenesulfonic acid in a solvent such as CH₂Cl₂, CHCl₃, THF, MeOH, EtOH or H₂O at 0 to 60°C.

- 5 Preferred conditions are 2N HCl in EtOH at reflux for 1 -3 hrs or 4N HCl in dioxane at r.t. overnight.

Step D: Cyclisation of the amino alcohol to the corresponding 2-aminooxazoline can be accomplished by treatment with cyanogen bromide in THF as solvent and K₂CO₃ as base at r.t. overnight, or by treatment with cyanogen bromide in methanol as solvent and

- 10 sodium acetate as base at 0 °C to r.t. overnight.

Scheme 3



- Step A:** The synthesis of the Julia reagent (benzothiazole-2-sulfonyl derivative) IX from 'Garner's alcohol' VIII was accomplished as described in literature (Dandanpani, S. *et al.*, *Journal of Organic Chemistry* 2005, 70(23), 9447).

- Step B:** Julia reaction between an Y-aldehyde or ketone and the benzothiazole sulfonyl compound can be accomplished by using a base such as LiHMDS, NaHMDS, KHMDS, LDA, KOtBu, DBU in a solvent such as THF, diethyl ether, 1,2-dimethoxyethane, dichloromethane, DMF or mixtures thereof at temperatures from -100°C – r.t. for 15 min – 8 hrs for anion generation and then condensing the ylide with

the carbonyl compound in the same solvent at temperatures between -100°C and r.t. for 1 – 24 hrs.

Preferred conditions are anion generation with LiHMDS at -78°C in THF and subsequent condensation with the carbonyl component under the same conditions.


- 5 **Step C:** Simultaneous cleavage of the amino alcohol protecting groups can be effected with a mineral acid such as HCl, H₂SO₄ or H₃PO₄ or a organic acid such as CF₃COOH, CHCl₂COOH, HOAc or p-toluenesulfonic acid in a solvent such as CH₂Cl₂, CHCl₃, THF, MeOH, EtOH or H₂O at 0 to 60°C.

Preferred conditions are 2N HCl in EtOH at reflux for 1 -3 hrs or 4N HCl in dioxane at
10 r.t. overnight.

Step D: Cyclisation of the amino alcohol to the corresponding 2-aminooxazoline can be accomplished by treatment with cyanogen bromide in THF as solvent and K₂CO₃ as base at r.t. overnight, or by treatment with cyanogen bromide in methanol as solvent and sodium acetate as base at 0 °C to r.t. overnight.

15

Scheme 4



- Step A:** Mitsunobu reaction of 'Garner's alcohol' VIII with phenol derivatives X or thiophenol derivatives X can be accomplished by using a phosphine such as triphenylphosphine and an azodicarboxylate reagent such as diethylazodicarboxylate,
20

diisopropylazodicarboxylate, or di-tert-butylazodicarboxylate in a solvent such as THF at temperatures from 50 °C – 70 °C for 1 – 18 hrs.

Preferred conditions are triphenylphosphine and di-tert-butylazodicarboxylate in THF at 60 °C for 16 h.


- 5 **Step B:** Simultaneous cleavage of the amino alcohol protecting groups can be effected with a mineral acid such as HCl, H₂SO₄ or H₃PO₄ or a organic acid such as CF₃COOH, CHCl₂COOH, HOAc or p-toluenesulfonic acid in a solvent such as CH₂Cl₂, CHCl₃, THF, MeOH, EtOH or H₂O at 0 to 60°C.

- Preferred conditions are 2N HCl in EtOH at reflux for 1 -3 hrs or 4N HCl in dioxane at
10 r.t. overnight.

Step C: Cyclisation of the amino alcohol to the corresponding 2-aminooxazoline can be accomplished by treatment with cyanogen bromide in THF as solvent and K₂CO₃ as base at r.t. overnight, or by treatment with cyanogen bromide in methanol as solvent and sodium acetate as base at 0 °C to r.t. overnight.

15

Scheme 5



Step A: Conversion of Garner's aldehyde IV to the dibromo-alkene derivative XII can be accomplished by using a brominating agent such as carbon tetrabromide in the presence of a phosphine such as triphenylphosphine in a chlorinated solvent such as dichloromethane at temperatures between 0 °C and room temperature.

Step B: Suzuki reaction of dibromo-alkene derivative XII with an arylboronic acid XIII can be accomplished using a palladium catalyst such as tris(dibenzylideneacetone)dipalladium (0) in the presence of a phosphine such as tris(2-furyl)phosphine and a base such as aqueous sodium carbonate in a solvent such as THF, dioxane, 1,2-dimethoxyethan, DMF, benzene, toluene or mixtures thereof at temperatures from 50 °C – 100°C for 1 – 18 hrs.

Step C: Negishi reaction of bromo-alkene derivative XIV with a dialkylzinc reagent XV can be accomplished using a palladium catalyst such as bis(tri-tert-

butylphosphine)dipalladium (0) in a solvent such as THF, dioxane, 1,2-dimethoxyethan, DMF, benzene, toluene or mixtures thereof at temperatures from 20 °C – 100°C for 1 – 18 hrs. Preferred conditions are a THF-toluene mixture at room temperature.

Step D: Reduction of the alkene can be effected by hydrogenation with hydrogen under
5 normal or elevated pressure or by transfer hydrogenation using ammonium formate or cyclohexadiene as hydrogen source with a catalyst such as PtO₂, Pd-C or Raney nickel in solvents such as MeOH, EtOH, H₂O, dioxane, THF, HOAc, EtOAc CH₂Cl₂, CHCl₃, DMF or mixtures thereof. Alternatively, the reduction of the alkene can be effected by Mg in MeOH or by LiAlH₄ in THF or diethylether.

10 Preferred conditions for R¹ ≠ chlorine are hydrogenation in the presence of Pd/C as catalyst with EtOH as solvent.

Preferred conditions for R¹ = chlorine are hydrogenation in the presence of Pt/C as catalyst with EtOH as solvent.


Step E: Simultaneous cleavage of the amino alcohol protecting groups can be effected
15 with a mineral acid such as HCl, H₂SO₄ or H₃PO₄ or an organic acid such as CF₃COOH, CHCl₂COOH, HOAc or p-toluenesulfonic acid in a solvent such as CH₂Cl₂, CHCl₃, THF, MeOH, EtOH or H₂O at 0 to 60°C.

Preferred conditions are 2N HCl in EtOH at reflux for 1 -3 hrs or 4N HCl in dioxane at r.t. overnight.

20 *Steps D* and *E* can also be carried out in the opposite order, in which case the stereochemical preference of the hydrogenation step is typically reversed.

Step F: Cyclisation of the amino alcohol to the corresponding 2-aminooxazoline can be accomplished by treatment with cyanogen bromide in THF as solvent and K₂CO₃ as base at r.t. overnight, or by treatment with cyanogen bromide in methanol as solvent and
25 sodium acetate as base at 0 °C to r.t. overnight.

Scheme 6



Step A: Coupling of 4-ethynyl-2,2-dimethyl-1,3-oxazolidine-3-carboxylate XVIII (Dickson, H. D. *et al Tetrahedron Lett.* 2004, 45 (29), 5597-5599; Pietruszka, J. *et al Eur. J.*

5 *Org. Chem.* 2003, 3219-3229) with an aryl or hetaryl bromide or iodide XIX in the presence of a palladium and a copper(I) salt in a solvent such as dioxane, tetrahydrofurane, benzene, triethylamine or the like.

Preferred conditions are the use of copper(I)-iodide and bis(triphenylphosphine)palladium(II) chloride with triethylamine as solvent at room
10 temperature.

Step B: Reduction of the alkyne XX can be effected by hydrogenation with hydrogen under normal or elevated pressure or by transfer hydrogenation using ammonium formate or cyclohexadiene as hydrogen source with a catalyst such as PtO₂, Pd-C or Raney nickel in solvents such as MeOH, EtOH, H₂O, dioxane, THF, HOAc, EtOAc

15 CH₂Cl₂, CHCl₃, DMF or mixtures thereof. Alternatively, the reduction of the alkyne can be effected by Mg in MeOH or by LiAlH₄ in THF or diethylether.

Preferred conditions are transfer hydrogenation using ammonium formate in the presence of Pd/C as catalyst with MeOH as solvent.

Step C: Simultaneous cleavage of the amino alcohol protecting groups can be effected

20 with a mineral acid such as HCl, H₂SO₄ or H₃PO₄ or an organic acid such as CF₃COOH,


CHCl_2COOH , HOAc or p -toluenesulfonic acid in a solvent such as CH_2Cl_2 , CHCl_3 , THF, MeOH, EtOH or H_2O at 0 to 60 °C.

Preferred conditions are 2N HCl in EtOH at reflux for 1 -3 hrs or 4N HCl in dioxane at r.t. overnight.

- 5 **Step D:** Cyclisation of the amino alcohol to the corresponding 2-aminooxazoline can be accomplished by treatment with cyanogen bromide in THF as solvent and K_2CO_3 as base at r.t. overnight, or by treatment with cyanogen bromide in methanol as solvent and sodium acetate as base at 0 °C to r.t. overnight.

10

Scheme 7



- Step A:** Deprotonation of bis-lactimether XXI (also called "Schöllkopf's chiral auxiliary") with a suitable base such as n -butyl-lithium or $tert$ -butyl-lithium in an appropriate organic solvent such as tetrahydrofuran at a low temperature followed by addition of the organic halide XXII and reaction for several hours leads to product XXIII (Vassiliou, S. *et al Synlett* 2003, 2398-2400; Schöllkopf, U. *Topics Curr. Chem.* 1983, 109, 65).

Preferred conditions are the use of $tert$ -butyllithium and an organic iodide in tetrahydrofuran at -78 °C and allowing the mixture to reach room temperature overnight.

- 20 **Step B:** Cleavage of bis-lactim ether product XXIII under acidic conditions using a mineral acid such as HCl, H_2SO_4 or H_3PO_4 or an organic acid such as CF_3COOH ,

CHCl₂COOH, HOAc or p-toluenesulfonic acid in a solvent such as acetonitrile, CH₂Cl₂, CHCl₃, THF, MeOH, EtOH or H₂O at 0 to 60°C.

Preferred conditions are a 10% trifluoroacetic acid in a mixture of water and acetonitrile (1:3) at 40°C overnight.

- 5 *Step C:* Reduction of the ester XXIV can be effected by treatment with LiAlH₄, LiBH₄, NaBH₄ or Red-Al in a suitable solvent such as 1,2-dimethoxyethane, THF, diethylether, toluene, MeOH or EtOH at -78 °C -> reflux for 1 – 24 hrs.

Preferred conditions for acids and esters are LiAlH₄ in THF at r.t. overnight.

- Step D:* Cyclisation of the amino alcohol II-4 to the corresponding 2-aminooxazoline I-4
10 can be accomplished by treatment with cyanogen bromide in THF as solvent and K₂CO₃ as base at r.t. overnight, or by treatment with cyanogen bromide in methanol as solvent and sodium acetate as base at 0 °C to r.t. overnight.

15


20

25

30

35

Scheme 8



5

Homochiral alcohols of formula XXVIII may be prepared by a variety of methods reported in the chemical literature, for instance starting from carboxylic acids of formula XXV and using the methodologies of Evans *et al.* (ref [1]) or Meyers *et al.* (ref [2]). According to these procedures, introduction of a chiral auxiliary, such as the Evans

oxazolidinone auxiliary (ref [1]) or the Meyers pseudoephedrine-derived auxiliary (ref [2]) affords a homochiral acyl compound of formula XXVI. Enolisation of the acyl compound XX with a suitable base followed by treatment with an alkyl halide affords compounds of formula XXVII. Reductive removal of the chiral auxiliary then affords the homochiral alcohols of formula XXVIII.

[1] Evans, D. A. *et al. J. Am. Chem. Soc.* 1982, 104, 1737-1739.

[2] Meyers, A. G. *et al. J. Am. Chem. Soc.* 1997, 119, 6496-5611.

Step A: Homochiral alcohol XXVIII may be converted to the corresponding alkyl iodide XXIX using a reagent system comprising imidazole, triphenylphosphine and iodine in dichloromethane (Müller, P. & Boléa, C. *Helv. Chim. Acta* 2002, 85, 483-494) or sequential treatment with p-toluensulphonyl chloride/pyridine and sodium iodide in acetone (Taber, D. F. *et al. J. Am. Chem. Soc.* 1985, 107, 196-199).

Preferred conditions are the use of imidazole, triphenylphosphine and iodine in dichloromethane.

Step B: Deprotonation of bis-lactimether XXI (also called "Schöllkopf's chiral auxiliary") with a suitable base such as n-butyl-lithium or tert-butyl-lithium in an appropriate organic solvent such as tetrahydrofuran at a low temperature followed by addition of the homochiral alkyl iodide XXIX and reaction for several hours leads to product XXX (Vassiliou, S. *et al Synlett* 2003, 2398-2400; Schöllkopf, U. *Topics Curr. Chem.* 1983, 109, 65).

Preferred conditions are the use of n-butyllithium at -78 °C and allowing the mixture to reach room temperature overnight.

Step C: Cleavage of bis-lactim ether product XXX under acidic conditions using a mineral acid such as HCl, H₂SO₄ or H₃PO₄ or an organic acid such as CF₃COOH, CHCl₂COOH, HOAc or p-toluenesulfonic acid in a solvent such as acetonitrile, CH₂Cl₂, CHCl₃, THF, MeOH, EtOH or H₂O at 0 to 60°C.

Preferred conditions are a 10% trifluoroacetic acid in a mixture of water and acetonitrile (1:3) at room temperature overnight.

Step D: Reduction of the ester XXXI can be effected by treatment with LiAlH₄, LiBH₄, NaBH₄ or Red-Al in a suitable solvent such as 1,2-dimethoxyethane, THF, diethylether, toluene, MeOH or EtOH at -78 °C -> reflux for 1 – 24 hrs.



Preferred conditions for acids and esters are LiAlH₄ in THF at r.t. overnight.

Step E: Cyclisation of the amino alcohol II-5 to the corresponding 2-aminooxazoline I-5 can be accomplished by treatment with cyanogen bromide in THF as solvent and K₂CO₃

as base at r.t. overnight, or by treatment with cyanogen bromide in methanol as solvent and sodium acetate as base at 0 °C to r.t. overnight.

5

Scheme 9



Step A: Reductive amination of optically active Garner's aldehyde ($R^2=H$; from L- or D-serine; Garner, P.; Park, J.M. *Org. Synth.* 1998, IX, 300) or α -methyl-substituted Garner's aldehyde ($R^2=\text{methyl}$; from L- or D- α -methylserine; Avenoza, A. *et al. Tetrahedron Asymm.* 2001, 12, 949) with a primary amine compound of formula XXXII-1 can be
5 accomplished by a reducing agent such as NaBH_4 , LiBH_4 , $\text{NaBH}(\text{OAc})_3$ or $\text{Na}(\text{CN})\text{BH}_3$ in a solvent such as MeOH, EtOH, dichloromethane, 1,2-dichloroethane, THF, dioxane or mixtures thereof in the presence of an activating protic acid such as HCl or a carboxylic acid or an activating Lewis acid such as ZnCl_2 or $\text{Ti}(\text{OiPr})_4$ at a temperature of -10 to 60 °C for 1 - 40 h.

10 Preferred conditions are heating of compound XXXII-1 and compound IV in MeOH at 60 °C overnight, followed by treatment with NaBH_4 in MeOH at room temperature.

Step B: Alkylation of the compound of formula XXXIII-1 to compound of formula XXXIII-2 can be accomplished by treatment with a suitable aldehyde RCHO in the presence of a reducing agent such as NaBH_4 , LiBH_4 , $\text{NaBH}(\text{OAc})_3$ or $\text{Na}(\text{CN})\text{BH}_3$ in a
15 solvent such as MeOH, EtOH, dichloromethane, 1,2-dichloroethane, THF, dioxane or mixtures thereof in the presence of an activating protic acid such as HCl or a carboxylic acid or an activating Lewis acid such as ZnCl_2 or $\text{Ti}(\text{OiPr})_4$ at a temperature of -10 to 60 °C for 1-40 h.

Step C: Preparation of a compound of formula XXXIII-2 may alternatively be
20 accomplished by reductive amination of a secondary amine compound of formula XXXIII-2 and Garner's aldehyde (from L- or D-serine; Garner, P.; Park, J.M. *Org. Synth.* 1998, IX, 300) in the presence of a reducing agent such as NaBH_4 , LiBH_4 , $\text{NaBH}(\text{OAc})_3$ or $\text{Na}(\text{CN})\text{BH}_3$ in a solvent such as MeOH, EtOH, dichloromethane, 1,2-dichloroethane, THF, dioxane or mixtures thereof in the presence of an activating protic acid such as HCl
25 or a carboxylic acid or an activating Lewis acid such as ZnCl_2 or $\text{Ti}(\text{OiPr})_4$ at a temperature of -10 to 60 °C for 1-40 h.

Preferred conditions are NaBH_3CN and ZnCl_2 in MeOH at r.t. - 40 °C overnight.

Step D: Simultaneous cleavage of the amino alcohol protecting groups of the compound of formula XXXIII-2 can be effected with a mineral acid such as HCl, H_2SO_4 or H_3PO_4 or
30 a organic acid such as CF_3COOH , CHCl_2COOH , HOAc or p-toluenesulfonic acid in a solvent such as CH_2Cl_2 , CHCl_3 , THF, MeOH, EtOH or H_2O at 0 to 60°C.

Preferred conditions are 2N HCl in EtOH at reflux for 1 -3 hrs or 4N HCl in dioxane at r.t. overnight.

Step E: Cyclisation of the amino alcohol II-6 to the corresponding 2-aminooxazoline I-6
35 can be accomplished by treatment with cyanogen bromide in THF as solvent and K_2CO_3

as base at r.t. overnight, or by treatment with cyanogen bromide in methanol as solvent and sodium acetate as base at 0 °C to r.t. overnight.

Isolation and purification of the compounds

5 Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick-layer chromatography, preparative low or high-pressure liquid chromatography or a combination of these procedures. Specific illustrations of suitable
10 separation and isolation procedures can be had by reference to the preparations and examples herein below. However, other equivalent separation or isolation procedures could, of course, also be used. Racemic mixtures of chiral compounds of formula I can be separated using chiral HPLC.

Salts of compounds of formula I

15 The compounds of formula I are basic and may be converted to a corresponding acid addition salt. The conversion is accomplished by treatment with at least a stoichiometric amount of an appropriate acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic
20 acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Typically, the free base is dissolved in an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like, and the acid added in a similar solvent. The temperature is maintained between 0 °C and 50 °C. The
25 resulting salt precipitates spontaneously or may be brought out of solution with a less polar solvent.

The acid addition salts of the basic compounds of formula I may be converted to the corresponding free bases by treatment with at least a stoichiometric equivalent of a suitable base such as sodium or potassium hydroxide, potassium carbonate, sodium
30 bicarbonate, ammonia, and the like.

The compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. Specifically, it has been found that the compounds of the present invention have a good affinity to the trace amine associated receptors (TAARs), especially TAAR1.

The compounds were investigated in accordance with the test given hereinafter.

Materials and Methods

Construction of TAAR expression plasmids and stably transfected cell lines

- 5 For the construction of expression plasmids the coding sequences of human, rat and mouse TAAR 1 were amplified from genomic DNA essentially as described by Lindemann et al. [14]. The Expand High Fidelity PCR System (Roche Diagnostics) was used with 1.5 mM Mg²⁺ and purified PCR products were cloned into pCR2.1-TOPO cloning vector (Invitrogen) following the instructions of the manufacturer. PCR products
10 were subcloned into the pIRESneo2 vector (BD Clontech, Palo Alto, California), and expression vectors were sequence verified before introduction in cell lines.

- HEK293 cells (ATCC # CRL-1573) were cultured essentially as described Lindemann et al. (2005). For the generation of stably transfected cell lines HEK293 cells were transfected
15 with the pIRESneo2 expression plasmids containing the TAAR coding sequences (described above) with Lipofectamine 2000 (Invitrogen) according to the instructions of the manufacturer, and 24 hrs post transfection the culture medium was supplemented with 1 mg/ml G418 (Sigma, Buchs, Switzerland). After a culture period of about 10 d clones were isolated, expanded and tested for responsiveness to trace amines (all
20 compounds purchased from Sigma) with the cAMP Biotrak Enzyme immunoassay (EIA) System (Amersham) following the non-acetylation EIA procedure provided by the manufacturer. Monoclonal cell lines which displayed a stable EC₅₀ for a culture period of 15 passages were used for all subsequent studies.

25 Membrane preparation and radioligand binding

- Cells at confluence were rinsed with ice-cold phosphate buffered saline without Ca²⁺ and Mg²⁺ containing 10 mM EDTA and pelleted by centrifugation at 1000 rpm for 5 min at 4 °C. The pellet was then washed twice with ice-cold phosphate buffered saline and cell pellet was frozen immediately by immersion in liquid nitrogen and stored until use at -80 °C. Cell pellet was then suspended in 20 ml HEPES-NaOH (20 mM), pH 7.4 containing
30 10 mM EDTA, and homogenized with a Polytron (PT 3000, Kinematica) at 10,000 rpm for 10 s. The homogenate was centrifuged at 48,000×g for 30 min at 4 °C and the pellet resuspended in 20 ml HEPES-NaOH (20 mM), pH 7.4 containing 0.1 mM EDTA (buffer A), and homogenized with a Polytron at 10,000 rpm for 10 s. The homogenate was then
35 centrifuged at 48,000×g for 30 min at 4 °C and the pellet resuspended in 20 ml buffer A,

and homogenized with a Polytron at 10,000 rpm for 10 s. Protein concentration was determined by the method of Pierce (Rockford, IL). The homogenate was then centrifuged at 48,000×g for 10 min at 4 °C, resuspended in HEPES-NaOH (20 mM), pH 7.0 including MgCl₂ (10 mM) and CaCl₂ g protein per ml and (2 mM) (buffer B) at 200
5 homogenized with a Polytron at 10,000 rpm for 10 s.

Binding assay was performed at 4 °C in a final volume of 1 ml, and with an incubation time of 30 min. The radioligand [³H]-rac-2-(1,2,3,4-tetrahydro-1-naphthyl)-2-imidazoline was used at a concentration equal to the calculated K_d value of 60 nM to give
10 a bound at around 0.1 % of the total added radioligand concentration, and a specific binding which represented approximately 70 – 80 % of the total binding. Non-specific binding was defined as the amount of [³H]-rac-2-(1,2,3,4-tetrahydro-1-naphthyl)-2-imidazoline bound in the presence of the appropriate unlabelled ligand (10 μM). Competing ligands were tested in a wide range of concentrations (10 pM – 30 μM). The
15 final dimethylsulphoxide concentration in the assay was 2%, and it did not affect radioligand binding. Each experiment was performed in duplicate. All incubations were terminated by rapid filtration through UniFilter-96 plates (Packard Instrument Company) and glass filter GF/C, pre-soaked for at least 2 h in polyethylenimine 0.3%, and using a Filtermate 96 Cell Harvester (Packard Instrument Company). The tubes and
20 filters were then washed 3 times with 1 ml aliquots of cold buffer B. Filters were not dried and soaked in Ultima gold (45 μl/well, Packard Instrument Company) and bound radioactivity was counted by a TopCount Microplate Scintillation Counter (Packard Instrument Company).

The preferred compounds show a K_i value (μM) in mouse or rat on TAAR1 in the
25 range of <0.01 μM as shown in the table below.

Example	K _i (μM) mouse/rat	Example	K _i (μM) mouse/rat	Example	K _i (μM) mouse/rat
4	0.0012	147	0.0041	255	0.0074
5	0.0021	149	0.0019	256	0.0006
6	0.0038	150	0.0009	257	0.0074
7	0.0083	151	0.001	259	0.0088

8	0.0058	153	0.0083	260	0.0013
9	0.0034	154	0.0034	263	0.0023
10	0.0025	156	0.0064	265	0.0009
12	0.008	158	0.0068	266	0.0016
14	0.0005	159	0.001	267	0.0011
16	0.0048	160	0.0028	269	0.0083
17	0.0057	161	0.0062	270	0.0016
18	0.0022	162	0.0025	271	0.0013
19	0.0018	163	0.0037	272	0.0013
20	0.0009	165	0.0012	273	0.0095
21 (S)	0.0008	166	0.0047	274	0.0011
22	0.0011	168	0.0006	277	0.0016
29 (S)	0.0054	169	0.0014	281	0.0019 rat
31	0.0022	170	0.0011	284	0.0028 rat
32	0.0029	172	0.0019	285	0.0045 rat
33	0.0007	174	0.0006	287	0.0027 rat
34	0.0011	176	0.002	289	0.0017
35	0.0033	178	0.0004	291	0.0008
36	0.0034	180	0.0088	292	0.0035

37b (S)	0.0087	184	0.0063	293	0.0062
39a (S)	0.0025	185	0.005	294	0.0038
48	0.0002	186	0.0045	295	0.0082
49	0.0054	187	0.0021	296	0.0004
60	0.0047	188	0.0038	298	0.0004
63	0.0086	189	0.0008	299	0.0042
73	0.0089	190	0.0008	301	0.0023
78	0.0064	192	0.0019	302	0.0017
80 (S)	0.0008	193	0.0043	303	0.0011
80 (R)	0.0083	194	0.0073	304	0.0033
81 (S)	0.0064	195	0.0018	306	0.0027
82 (S,S)	0.0080	196	0.0066	308	0.0009
82 (S,R)	0.0016	198	0.002	310	0.009 rat
84	0.0017	199	0.0093	311	0.0042 rat
85	0.0011	201	0.0002	313	0.005 rat
86	0.0008	202	0.0017	314	0.003 rat
88	0.001	203	0.0039	315	0.0016 rat
89	0.0013	206	0.0032	316	0.0003 rat

91	0.0006	210	0.0014	318	0.002 rat
101	0.0034	211	0.0024	321	0.0014 rat
103	0.0004	212	0.0068	322	0.002 rat
105	0.0007	213	0.003	326	0.001
107	0.004	215	0.0024	328	0.0052
109	0.0014	216	0.002	330	0.0008
110	0.0018	217	0.0015	332	0.0061
111	0.0011	219	0.0009	333	0.0021
112	0.0012	220	0.0084	337	0.0034
113	0.0016	221	0.0022	338	0.0031
114	0.0021	222	0.0048	340	0.002
115	0.001	223	0.0059	341	0.0046
116	0.0012	224	0.0063	342	0.0045
118	0.003	225	0.0062	343	0.0028
119	0.0026	226	0.0054	344	0.0025
120	0.0014	227	0.0081	348	0.0036
122	0.0034	228	0.004	349	0.0023
124	0.0044	229	0-003	350	0.0064
127	0.0003	231	0.0025	351	0.0024
129	0.0029	232	0.0006	353	0.0014

131	0.0024	234	0.0093	354	0.0003
132	0.0007	235	0.001	355	0.0043
133	0.0022	236	0.002	356	0.0043
135	0.0009	237	0.0025	357	0.0068
136	0.0038	238	0.003	358	0.0084
137	0.0025	240	0.0032	359	0.0021
138	0.0012	242	0.0072	364	0.0020
139	0.0019	243	0.0094	365	0.0029
140	0.001	244	0.0057	367	0.001
141	0.0027	246	0.0055	369	0.0009
142	0.0018	248	0.0029	370	0.0037
143	0.0007	249	0.0075	371	0.0096
144	0.0012	250	0.0022	374	0.0006
145	0.0026	251	0.0086	D	0.001
146	0.0041	252	0.0008		

The compounds of formula I and the pharmaceutically acceptable salts of the compounds of formula I can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.

The compounds of formula I can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used,

for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are however usually required in the case of soft gelatine capsules.

- 5 Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

The pharmaceutical preparations can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying
10 the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.

Medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also an object of the present invention, as is a process for their production, which comprises bringing one or more
15 compounds of formula I and/or pharmaceutically acceptable acid addition salts and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.

The most preferred indications in accordance with the present invention are those, which include disorders of the central nervous system, for example the treatment or
20 prevention of depression, psychosis, Parkinson's disease, anxiety and attention deficit hyperactivity disorder (ADHD).

The dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case. In the case of oral administration the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound
25 of general formula I or of the corresponding amount of a pharmaceutically acceptable salt thereof. The daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.

Tablet Formulation (Wet Granulation)

Item	Ingredients	mg/tablet	5 mg	25 mg	100 mg	500 mg
30						

- 41 -

1.	Compound of formula I	5	25	100	500
2.	Lactose Anhydrous DTG	125	105	30	150
3.	Sta-Rx 1500	6	6	6	30
4.	Microcrystalline Cellulose	30	30	30	150
5 5.	Magnesium Stearate	1	1	1	1
	Total	167	167	167	831

Manufacturing Procedure

1. Mix items 1, 2, 3 and 4 and granulate with purified water.
2. Dry the granules at 50°C.
- 10 3. Pass the granules through suitable milling equipment.
4. Add item 5 and mix for three minutes; compress on a suitable press.

15

Capsule Formulation

<u>Item</u>	<u>Ingredients</u>	<u>mg/capsule</u>			
		5 mg	25 mg	100 mg	500 mg
1.	Compound of formula I	5	25	100	500
20 2.	Hydrous Lactose	159	123	148	---
3.	Corn Starch	25	35	40	70
4.	Talc	10	15	10	25
5.	Magnesium Stearate	1	2	2	5
	Total	200	200	300	600

25 Manufacturing Procedure


1. Mix items 1, 2 and 3 in a suitable mixer for 30 minutes.
2. Add items 4 and 5 and mix for 3 minutes.
3. Fill into a suitable capsule.

Experimental

The following examples illustrate the invention but are not intended to limit its scope.

Example 1

(RS)-4-Methyl-4-phenyl-4,5-dihydro-oxazol-2-ylamine



5

a) (RS)-2-Amino-2-phenyl-propan-1-ol

To a stirred, cooled suspension of 2-amino-2-phenyl-propionic acid (488 mg) at r.t. in THF (10 ml) under an argon atmosphere was added portionwise LiAlH_4 (244 mg). The ice bath was removed and stirring at r.t. was then continued for 20 h. The mixture was cooled in an ice bath, diluted with 5 ml THF and H_2O (0.23 ml), 4 N NaOH (0.23 ml) and H_2O (0.92 ml) were added successively and carefully. After 30 min stirring at r.t., the mixture was filtered and the cake was washed with THF. The filtrate was concentrated. The crude product was purified by column chromatography (silica gel; gradient: CH_2Cl_2 - $> \text{CH}_2\text{Cl}_2/\text{MeOH}$ 9:1) to give 2-amino-2-phenyl-propan-1-ol (266 mg) as colorless viscous oil. MS (ISP): 152.3 ($[\text{M}+\text{H}]^+$)

15

b) (RS)-4-Methyl-4-phenyl-4,5-dihydro-oxazol-2-ylamine

To a stirred, cooled (0°C) mixture of 2-amino-2-phenyl-propan-1-ol (266 mg) and K_2CO_3 (292 mg) in THF (5 ml) under an argon atmosphere was added a solution of cyanogen bromide (292 mg) in THF (5 ml). The ice bath was removed and stirring at r.t. was continued for 18 h. The mixture (white suspension) was taken up in $\text{EtOAc}/\text{H}_2\text{O}$ 1:1. The aqueous phase was back extracted with EtOAc . The combined organics were washed with brine, dried over MgSO_4 , filtered and concentrated. The crude product was purified by column chromatography (silica gel; gradient: CH_2Cl_2 - $> \text{CH}_2\text{Cl}_2/\text{MeOH}$ 9:1) to give 4-methyl-4-phenyl-4,5-dihydro-oxazol-2-ylamine (204 mg) as white solid. MS (ISP): 177.1 ($[\text{M}+\text{H}]^+$)

25


In analogy to example 1 and starting from the respective amino acid or amino acid derivative were prepared:

30

Example 2

(S)-4-(4-Trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

- 43 -




From L-4-(trifluoromethyl)phenylglycine. Off-white solid.

MS (ISP): 231.3 ($[M+H]^+$)

Example 3

5 (S)-4-(4-Fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




From L-4-fluorophenylglycine. Off-white solid.

MS (ISP): 180.9 ($[M+H]^+$)

Example 4

10 (S)-4-(2-Chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine




From L-2-chlorophenylglycine. Light yellow solid.

MS (ISP): 197.3 ($[M+H]^+$)

Example 5

15 (RS)-4-(4-Chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine




From DL-4-chlorophenylglycine. Light yellow solid.

MS (ISP): 197.1 ($[M+H]^+$)

Example 6

20

(RS)-4-(2-Trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




From DL-2-(trifluoromethyl)phenylglycine. Off-white solid.

MS (ISP): 231.3 ($[M+H]^+$)

5

Example 7

(RS)-4-(2,4-Difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




From DL-2,4-difluorophenylglycine. Off-white solid.

MS (ISP): 198.9 ($[M+H]^+$)

10

Example 8

(RS)-4-o-Tolyl-4,5-dihydro-oxazol-2-ylamine




From (RS)- α -amino-(2-methylphenyl)acetic acid. Off-white solid.

MS (ISP): 177.3 ($[M+H]^+$)

15

Example 9

(S)-4-(2,3-Difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine



From L-2,3-difluorophenylglycine. Off-white solid.


MS (ISP): 199.3 ($[M+H]^+$)

20

Example 10

(RS)-4-Biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine

- 45 -




From (RS)-amino-biphenyl-4-yl-acetic acid. Off-white solid.

MS (ISP): 239.1 ($[M+H]^+$)

Example 11

5 (RS)-4-(2-Fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




From DL-2-fluorophenylglycine. Off-white solid.

MS (ISP): 180.9 ($[M+H]^+$)

Example 12

10 (RS)-4-(4-Trifluoromethoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine




From DL-4-(trifluoromethoxy)phenylglycine. Off-white solid.

MS (ISP): 247.3 ($[M+H]^+$)

15

Example 13

(RS)-4-(3-Trifluoromethoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine




From DL-3-(trifluoromethoxy)phenylglycine. Off-white solid.

20 MS (ISP): 247.3 ($[M+H]^+$)

Example 14

(RS)-4-(3,4-Dichlorophenyl)-4,5-dihydro-oxazol-2-ylamine


- 46 -



From DL-3,4-dichlorophenylglycine. Off-white solid. MS (ISP): 231.1 ($[M+H]^+$)

Example 15

5 (RS)-4-(2-Methoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine




From DL-2-methoxyphenylglycine. Off-white solid.

MS (ISP): 193.4 ($[M+H]^+$)

Example 16

10 (RS)-4-(2,5-Difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




From DL-2,5-difluorophenylglycine. Off-white solid.

MS (ISP): 199.1 ($[M+H]^+$)

Example 17

15 (RS)-4-(2,3,4-Trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




From DL-2,3,4-trifluorophenylglycine. Off-white solid.

MS (ISP): 217.3 ($[M+H]^+$)

Example 18

(RS)-4-(3-Chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




From DL-3-chloro-2-fluorophenylglycine. Off-white solid.

5 MS (ISP): 215.1 ($[M+H]^+$)

Example 19

(RS)-4-(5-Chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




From DL-5-chloro-2-fluorophenylglycine. Off-white solid.

10 MS (ISP): 215.1 ($[M+H]^+$)

Example 20

(RS)-4-(4-Bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine


From DL-4-bromophenylglycine. Off-white solid. MS (ISP): 243.1 ($[M+H]^+$)

15

Example 21

(S)-4-Biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine and (R)-4-biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine

20




(RS)-4-Biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine (example 10) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 15:85) to yield (S)-4-biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine (off-white solid; MS (ISP): 239.3 ($[M+H]^+$)) and (R)-4-biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine (off-white solid; MS (ISP): 239.3 ($[M+H]^+$))

In analogy to example 1 and starting from the respective amino acid or amino acid derivative were prepared:

Example 22


10 (RS)-4-(4-Benzyloxy-phenyl)-4,5-dihydro-oxazol-2-ylamine



From (RS)-amino-(4-benzyloxy-phenyl)-acetic acid methyl ester. White solid.
MS (ISP): 269.4 ($[M+H]^+$)

Example 23

15 (RS)-4-(4-Phenoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine




From (RS)-amino-(4-phenoxy-phenyl)-acetic acid methyl ester. White solid.
MS (ISP): 255.4 ($[M+H]^+$)

Example 24

20 (RS)-4-(3-Benzyloxy-phenyl)-4,5-dihydro-oxazol-2-ylamine

- 49 -




From (RS)-amino-(3-benzyloxy-phenyl)-acetic acid methyl ester. White solid.

MS (ISP): 269.3 ($[M+H]^+$)

Example 25

5 (RS)-4-(3-Phenoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine




From (RS)-amino-(3-phenoxy-phenyl)-acetic acid methyl ester. White solid.

MS (ISP): 255.4 ($[M+H]^+$)

Example 26

10 (S)-4-Methyl-4-phenyl-4,5-dihydro-oxazol-2-ylamine and (R)-4-methyl-4-phenyl-4,5-dihydro-oxazol-2-ylamine




(RS)-4-Methyl-4-phenyl-4,5-dihydro-oxazol-2-ylamine (example 1) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 15:85) to yield (S)-4-methyl-4-phenyl-4,5-dihydro-oxazol-2-ylamine (off-white solid; MS (ISP): 177.3 ($[M+H]^+$)) and (R)-4-methyl-4-phenyl-4,5-dihydro-oxazol-2-ylamine (off-white solid; MS (ISP): 177.4 ($[M+H]^+$)).

In analogy to example 1 and starting from the respective amino acid or amino acid derivative were prepared:

Example 27

(RS)-4-Biphenyl-3-yl-4,5-dihydro-oxazol-2-ylamine

- 50 -




From (RS)-amino-biphenyl-3-yl-acetic acid. Off-white solid.

MS (ISP): 239.1 ($[M+H]^+$)

Example 28

5 (RS)-4-Ethyl-4-phenyl-4,5-dihydro-oxazol-2-ylamine




From (RS)-2-amino-2-phenylbutyric acid. Off-white solid.

MS (ISP): 191.3 ($[M+H]^+$)


Example 29

10

(S)-4-(3-Bromo-2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine and (R)-4-(3-bromo-2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine



and



a) (RS)- 4-(3-Bromo-2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

- 15 A solution of lithium diisopropylamide in THF (2 M, 5.05 ml) was cooled to -55°C and treated with (RS)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (667 mg, example 7) in THF (6 ml). The reaction mixture was stirred at -55°C for 2 hrs, then treated dropwise with 1,2-dibromoethane (0.58 ml). The reaction mixture was warmed to r.t., then stirred overnight at r.t. It was quenched with H₂O and extracted with EtOAc.
- 20 The organic layer was dried over MgSO₄, filtrated and concentrated. The crude product was purified by column chromatography (SiO₂; gradient: CH₂Cl₂ -> CH₂Cl₂/MeOH 95:5) to give (RS)-4-(3-bromo-2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (61 mg) as light yellow solid.

MS (ISP): 279.1 ($[M+H]^+$)


b) (S)-4-(3-Bromo-2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine and (R)-4-(3-bromo-2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

- 5 (RS)-4-(3-Bromo-2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 10:90) to yield (S)-4-(3-bromo-2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (off-white solid; MS (ISP): 279.1 ($[M+H]^+$)) and (R)-4-(3-bromo-2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (off-white solid; MS (ISP): 279.1 ($[M+H]^+$))

10

Example 30

(RS)-4-(4'-Fluoro-biphenyl-4-yl)-4,5-dihydro-oxazol-2-ylamine




- To a stirred solution of (RS)-4-(4-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine (80 mg; example 20) at r.t. in 1,2-dimethoxyethane (4 ml) under an argon atmosphere were added PdCl₂(dppf) (24 mg), 10 % aq. Na₂CO₃ (1 ml) and 4-fluorophenylboronic acid (186 mg). The mixture was heated to 85°C and stirring at that temperature was continued for 18 h. The dark brown mixture was cooled to r.t., diluted with EtOAc and washed with H₂O. The aqueous phase was back extracted with EtOAc. The combined organics were washed with H₂O and brine, dried over MgSO₄, filtered and concentrated. The crude product was purified by column chromatography (SiO₂; gradient: CH₂Cl₂ -> CH₂Cl₂/MeOH 9:1) to give (RS)-4-(4'-fluoro-biphenyl-4-yl)-4,5-dihydro-oxazol-2-ylamine (46 mg) as off-white solid. MS (ISP): 257.0 ($[M+H]^+$)

25

Example 31

(RS)-4-(4'-Chloro-biphenyl-4-yl)-4,5-dihydro-oxazol-2-ylamine




- In analogy to example 30, (RS)-4-(4-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine was reacted with 4-chlorophenylboronic acid to give (RS)-4-(4'-chloro-biphenyl-4-yl)-4,5-dihydro-oxazol-2-ylamine. Off-white solid. MS (ISP): 273.1 ($[M+H]^+$)

30

In analogy to example 1 and starting from the respective amino acid or amino acid derivative were prepared:

Example 32

(RS)-4-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-4,5-dihydro-oxazol-2-ylamine




5

From (RS)-amino-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-acetic acid. Off-white solid.

MS (ISP): 221.1 ($[M+H]^+$)

Example 33

(RS)-4-Naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine




10

From (RS)-amino-naphtalen-2-yl-acetic acid. Light yellow solid.

MS (ISP): 213.1 ($[M+H]^+$)

Example 34

(RS)-4-Naphthalen-1-yl-4,5-dihydro-oxazol-2-ylamine




15

From (RS)-amino-naphtalen-1-yl-acetic acid. Light yellow solid.

MS (ISP): 213.1 ($[M+H]^+$)

Example 35

(RS)-4-(4-Methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




20

From (RS)-amino-(4-methoxy-3-methylphenyl)-acetic acid. Off-white solid.

MS (ISP): 207.1 ($[M+H]^+$)

Example 36

(RS)-4-(3-Chloro-4-methoxyphenyl)-4,5-dihydro-oxazol-2-ylamine




From (RS)-amino-(3-chloro-4-methoxyphenyl) acetic acid. Off-white solid.

5 MS (ISP): 227.3 ($[M+H]^+$)

Example 37


(S)-4-(2,4-Difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine and (R)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine



10 (RS)-4-(2,4-Difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 7) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 10:90) to yield (S)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (light yellow solid; MS (ISP): 199.1 ($[M+H]^+$)) and (R)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (off-white solid; MS (ISP): 199.1 ($[M+H]^+$))

15

Example 38


(S)-4-(2,4-Difluoro-3- $[^3H]$ -phenyl)-4,5-dihydro-oxazol-2-ylamine

A solution of (S)-4-(3-bromo-2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (3.5 mg; example 29.b) in EtOAc (1 ml) was treated with 1.2 mg of 10% palladium on charcoal (1.2 mg) and triethylamine (20 μ ml) was stirred for 1h at room temperature under tritium gas. The volatiles were removed by vacuum transfer and 5 ml of ethanol/water 9:1 were added in three portions to the reaction flask. After brief stirring the volatiles were removed by vacuum transfer. The reaction flask was removed from the tritiation apparatus and the residue was suspended in ethanol. The suspension was
20 filtered through a 0.45 μ m PTFE filter cartouche ($\varnothing$ = 13 mm) and the filter was rinsed 5x
25

with ethanol, the filtrate was evaporated to about 0.5 ml and then partitioned between dichloromethane and water plus 10% sodium carbonate. After a second extraction with dichloromethane the organic phase was dried over potassium carbonate. Filtration, evaporation, dissolution in toluene and evaporation to remove residual triethylamin
5 furnished the crude product, which was dissolved in 50 ml of ethanol. The total activity was 229 mCi. Half of the crude product was purified by HPLC (column: XTerra RP-18 5 μ m 10 x 150 mm; mobile phase: A/B = 65 : 35; A: 100 mM ammonium-carbonate pH = 10 + 5 % acetonitrile; B: acetonitrile; flow rate: 5 ml/min; UV: 220 nm). The HPLC-eluate was evaporated to about half of its volume and then partitioned between
10 dichloromethane and water plus 10 % sodium carbonate as described above. Finally the purified product was dissolved in 25 ml of ethanol. The total activity was 98.29 mCi and the radiochemical purity was 100 % and 98 % according to radio-HPLC and radio-TLC respectively. The specific activity was 17.5 Ci/mole according to mass spectrometry. The enantiomeric purity was over 99 % according to HPLC (column: Chiralpak AD 10 μ m
15 4.6 x 250 mm; mobile phase: 10 % ethanol in n-heptane; flow rate: 1 ml/min; UV: 220 nm).

Example 39

(S)-4-o-Tolyl-4,5-dihydro-oxazol-2-ylamine and (R)-4-o-tolyl-4,5-dihydro-oxazol-2-ylamine



(RS)-4-o-Tolyl-4,5-dihydro-oxazol-2-ylamine (example 8) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 10:90) to yield (S)-4-o-tolyl-4,5-dihydro-oxazol-2-ylamine (light yellow solid; MS (ISP): 177.1 ($[M+H]^+$)) and (R)-4-o-tolyl-4,5-dihydro-oxazol-2-ylamine (light yellow solid; MS (ISP): 177.1 ($[M+H]^+$))


25

In analogy to example 1 and starting from the respective amino acid or amino acid derivative were prepared:

Example 40

(RS)-4-(2,3,5-Trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

- 55 -




From 2,4,5-trifluoro-DL-phenylglycine. White solid.

MS (ISP): 217.3 ($[M+H]^+$)

Example 41

5 (RS)-4-(2-Amino-4,5-dihydro-oxazol-4-yl)-benzoic acid methyl ester




From (RS)-4-(amino-methoxycarbonyl-methyl)-benzoic acid methyl ester. White solid.

MS (ISP): 221.13 ($[M+H]^+$)

10

Example 42

(RS)-4-Thiophen-2-yl-4,5-dihydro-oxazol-2-ylamine




From DL- α -aminothiophene-2-acetic acid methyl ester hydrochloride. Off-white solid.

15 MS (ISP): 169.1 ($[M+H]^+$)

Example 43

(RS)-(4-(5-Chloro-thiophen-2-yl))-4,5-dihydro-oxazol-2-ylamine




20 From (RS)-amino-(5-chloro-thiophen-2-yl)-acetic acid methyl ester hydrochloride. Off-white solid. MS (ISP): 203.3 ($[M+H]^+$)

Example 44

(RS)-4-Pyridin-3-yl-4,5-dihydro-oxazol-2-ylamine

- 56 -




From (RS)-3-pyridyl-aminoacetic acid hydrochloride. Light yellow solid.

In analogy to example 1 and starting from the respective amino acid or amino acid derivative were prepared:

5

Example 45

(R)-4-Naphthalen-2-ylmethyl-4,5-dihydro-oxazol-2-ylamine




From (R)-2-amino-3-naphthalen-2-yl-propionic acid. Light yellow viscous oil.

MS (ISP): 227.4 ($[M+H]^+$)

10

Example 46

(R)-4-Naphthalen-1-ylmethyl-4,5-dihydro-oxazol-2-ylamine




From (R)-2-amino-3-naphthalen-1-yl-propionic acid. Light yellow viscous oil.

MS (ISP): 227.4 ($[M+H]^+$)

15

Example 47

(R)-4-Benzyl-4,5-dihydro-oxazol-2-ylamine




From D-phenylalanine. Light yellow solid.

MS (ISP): 177.1 ($[M+H]^+$)

Example 48

(S)-4-Naphthalen-1-ylmethyl-4,5-dihydro-oxazol-2-ylamine




From (S)-2-amino-3-naphthalen-1-yl-propionic acid. Off-white solid.

5 MS (ISP): 227.4 ($[M+H]^+$)

Example 49

(S)-4-Naphthalen-2-ylmethyl-4,5-dihydro-oxazol-2-ylamine




10 From (S)-2-amino-3-naphthalen-2-yl-propionic acid. Light yellow amorphous solid.

MS (ISP): 227.1 ($[M+H]^+$)


Example 50

(RS)-4-Benzyl-4-methyl-4,5-dihydro-oxazol-2-ylamine

15 From α -methyl-DL-phenylalanine. Colorless viscous oil.MS (ISP): 191.1 ($[M+H]^+$)

Example 51

(S)-4-(4-Chloro-benzyl)-4,5-dihydro-oxazol-2-ylamine




20 From L-4-chlorophenylalanine. Light yellow viscous oil.

MS (ISP): 211.1 ($[M+H]^+$)

Example 52

(S)-4-(4-Methoxy-benzyl)-4,5-dihydro-oxazol-2-ylamine




From L-4-methoxyphenylalanine. Off-white solid.

MS (ISP): 207.1 ($[M+H]^+$)

5

Example 53

(S)-4-(4-Benzyloxy-benzyl)-4,5-dihydro-oxazol-2-ylamine




From L-4-benzyloxyphenylalanine. Off-white solid.

MS (ISP): 283.3 ($[M+H]^+$)

10

Example 54

(S)-4-(3-Fluoro-benzyl)-4,5-dihydro-oxazol-2-ylamine



From L-3-fluorophenylalanine. Light yellow amorphous solid.


MS (ISP): 195.1 ($[M+H]^+$)

15

Example 55

(S)-4-(2-Fluoro-benzyl)-4,5-dihydro-oxazol-2-ylamine

- 59 -




From L-2-fluorophenylalanine. Light yellow amorphous solid.

MS (ISP): 195.1 ($[M+H]^+$)

Example 56

5 (S)-4-(2-Trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




From L-2-trifluoromethylphenylalanine. Light yellow solid.

MS (ISP): 245.1 ($[M+H]^+$)

Example 57


10 (S)-4-Benzo[1,3]dioxol-5-ylmethyl-4,5-dihydro-oxazol-2-ylamine



From (S)-2-amino-3-benzo[1,3]dioxol-5-yl-propionic acid. Light yellow amorphous solid. MS (ISP): 221.3 ($[M+H]^+$)

Example 58

15 (S)-4-(3-Methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




From L-3-methylphenylalanine. Yellow amorphous solid.

MS (ISP): 191.4 ($[M+H]^+$)

Example 59

20 (S)-4-(4-Methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

- 60 -




From L-4-methylphenylalanine. Light yellow solid.

MS (ISP): 191.4 ([M+H]⁺)

Example 60

5 (S)-4-(2-Chloro-benzyl)-4,5-dihydro-oxazol-2-ylamine




From L-2-chlorophenylalanine. Light yellow oil.

MS (ISP): 211.1 ([M+H]⁺)

Example 61

10 (S)-4-(3-Chloro-benzyl)-4,5-dihydro-oxazol-2-ylamine




From L-3-chlorophenylalanine. Light yellow oil.

MS (ISP): 210.9 ([M+H]⁺)

Example 62

15 (S)-4-(2-Methyl-benzyl)-4,5-dihydro-oxazol-2-ylamine




From L-2-methylphenylalanine. Yellow oil.

MS (ISP): 191.4 ([M+H]⁺)

Example 63

(S)-4-(3-Trifluoromethyl-benzyl)-4,5-dihydro-oxazol-2-ylamine




From L-3-trifluoromethylphenylalanine. Yellow oil.

5 MS (ISP): 245.3 ($[M+H]^+$)

Example 64

(S)-4-(4-Trifluoromethyl-benzyl)-4,5-dihydro-oxazol-2-ylamine




From L-4-trifluoromethylphenylalanine. Yellow oil.

10 MS (ISP): 245.3 ($[M+H]^+$)

Example 65

(S)-4-(4-Fluoro-benzyl)-4,5-dihydro-oxazol-2-ylamine


From L-4-fluorophenylalanine. Yellow oil. MS (ISP): 195.1 ($[M+H]^+$)

15

Example 66

(RS)-4-(2,6-Dimethyl-benzyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

- 62 -




From (RS)-2-amino-3-(2,6-dimethyl-phenyl)-2-methyl-propionic acid hydrochloride.
White solid.

MS (ISP): 219.4 ($[M+H]^+$)

5

Example 67

(S)-4-(4-tert-Butoxy-benzyl)-4,5-dihydro-oxazol-2-ylamine




From L-4-tert-butoxyphenylalanine. Light yellow solid.

MS (ISP): 249.4 ($[M+H]^+$)

10

Example 68

4-(1-Phenyl-ethyl)-4,5-dihydro-oxazol-2-ylamine




From 2-amino-3-phenylbutanoic acid hydrochloride. Off-white solid.

MS (ISP): 191.4 ($[M+H]^+$)

15

Example 69

(RS)-4-(2-Chloro-6-fluoro-benzyl)-4,5-dihydro-oxazol-2-ylamine



From DL-2-chloro-6-fluorophenylalanine. Off-white solid.


MS (ISP): 229.4 ($[M+H]^+$)

20

Example 70

(S)-4-(3,4-Difluoro-benzyl)-4,5-dihydro-oxazol-2-ylamine

- 63 -




From L-3,4-difluorophenylalanine. Off-white solid.

MS (ISP): 213.1 ($[M+H]^+$)

Example 71

5 (S)-4-(3,4-Dimethoxy-benzyl)-4,5-dihydro-oxazol-2-ylamine




From L-3,4-dimethoxyphenylalanine. Light yellow gum.

MS (ISP): 237.1 ($[M+H]^+$)

Example 72

10 (RS)-4-(2-Phenoxy-benzyl)-4,5-dihydro-oxazol-2-ylamine




From DL-2-phenoxyphenylalanine. Colorless oil.

MS (ISP): 269.4 ($[M+H]^+$)

Example 73

15 (RS)-4-(2-Fluoro-5-methyl-benzyl)-4,5-dihydro-oxazol-2-ylamine




From DL-2-fluoro-5-methylphenylalanine. Light yellow viscous oil.

MS (ISP): 209.1 ($[M+H]^+$)

Example 74

20 (RS)-4-(2,6-Difluoro-3-methyl-benzyl)-4,5-dihydro-oxazol-2-ylamine

- 64 -




From DL-2,6-difluoro-3-methylphenylalanine. Off-white solid.

MS (ISP): 227.1 ($[M+H]^+$)

Example 75

5 (RS)-4-(2-Fluoro-6-trifluoromethyl-benzyl)-4,5-dihydro-oxazol-2-ylamine




From DL-2-fluoro-6-trifluoromethylphenylalanine. Light yellow viscous oil.

MS (ISP): 263.0 ($[M+H]^+$)

Example 76

10 (RS)-4-(2,6-Dimethyl-benzyl)-4,5-dihydro-oxazol-2-ylamine




From DL-2,6-dimethylphenylalanine. White solid.

MS (ISP): 205.1 ($[M+H]^+$)

Example 77

15 (RS)-4-(2,6-Diethyl-benzyl)-4,5-dihydro-oxazol-2-ylamine




From DL-2,6-diethylphenylalanine. Off-white amorphous solid.

MS (ISP): 233.3 ($[M+H]^+$)

In analogy to example 1 and starting from the respective amino acid or amino acid
5 derivative were prepared:

Example 78

(RS)-4-Methyl-4-phenethyl-4,5-dihydro-oxazol-2-ylamine




From (RS)-2-amino-2-methyl-4-phenyl-butyric acid. Off-white solid.

10 MS (ISP): 205.1 ($[M+H]^+$)

Example 79

(S)-4-(2-Phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine



15 a) (S)-2,2-dimethyl-4-((E)-2-phenyl-propenyl)-oxazolidine-3-carboxylic acid tert-butyl ester

A solution of diethyl 1-phenylethyl phosphonate (2.35 ml) in 1,2-dimethoxyethane (15 ml) was cooled under an argon atmosphere to 0 °C and treated dropwise with an n-butyllithium solution (5.9 ml; 1.6 M in hexane). The reaction mixture was stirred for 5 min at 0 °C, then treated dropwise with a solution of (R)-4-formyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (1.5 g) in 1,2-dimethoxyethane (15 ml).
20 The solution was warmed to r.t., then refluxed overnight. After cooling to r.t., the mixture was quenched with water and extracted with EtOAc. The organic layer was dried over MgSO₄, filtrated and concentrated. The crude product was isolated by column chromatography (SiO₂; gradient: cyclohexane -> cyclohexane/EtOAc 1:1) to give (S)-2,2-dimethyl-4-((E)-2-phenyl-propenyl)-oxazolidine-3-carboxylic acid tert-butyl ester (720
25 mg) as light yellow viscous oil.

MS (ISP): 318.3 ($[M+H]^+$)

b) (S)-2-amino-4-phenyl-pentan-1-ol

A solution of (S)-2,2-dimethyl-4-((E)-2-phenyl-propenyl)-oxazolidine-3-carboxylic acid tert-butyl ester (700 mg) in EtOH (30 ml) and CHCl₃ (15 ml) was treated with 10 % Pd/C (200 mg) and hydrogenated with a balloon overnight. The catalyst was filtered off, washed with EtOH and concentrated. The residue was dissolved in EtOH (10 ml) and treated with 2N HCl (15 ml). The mixture was heated for 90 min to 100°C, then concentrated. The residue was taken up in 1N NaOH and extracted with CH₂Cl₂/MeOH 4:1. The organic layer was dried over MgSO₄, filtrated and concentrated. The crude product was purified by column chromatography (SiO₂; gradient: CH₂Cl₂ -> CH₂Cl₂/MeOH 9:1) to give (S)-2-amino-4-phenyl-pentan-1-ol (342 mg) as off-white waxy solid.

MS (ISP): 180.3 ([M+H]⁺)


c) (S)-4-(2-Phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine

In analogy to example 1b (S)-2-amino-4-phenyl-pentan-1-ol was reacted with cyanogen bromide to give (S)-4-(2-phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine. Off-white waxy solid.

MS (ISP): 205.1 ([M+H]⁺)

Example 80

(S)-4-Phenethyl-4,5-dihydro-oxazol-2-ylamine and (R)-4-phenethyl-4,5-dihydro-oxazol-2-ylamine




(RS)-4-Phenethyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 15:85) to yield (S)-4-phenethyl-4,5-dihydro-oxazol-2-ylamine (off-white solid; MS (ISP): 191.3 ([M+H]⁺)) and (R)-4-phenethyl-4,5-dihydro-oxazol-2-ylamine (off-white solid; MS (ISP): 191.3 ([M+H]⁺))

30

Example 81


(S)-4-Methyl-4-phenethyl-4,5-dihydro-oxazol-2-ylamine and (R)-4-methyl-4-phenethyl-4,5-dihydro-oxazol-2-ylamine



(RS)-4-Methyl-4-phenethyl-4,5-dihydro-oxazol-2-ylamine (example 75) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 10:90) to yield (S)-4-methyl-4-phenethyl-4,5-dihydro-oxazol-2-ylamine (off-white solid; MS (ISP): 205.3 ($[M+H]^+$)) and (R)-4-methyl-4-phenethyl-4,5-dihydro-oxazol-2-ylamine (off-white solid; MS (ISP): 205.1 ($[M+H]^+$))

Example 82

(S)-4-((R)-2-Phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine and (S)-4-((S)-2-phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine




10

(S)-4-(2-Phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine (example 79.c) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 15:85) to yield (S)-4-((R)-2-phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine (off-white solid; MS (ISP): 205.1 ($[M+H]^+$)) and (R)-4-((S)-2-phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine (off-white solid; MS (ISP): 205.3 ($[M+H]^+$))

15

Example 83

(R)-4-[2-(4-Fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine



a) (S)-4-(Benzothiazol-2-ylsulfanyl-methyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid
tert-butyl ester

20

To a stirred, cooled (0°C) solution of (R)-4-hydroxymethyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (1.36 g; CAS 108149-65-1), 2-mercaptobenzothiazole (1.48 g) and triphenylphosphine (2.32 g) in THF (80 ml) under an argon atmosphere was added diethyl azodicarboxylate (4.1 ml; 40% solution in toluene). The mixture (soon
5 turning to a yellow suspension, slowly warming up to r.t.) was stirred for 18 h overnight, then diluted with EtOAc and washed with sat. aq. Na₂CO₃. The aqueous phase was back extracted with EtOAc. The combined organics were washed with brine, dried over MgSO₄, filtered and concentrated. The crude product was purified by column chromatography (SiO₂; gradient: cyclohexane -> cyclohexane/EtOAc 85:15) to give (S)-4-
10 (benzothiazol-2-ylsulfanyl-methyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (2.0 g) as light yellow viscous oil.

b) (S)-4-(Benzothiazole-2-sulfonylmethyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester

15 To a stirred solution of (S)-4-(benzothiazol-2-ylsulfanyl-methyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (2.0 g) at 0°C in dichloromethane (80 ml) under an argon atmosphere was added 3-chloroperbenzoic acid (2.29 g) in one portion. The mixture (slowly warming up to r.t.) was stirred overnight. The mixture was washed with 10 % aq. sodium bisulfite (80 ml), sat. aq. Na₂CO₃ and brine, dried over MgSO₄,
20 filtered and concentrated. The crude product was isolated by column chromatography (SiO₂; gradient: cyclohexane -> cyclohexane/EtOAc 3:2) to give (S)-4-(benzothiazole-2-sulfonylmethyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (1.64 g) as white solid. MS (ISP): 413.3 ([M+H]⁺)

25 c) ((R)-4-[(E)-2-(4-Fluoro-phenyl)-vinyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester

To a stirred, cooled (-78°C) solution of (S)-4-(benzothiazole-2-sulfonylmethyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (0.484 mg) in THF (12 ml) under an argon atmosphere was added slowly a 1 M solution of LiHMDS in THF (1.1 ml). The
30 mixture was warmed to -40°C and stirring at that temperature was continued for 30 min. The mixture was cooled again to -78°C and a solution of 4-fluorobenzaldehyde (0.112 g) in THF (3 ml) was then added slowly via a syringe. Stirring at -78°C was continued for 2 h, and then the reaction mixture was slowly allowed to warm to 0°C. The mixture was quenched by the addition of sat. aq. NH₄Cl (15 ml) and H₂O (15 ml) and extracted with
35 EtOAc. The aqueous phase was back extracted with EtOAc. The combined organics were

washed with brine, dried over MgSO_4 , filtered and concentrated. The crude product was purified by column chromatography (SiO_2 ; gradient: cyclohexane $\rightarrow$ cyclohexane/EtOAc 85:15) to give (R)-4-[(E)-2-(4-fluoro-phenyl)-vinyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (0.201 g) as colorless viscous oil. MS (ISP): 322.4

5 ([M+H]⁺)

d) (R)-4-[2-(4-Fluoro-phenyl)-ethyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester

To a stirred solution of (R)-4-[(E)-2-(4-fluoro-phenyl)-vinyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (0.205 g) at r.t. in ethanol (5 ml) under an argon atmosphere was added 10 % Pd/C (20 mg). The mixture was stirred at r.t. under a hydrogen atmosphere for 3 hrs. The catalyst was filtered off and the filtrate was concentrated to give (R)-4-[2-(4-fluoro-phenyl)-ethyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (0.195 g) as light brown viscous oil. MS (ISP): 324.5

15 ([M+H]⁺)

e) (R)-2-Amino-4-(4-fluoro-phenyl)-butan-1-ol

To a stirred solution of (R)-4-[2-(4-fluoro-phenyl)-ethyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (190 mg) at r.t. in dioxane (3.5 ml) under an argon atmosphere was added 4 M HCl solution in dioxane (1.47 ml). The mixture was stirred for 16 h. The mixture was concentrated. The crude product was purified by column chromatography (SiO_2 ; gradient: $\text{CH}_2\text{Cl}_2 \rightarrow \text{CH}_2\text{Cl}_2/\text{MeOH}$ 9:1) to give (R)-2-amino-4-(4-fluoro-phenyl)-butan-1-ol (78 mg) as off-white solid. MS (ISP): 184.1 ([M+H]⁺)

25 f) (R)-4-[2-(4-Fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine


In analogy to example 1b (R)-2-amino-4-(4-fluoro-phenyl)-butan-1-ol was reacted with cyanogen bromide to give (R)-4-[2-(4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine. White solid. MS (ISP): 209.3 ([M+H]⁺)

30 In analogy to example 1 and starting from the respective amino acid or amino acid derivative was prepared:

Example 84

(RS)-4-(1,2,3,4-Tetrahydro-naphthalen-2-yl)-4,5-dihydro-oxazol-2-ylamine

- 70 -




From (RS)-amino-(1,2,3,4-tetrahydro-naphthalen-2-yl)-acetic acid. Off-white solid.

MS (ISP): 217.3 ($[M+H]^+$)

- 5 In analogy to example 83, starting from (S)-4-hydroxymethyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester and using the respective benzaldehyde were prepared:

Example 85

(S)-4-[2-(4-Fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




10

From 4-fluorobenzaldehyde. White solid. MS (ISP): 209.3 ($[M+H]^+$)

Example 86

(S)-4-[2-(4-Fluoro-3-methoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




15

From 4-fluoro-3-methoxybenzaldehyde. Off-white solid. MS (ISP): 239.3 ($[M+H]^+$)

Example 87

(R)-4-Phenoxymethyl-4,5-dihydro-oxazol-2-ylamine

- 71 -



a) (R)-2,2-Dimethyl-4-phenoxymethyl-oxazolidine-3-carboxylic acid tert-butyl ester

To a stirred solution of tert-butyl (R)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylate (400 mg; CAS 108149-63-9) in THF (20 ml) were added phenol
 5 (197 mg), triphenylphosphine (573 mg) and di-tert-butyl azodicarboxylate (488 mg). The resulting yellow solution was stirred at 70 °C for 18 h overnight, then concentrated in vacuo. The crude product was purified by column chromatography (SiO₂; gradient: heptane/EtOAc 100:0 -> 70:30) to give (R)-2,2-dimethyl-4-phenoxymethyl-oxazolidine-3-carboxylic acid tert-butyl ester (336 mg, 63%) as a colourless viscous oil. MS (ISP):
 10 308.3 ([M+H]⁺)).

b) (S)-2-Amino-3-phenoxy-propan-1-ol

To a stirred solution of (R)-2,2-dimethyl-4-phenoxymethyl-oxazolidine-3-carboxylic acid tert-butyl ester (300 mg) at r.t. in dioxane (5 ml) under an argon atmosphere was
 15 added 4 M HCl solution in dioxane (2.44 ml). The mixture was stirred for 16 h. The mixture was concentrated. The residue was resuspended in saturated aq sodium carbonate solution and the mixture was extracted twice with ethyl acetate. The combined organic phases were dried over sodium sulphate and concentrated in vacuo. The crude product was purified by column chromatography (SiO₂; gradient: CH₂Cl₂ ->
 20 CH₂Cl₂/MeOH 9:1) to give (S)-2-amino-3-phenoxy-propan-1-ol (108 mg, 66%) as a white solid. MS (ISP): 168.3 ([M+H]⁺)).

c) (R)-4-Phenoxymethyl-4,5-dihydro-oxazol-2-ylamine


In analogy to example 1b (S)-2-amino-3-phenoxy-propan-1-ol was reacted with
 25 cyanogen bromide to give (R)-4-phenoxymethyl-4,5-dihydro-oxazol-2-ylamine. Colourless gum. MS (ISP): 193.1 ([M+H]⁺))

In analogy to example 83, starting from (S)-4-hydroxymethyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester and using the respective benzaldehyde were prepared:

30

Example 88

((S)-4-[2-(2,4-Difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




From 2,4-difluoro-benzaldehyde. Off-white solid. MS (ISP): 227.1 ($[M+H]^+$)

5

Example 89

(S)-4-[2-(3,4-Difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




From 3,4-difluoro-benzaldehyde. Off-white solid. MS (ISP): 227.1 ($[M+H]^+$)

10

Example 90

(R)-4-(3,4-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(3,4-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 14) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 20:80) to give (R)-4-(3,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. Off-white solid. MS (ISP): 231.1 ($[M+H]^+$)

15

Example 91

(S)-4-(3,4-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine

- 73 -




(RS)-4-(3,4-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 14) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 20:80) to give (S)-4-(3,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Off-white solid. MS (ISP):

5 231.1 ($[M+H]^+$)

Example 92

(RS)-4-(3-Cyclohexylamino-phenyl)-4,5-dihydro-oxazol-2-ylamine



a) (RS)-tert-Butoxycarbonylamino-(3-cyclohexylamino-phenyl)-acetic acid methyl ester

10 A solution of (3-amino-phenyl)-tert-butoxycarbonylamino-acetic acid methyl ester (165 mg, CAS 180081-34-9) in MeOH (5 ml) was treated under an argon atmosphere with cyclohexanone (0.07 ml), zinc chloride (321 mg) and NaBH_3CN (111 mg) and stirred overnight at 40°C. The MeOH was distilled off. The residue was taken up in EtOAc and H_2O . The aqueous phase was back extracted with EtOAc. The combined organics were
15 washed with water, dried over MgSO_4 , filtered and concentrated. The crude product was purified by column chromatography (silica gel; gradient: cyclohexane -> cyclohexane/EtOAc 14:1) to give (RS)-tert-butoxycarbonylamino-(3-cyclohexylamino-phenyl)-acetic acid methyl ester (200 mg, 94%) as viscous colorless oil.
MS (ISP): 363.4 ($[M+H]^+$)

20

b) (RS)-Amino-(3-cyclohexylamino-phenyl)-acetic acid methyl ester

A solution of (RS)-tert-butoxycarbonylamino-(3-cyclohexylamino-phenyl)-acetic acid methyl ester (200 mg) in dioxane (5 ml) was treated with 4M HCl in dioxane (2.76 ml) and stirred at r.t. overnight, then concentrated. The crude product was purified by
25 column chromatography (silica gel; gradient: CH_2Cl_2 -> $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 9:1) to give (RS)-

amino-(3-cyclohexylamino-phenyl)-acetic acid methyl ester (126 mg, 87%) as light yellow viscous oil.

MS (ISP): 263.0 ($[M+H]^+$)

5 c) (RS)-2-Amino-2-(3-cyclohexylamino-phenyl)-ethanol

A solution of (RS)-amino-(3-cyclohexylamino-phenyl)-acetic acid methyl ester (120 mg) in THF (1 ml) was treated under an argon atmosphere with lithium chloride (78 mg), sodium borohydride (68 mg) and EtOH (1.8 ml) and stirred at r.t. overnight. The mixture was filtrated. The residue was washed with EtOH. The filtrate was concentrated.

10 The residue was taken up in CH_2Cl_2 . The solids were removed by filtration. The filtrate was concentrated. The crude product was isolated by column chromatography (silica gel; gradient: $CH_2Cl_2 \rightarrow CH_2Cl_2/MeOH$ 9:1) to give (RS)-2-amino-2-(3-cyclohexylamino-phenyl)-ethanol (87 mg, 65%) as colorless viscous oil.

MS (ISP): 235.3 ($[M+H]^+$)

15

d) (RS)-4-(3-Cyclohexylamino-phenyl)-4,5-dihydro-oxazol-2-ylamine


In analogy to example 1.b (RS)-2-amino-2-(3-cyclohexylamino-phenyl)-ethanol was converted to the title compound. Colorless viscous oil.

MS (ISP): 235.3 ($[M+H]^+$)

20

Example 93

(R)-4-[2-(3,5-Difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




In analogy to example 83, the title compound was prepared starting from (R)-4-hydroxymethyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester and 3,5-difluorobenzaldehyde. Off-white solid. MS (ISP): 227.4 ($[M+H]^+$)

25

Example 94

(RS)-4-[3-(Tetrahydro-pyran-4-yloxy)-phenyl]-4,5-dihydro-oxazol-2-ylamine

- 75 -



a) (RS)-(tert-Butoxycarbonylamino-[3-(tetrahydro-pyran-4-yloxy)-phenyl]-acetic acid methyl ester

- A solution of (RS)-tert-butoxycarbonylamino-(3-hydroxy-phenyl)-acetic acid methyl ester (CAS 526217-60-7) in THF (10 ml) was treated under an argon atmosphere with tetrahydro-pyran-4-ol (0.24 ml), triphenylphosphine (649 mg) and di-tert-butyl azodicarboxylate (570 mg) and stirred at r.t. overnight. The reaction mixture was concentrated. The crude product was purified by column chromatography (silical gel; gradient: cyclohexane -> cyclohexane/EtOAc 1:1) to give (RS)-tert-butoxycarbonylamino-[3-(tetrahydro-pyran-4-yloxy)-phenyl]-acetic acid methyl ester (884 mg, 82%) as viscous light yellow oil.
- MS (ISP): 366.3 ([M+H]⁺)


b) (RS)-4-[3-(Tetrahydro-pyran-4-yloxy)-phenyl]-4,5-dihydro-oxazol-2-ylamine

- In analogy to examples 92.b, 1.a and 92.d, (RS)-tert-butoxycarbonylamino-[3-(tetrahydro-pyran-4-yloxy)-phenyl]-acetic acid methyl ester was converted to the title compound. Light yellow solid.
- MS (ISP): 263.0 ([M+H]⁺)
- In analogy to example 87 were prepared:

20

Example 95

(R)-4-(4-Chloro-phenoxy-methyl)-4,5-dihydro-oxazol-2-ylamine




- From tert-butyl (R)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylate and 4-chlorophenol. White solid.

MS (ISP): 229.2 ([³⁷Cl]M+H)⁺, 227.2 ([³⁵Cl]M+H)⁺.

Example 96

(R)-4-(4-Trifluoromethyl-phenoxy)methyl-4,5-dihydro-oxazol-2-ylamine




- 5 From tert-butyl (R)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylate and 4-(trifluoromethyl)-phenol. White solid.

MS (ISP): 261.0 ($[M+H]^+$).

Example 97

(R)-4-(4-Fluoro-phenoxy)methyl-4,5-dihydro-oxazol-2-ylamine




10

- From tert-butyl (R)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylate and 4-fluorophenol. White solid.

MS (ISP): 211.1 ($[M+H]^+$).

Example 98

(R)-4-(4-Bromo-phenoxy)methyl-4,5-dihydro-oxazol-2-ylamine



15


- From tert-butyl (R)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylate and 4-bromophenol. White solid.

MS (ISP): 273.0 ($[^{81}\text{Br}]M+H^+$), 271.0 ($[^{79}\text{Br}]M+H^+$).

20

Example 99

(RS)-4-[4-(2-Methoxy-ethoxy)-phenyl]-4,5-dihydro-oxazol-2-ylamine



a) (RS)-tert-Butoxycarbonylamino-[4-(2-methoxy-ethoxy)-phenyl]-acetic acid methyl ester

A solution of (RS)-tert-butoxycarbonylamino-(4-hydroxy-phenyl)-acetic acid methyl ester (500 mg, CAS 143323-49-3) in DMF (4 ml) was treated under an argon atmosphere with 2-bromoethyl methyl ether (0.34 ml), cesium carbonate (695 mg) and tetrabutylammonium iodide (66 mg) and stirred at r.t. overnight. Then it was quenched with H₂O and extracted with EtOAc. The organics were washed with water, dried over MgSO₄, filtrated and concentrated. The crude product was purified by column chromatography (silica gel; gradient: cyclohexane -> cyclohexane/EtOAc 4:1) to give (RS)-tert-butoxycarbonylamino-[4-(2-methoxy-ethoxy)-phenyl]-acetic acid methyl ester (434 mg, 72%) as viscous colorless oil.

MS (ISP): 340.4 ([M+H]⁺)


b) (RS)-4-[4-(2-Methoxy-ethoxy)-phenyl]-4,5-dihydro-oxazol-2-ylamine

In analogy to examples 92.b, 1.a and 92.d, (RS)-tert-butoxycarbonylamino-[4-(2-methoxy-ethoxy)-phenyl]-acetic acid methyl ester was converted to the title compound. White solid.

MS (ISP): 237.1 ([M+H]⁺)

Example 100

(R)-4-(2,5-Difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(2,5-Difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 16) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 15:85) to give (R)-4-(2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. Light yellow solid.
MS (ISP): 199.1 ($[M+H]^+$)

5

Example 101

(S)-4-(2,5-Difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(2,5-Difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 16) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 15:85) to give (S)-4-(2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Light yellow solid.
MS (ISP): 199.1 ($[M+H]^+$)

10

Example 102

(R)-4-Naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine




(RS)-4-Naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine (example 33) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 20:80) to give (R)-4-naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Off-white solid. MS (ISP): 213.3 ($[M+H]^+$)

15

Example 103

(S)-4-Naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine




20

(RS)-4-Naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine (example 33) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 20:80) to give (S)-4-naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. Off-white solid. MS (ISP): 213.3 ($[M+H]^+$)

25

Example 104


(R)-4-(4-Bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine



(RS)-4-(4-Bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 20) was separated by
5 chiral HPLC (Chiralpak AD, EtOH/heptane = 20:80) to give (R)-4-(4-bromo-phenyl)-
4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. Off-white solid. MS (ISP): 241.1
([M+H]⁺)

Example 105

(S)-4-(4-Bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine




10

(RS)-4-(4-Bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 20) was separated by
chiral HPLC (Chiralpak AD, EtOH/heptane = 20:80) to give (S)-4-(4-bromo-phenyl)-
4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Off-white solid.
MS (ISP): 241.1 ([M+H]⁺)

15

Example 106

(R)-4-(2,4,5-Trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine



a) (RS)-4-(2,4,5-Trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine


In analogy to example 1, the title compound was obtained from 2,4,5-trifluoro-DL-
20 phenylglycine. Off-white solid.
MS (ISP): 217.1 ([M+H]⁺)

b) ((R)-4-(2,4,5-Trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(2,4,5-Trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 20) was separated by chiral HPLC (Chiralpak AD, isopropanol/heptane = 10:90) to give (R)-4-(2,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. White solid. MS (ISP): 217.1 ($[M+H]^+$)

Example 107


(S)-4-(2,4,5-Trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine



(RS)-4-(2,4,5-Trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 106) was separated by chiral HPLC (Chiralpak AD, isopropanol/heptane = 10:90) to give (S)-4-(2,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. White solid. MS (ISP): 217.4 ($[M+H]^+$)

Example 108

(R)-4-(3-Chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(3-Chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 18) was separated by chiral HPLC (Chiralpak AD, isopropanol/heptane = 1:9) to give (R)-4-(3-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. Off-white solid.

MS (ISP): 215.3 ($[M+H]^+$)

Example 109

(S)-4-(3-Chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

- 81 -




(RS)-4-(3-Chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 18) was separated by chiral HPLC (Chiralpak AD, isopropanol/heptane = 1:9) to give (S)-4-(3-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Off-white solid.

MS (ISP): 215.1 ($[M+H]^+$)

In analogy to example 83, starting from (S)-4-hydroxymethyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester and using the respective benzaldehyde were prepared:

Example 110


(S)-4-[2-(2-Trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine



From 2-trifluoromethylbenzaldehyde. White solid. MS (ISP): 259.0 ($[M+H]^+$)

Example 111


(S)-4-[2-(2-Fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine



From 2-fluorobenzaldehyde. White solid. MS (ISP): 209.3 ($[M+H]^+$)

Example 112

(S)-4-[2-(3-Fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




From 3-fluorobenzaldehyde. White solid. MS (ISP): 209.1 ($[M+H]^+$)

5

Example 113

(S)-4-[2-(3,5-Difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




From 3,5-difluorobenzaldehyde. White solid. MS (ISP): 227.1 ($[M+H]^+$)

10

Example 114

(S)-4-(2-o-Tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine




From o-tolylaldehyde. Off-white solid. MS (ISP): 205.3 ($[M+H]^+$)

15

Example 115

(S)-4-(2-m-Tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine

- 83 -




From m-tolylaldehyde. Off-white solid. MS (ISP): 205.3 ($[M+H]^+$)

Example 116

5

(S)-4-(2-p-Tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine




From p-tolylaldehyde. Off-white solid. MS (ISP): 205.3 ($[M+H]^+$)

Example 117

10

(R)-4-(2,3,5-Trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine



(RS)-4-(2,3,5-Trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 40) was separated by chiral HPLC (Chiralpak AD, isopropanol/heptane = 10:90) to give (R)-4-(2,3,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. Off-white solid.


15

MS (ISP): 217.4 ($[M+H]^+$)

Example 118

(S)-4-(2,3,5-Trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

- 84 -




(RS)-4-(2,3,5-Trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 40) was separated by chiral HPLC (Chiralpak AD, isopropanol/heptane = 10:90) to give (S)-4-(2,3,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Off-white solid.

MS (ISP): 217.4 ([M+H]⁺)

In analogy to example 83, starting from (S)-4-hydroxymethyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester and using the respective benzaldehyde were prepared:

Example 119


(S)-4-[2-(4-Trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine



From 4-trifluoromethylbenzaldehyde. Off-white solid. MS (ISP): 259.1 ([M+H]⁺)

Example 120


(S)-4-[2-(3-Trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine



From 3-trifluoromethylbenzaldehyde. White solid. MS (ISP): 259.1 ($[M+H]^+$)

Example 121

(R)-4-(2-Trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




5

(RS)-4-(2-Trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 40) was separated by chiral HPLC (Chiralpak AD, isopropanol/heptane = 5:95) to give (R)-4-(2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. Off-white solid.

10 MS (ISP): 231.4 ($[M+H]^+$)

Example 122

(S)-4-(2-Trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine



(RS)-4-(2-Trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 40) was separated by chiral HPLC (Chiralpak AD, isopropanol/heptane = 5:95) to give (S)-4-(2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Off-white solid.

15

MS (ISP): 231.4 ($[M+H]^+$)


In analogy to example 87 was prepared:

20

Example 123

(R)-4-p-Tolyloxymethyl-4,5-dihydro-oxazol-2-ylamine

- 86 -




From tert-butyl (R)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylate and 4-methylphenol. White solid.

MS (ISP): 207.1 ($[M+H]^+$).

- 5 In analogy to example 83, starting from the respective benzaldehyde was prepared:

Example 124


(R)-4-[2-(3,4-Dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine



- 10 From 3,4-dichlorobenzaldehyde. Colorless gum. MS (ISP): 259.0 ($[M+H]^+$)
In analogy to example 1 and starting from the respective amino acid were prepared:

Example 125


(S)-4-Biphenyl-4-ylmethyl-4,5-dihydro-oxazol-2-ylamine



- 15 From (S)-2-amino-3-phenyl-propionic acid. Off-white solid. MS (ISP): 253.1 ($[M+H]^+$)

Example 126

(S)-4-(4-Fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine



a) ((RS)-4-(4-Fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

In analogy to example 1, the title compound was obtained from 2-(4-fluorophenyl)alanine. White solid.

MS (ISP): 195.3 ([M+H]⁺)

b) (S)-4-(4-Fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine


(RS)-4-(4-Fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 2:8) to give (S)-4-(4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Off-white solid.

MS (ISP): 195.3 ([M+H]⁺)

In analogy to example 83 and starting from (S)-4-hydroxymethyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester and the respective benzaldehyde was prepared:

Example 127

(S)-4-[2-(3,4-Dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




From 3,4-dichlorobenzaldehyde. Viscous colorless oil. MS (ISP): 259.0 ([M+H]⁺)

Example 128

(R)-4-(4-Methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

- 88 -




(RS)-4-(4-Methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 35) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 20:80) to give (R)-4-(4-methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. Off-white solid.

MS (ISP): 206.9 ($[M+H]^+$)

Example 129

(S)-4-(4-Methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(4-Methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 35) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 20:80) to give (S)-4-(4-methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Off-white solid.

MS (ISP): 207.1 ($[M+H]^+$)

Example 130

(R)-4-(3-Chloro-4-methoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(3-Chloro-4-methoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 36) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 20:80) to give (R)-4-(3-

chloro-4-methoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. Off-white solid.

MS (ISP): 227.1 ($[M+H]^+$)

Example 131

5 (S)-4-(3-Chloro-4-methoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(3-Chloro-4-methoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 36) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 20:80) to give (S)-4-(3-chloro-4-methoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Off-white solid.

MS (ISP): 227.1 ($[M+H]^+$)

In analogy to example 83, starting from (S)-4-hydroxymethyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester and using the respective benzaldehyde were prepared:

Example 132

(S)-4-[2-(4-Chloro-2-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




From 4-chloro-2-fluorobenzaldehyde. White solid. MS (ISP): 243.3 ($[M+H]^+$)

Example 133

(S)-4-[2-(4-Fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine


- 90 -



From 4-fluoro-3-trifluoromethyl-benzaldehyde. Off-white solid. MS (ISP): 277.0
 ([M+H]⁺)

Example 134

5 (R)-4-(3,4-Dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine



a) (RS)- 2-Amino-2-(3,4-dichloro-phenyl)-propionic acid hydrochloride

A solution of 5-(3,4-dichloro-phenyl)-5-methyl-imidazolidine-2,4-dione (3.0 g; CAS
 52715-57-8) in 3N NaOH (30 ml) was refluxed overnight. The reaction mixture was
 10 cooled to 0°, then brought to pH 1 by dropwise addition of concentrated HCl. The
 resulting white slurry was filtered. The solid was washed extensively with H₂O, dried in
 the vacuum, resuspended in EtOH (25 ml), collected by filtration, washed with EtOH and
 diethylether and dried in the vacuum to give (RS)-2-amino-2-(3,4-dichloro-phenyl)-
 propionic acid hydrochloride (1.35 g, 27%) as off white solid.

15 MS (ISP): 266.9 ([M+Na]⁺)

b) (RS)-4-(3,4-Dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

In analogy to example 1 (RS)-2-amino-2-(3,4-dichloro-phenyl)-propionic acid
 hydrochloride was converted to the title compound. Off-white solid.


20 MS (ISP): 244.9 ([M+H]⁺)

c) (R)-4-(3,4-Dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

((RS)-4-(3,4-Dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine was separated by
 chiral HPLC (Chiralpak AD, EtOH/heptane = 15:85) to give (R)-4-(3,4-dichloro-
 25 phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. Off-white solid.
 MS (ISP): 245.3 ([M+H]⁺)

Example 135


(S)-4-(3,4-Dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine



- 5 ((RS)-4-(3,4-Dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 15:85) to give (S)-4-(3,4-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Off-white solid.
MS (ISP): 245.3 ([M+H]⁺)

Example 136

10 (S)-4-(4-Chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine




- In analogy to example 126 (RS)-2-amino-2-(4-chloro-phenyl)-propionic acid was converted to (RS)-4-(4-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine which was subsequently separated by chiral HPLC (Chiralpak AD, EtOH/heptane 15:85) to give
15 (S)-4-(4-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. Off-white solid.
MS (ISP): 211.1 ([M+H]⁺)

In analogy to example 83, starting from (S)-4-hydroxymethyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester and using the respective benzaldehyde were prepared:

20

Example 137


(S)-4-[2-(3-Fluoro-4-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine



From 3-fluoro-4-trifluoromethyl-benzaldehyde. Off-white solid. MS (ISP): 277.0
([M+H]⁺)

Example 138

(S)-4-[2-(3,5-Dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




5

From 3,5-dichloro-benzaldehyde. Light yellow solid. MS (ISP): 259.0 ([M+H]⁺)

Example 139

(S)-4-[2-(2-Chloro-4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




10

From 2-chloro-4-fluoro-benzaldehyde. Off-white solid. MS (ISP): 243.3 ([M+H]⁺)

Example 140

(S)-4-[2-(4-Fluoro-3-methyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




15

From 4-fluoro-3-methyl-benzaldehyde. White solid. MS (ISP): 223.3 ([M+H]⁺)

Example 141

(S)-4-{2-[3-(1,1,2,2-Tetrafluoro-ethoxy)-phenyl]-ethyl}-4,5-dihydro-oxazol-2-ylamine




From 3-(1,1,2,2-tetrafluoro-ethoxy)-benzaldehyde. Colorless oil. MS (ISP): 307.0
([M+H]⁺)

5

Example 142

(S)-4-[2-(2-Fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




From 2-fluoro-3-trifluoromethyl-benzaldehyde. Off-white solid. MS (ISP): 277.0
([M+H]⁺)

10

Example 143

(S)-4-[2-(3-Bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




From 3-bromo-benzaldehyde. Off-white waxy solid. MS (ISP): 269.0 ([M+H]⁺)

15

Example 144

(S)-4-[2-(4-Chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine


- 94 -



From 4-chloro-3-trifluoromethyl-benzaldehyde. Colorless viscous oil. MS (ISP): 293.0
([M+H]⁺)

Example 145


- 5 (S)-4-[2-(3-Fluoro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine



From 3-fluoro-4-trifluoromethoxy-benzaldehyde. Off-white solid. MS (ISP): 293.0
([M+H]⁺)

Example 146

- 10 (S)-4-[2-(4-Fluoro-3-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




From 4-fluoro-3-trifluoromethoxy-benzaldehyde. Viscous colorless oil. MS (ISP): 293.0
([M+H]⁺)

Example 147

- 15 (S)-4-Methyl-4-(4-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

- 95 -



a) (RS)-5-Methyl-5-(4-trifluoromethyl-phenyl)-imidazolidine-2,4-dione

A solution of 2-(trifluoromethyl)acetophenone (4.0 g) in EtOH/H₂O 1:1 (60 ml) were treated under an argon atmosphere with ammoniumcarbonate (10.21 g) and NaCN (1.25 g). The reaction mixture was heated to 60° C and stirred for 3 hours. It was cooled to 0° C and the solution was brought to acidic pH by dropwise addition of 3N HCl (ca. 80 ml). Then, N₂ was bubbled through the solution for 90 minutes to remove the remaining HCN.

EtOH and part of the water were removed by distillation. The remaining aqueous solution was extracted with EtOAc. The crude product was purified by column chromatography (silica gel; gradient: cyclohexane -> cyclohexane/EtOAc 3:7) to give 5-methyl-5-(4-trifluoromethyl-phenyl)-imidazolidine-2,4-dione (3.14 g, 57%) as off-white solid.

MS (ISP): 276.3 ([M+H]⁺)

b) (RS)-2-Amino-2-(4-trifluoromethyl-phenyl)-propionic acid

In analogy to example 134.a 5-methyl-5-(4-trifluoromethyl-phenyl)-imidazolidine-2,4-dione was converted to (RS)-2-amino-2-(4-trifluoromethyl-phenyl)-propionic acid.

MS (ISP): 234.1 ([M+H]⁺)

c) (RS)-4-Methyl-4-(4-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

In analogy to example 1 (RS)-2-amino-2-(4-trifluoromethyl-phenyl)-propionic acid was converted to the title compound. Off-white solid.

MS (ISP): 245.3 ([M+H]⁺)

c) (S)-4-Methyl-4-(4-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine


(RS)-4-Methyl-4-(4-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 10:90) to give (S)-4-methyl-4-(4-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine.

(-)-Enantio-mer. Light yellow solid.

MS (ISP): 245.3 ([M+H]⁺)

Example 148

(R)-4-methyl-4-(4-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine



- 5 (RS)-4-Methyl-4-(4-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 147) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 10:90) to give (R)-4-methyl-4-(4-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Off-white solid.


MS (ISP): 245.3 ($[M+H]^+$)

10

In analogy to example 83, starting from (S)-4-hydroxymethyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester and using the respective benzaldehyde were prepared:

Example 149

- 15 (S)-4-[2-(2,3-Dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




From 2,3-dichloro-benzaldehyde. Light yellow solid. MS (ISP): 259.0 ($[M+H]^+$)

Example 150

- 20 (S)-4-[2-(3-Chloro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine


- 97 -



From 3-chloro-4-trifluoromethoxy-benzaldehyde. Light yellow viscous oil. MS (ISP): 309.3 ($[M+H]^+$)

Example 151


- 5 (S)-4-[2-(2-Chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine



From 2-chloro-3-trifluoromethyl-benzaldehyde. Off-white solid. MS (ISP): 293.1 ($[M+H]^+$)

Example 152

- 10 (R)-4-(3-Trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine



a) (RS)-4-(3-Trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

In analogy to example 1, the title compound was obtained from 2-(3-trifluoromethyl-phenyl)-DL-glycine. Off-white solid.

- 15 MS (ISP): 231.3 ($[M+H]^+$)


b) (R)-4-(3-Trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(3-Trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 15:85) to give (R)-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. Off-white solid.

5 MS (ISP): 231.4 ($[M+H]^+$)

Example 153

(S)-4-(3-Trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




10 ((RS)-4-(3-Trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 15:85) to give (S)-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Off-white solid.

MS (ISP): 231.1 ($[M+H]^+$)

Example 154

(S)-4-(1-Methyl-2-phenyl-ethyl)-4,5-dihydro-oxazol-2-ylamine



15

a) (R)-4-(1-Hydroxy-1-methyl-2-phenyl-ethyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester

A solution of (R)-4-acetyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (2.80 g, CAS 167102-63-8) in THF (40 ml) was cooled under an argon atmosphere to 0°C and treated dropwise with benzylmagnesium chloride solution (1M in diethylether, 34.5 ml). The reaction mixture was stirred at r.t. overnight, then quenched with saturated aqueous NH_4Cl (50 ml) and extracted with EtOAc. The organic layer was washed with H_2O and brine, dried over $MgSO_4$, filtered and concentrated. The crude product was purified by column chromatography (silica gel; gradient: cyclohexane -> cyclohexane/EtOAc 3:1) to give (R)-4-(1-hydroxy-1-methyl-2-phenyl-ethyl)-2,2-

20

25

dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (3.45 g, 89%) as off-white waxy solid.

MS (ISP): 336.4 ($[M+H]^+$)

5 b) (S)-2-Amino-3-methyl-4-phenyl-butan-1-ol

A stirred solution of (R)-4-(1-hydroxy-1-methyl-2-phenyl-ethyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (0.50 g) in THF (25 ml) was cooled under an argon atmosphere to -78°C and treated dropwise with 1M lithium-bis-(trimethylsilyl)amide in THF (1.79 ml). The solution was allowed to warm to r.t.. Then,
10 phenyl chlorothionoformate (0.3 ml) was added. After stirring at r.t. for 2 hrs, the reaction mixture was quenched with saturated aqueous NH_4Cl solution and extracted with EtOAc. The organic layer was washed with brine, dried over $MgSO_4$ and concentrated to give crude (R)-2,2-dimethyl-4-(1-methyl-1-phenoxythiocarbonyloxy-2-phenyl-ethyl)-oxazolidine-3-carboxylic acid tert-butyl ester as pale yellow oil which was
15 used in the next reaction step without further purification.

A solution of crude (R)-2,2-dimethyl-4-(1-methyl-1-phenoxythiocarbonyloxy-2-phenyl-ethyl)-oxazolidine-3-carboxylic acid tert-butyl ester (700 mg) in toluene (5 ml) was treated under an argon atmosphere with 2,2'-azobis(2-methylpropanitrile) (122 mg) and tri-N-butyltin hydride (0.79 ml). The reaction mixture was refluxed for 30 min, then
20 cooled to r.t. and then directly purified by column chromatography (silica gel, gradient: cyclohexane -> cyclohexane/EtOAc 10:1) to give (S)-2,2-dimethyl-4-(1-methyl-2-phenyl-vinyl)-oxazolidine-3-carboxylic acid tert-butyl ester (279 mg, 59%) as light yellow waxy solid. MS (ISP): 318.3 ($[M+H]^+$)

A solution of (S)-2,2-dimethyl-4-(1-methyl-2-phenyl-vinyl)-oxazolidine-3-carboxylic acid tert-butyl ester (250 mg) in 4M HCl in dioxane (2 ml) was stirred at r.t. overnight.
25 The reaction mixture was concentrated. The crude product was purified by column chromatography (silica gel; gradient: CH_2Cl_2 -> $CH_2Cl_2/MeOH$ 9:1) to give (S)-2-amino-3-methyl-4-phenyl-but-3-en-1-ol (122 mg, 87%) as light yellow oil. MS (ISP): 177.9 ($[M+H]^+$)

30 A solution of (S)-2-amino-3-methyl-4-phenyl-but-3-en-1-ol (115 mg) in EtOH (5 ml) was hydrogenated at normal pressure (balloon) overnight in the presence of 10% Pd/C (10 mg). The reaction mixture was filtered and concentrated. The crude product was purified by column chromatography (silica gel; gradient: CH_2Cl_2 -> $CH_2Cl_2/MeOH$ 9:1) to give (S)-2-amino-3-methyl-4-phenyl-butan-1-ol (57 mg, 49%) as light yellow oil. MS
35 (ISP): 180.3 ($[M+H]^+$)

c) (S)-4-(1-Methyl-2-phenyl-ethyl)-4,5-dihydro-oxazol-2-ylamine


In analogy to example 1b (S)-2-amino-3-methyl-4-phenyl-butan-1-ol was reacted with
5 cyanogen bromide to give (S)-4-(1-methyl-2-phenyl-ethyl)-4,5-dihydro-oxazol-2-ylamine. Off-white amorphous solid.

MS (ISP): 205.1 ($[M+H]^+$)

In analogy to example 83, starting from (S)-4-hydroxymethyl-2,2-dimethyl-oxazolidine-
10 3-carboxylic acid tert-butyl ester and using the respective benzaldehyde were prepared:

Example 155


(S)-4-[2-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine



15 From 3,5-bis-trifluoromethyl-benzaldehyde. Off-white solid. MS (ISP): 327.3 ($[M+H]^+$)

Example 156

(S)-4-[2-(2-Fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




20 From 2-fluoro-5-trifluoromethyl-benzaldehyde. White solid. MS (ISP): 277.0 ($[M+H]^+$)

Example 157

(S)-4-[2-(6-Trifluoromethyl-pyridin-3-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine


- 101 -



From 6-(trifluoromethyl)pyridine-3-carboxaldehyde. Colorless gum. MS (ISP): 260.3 ($[M+H]^+$)

Example 158


5 (S)-4-[2-(3-Fluoro-pyridin-4-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine



From 3-fluoro-isonicotinaldehyde. Light yellow solid. MS (ISP): 210.1 ($[M+H]^+$)

Example 159

10 (S)-4-[2-(3-Fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




From 3-fluoro-5-trifluoromethyl-benzaldehyde. Colorless viscous oil. MS (ISP): 277.1 ($[M+H]^+$)

Example 160

15 (S)-4-[2-(2,5-Bis-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine

- 102 -




From 2,5-bis-trifluoromethyl-benzaldehyde. Colorless viscous oil. MS (ISP): 327.1 ([M+H]⁺)

Example 161

5

(S)-4-Methyl-4-p-tolyl-4,5-dihydro-oxazol-2-ylamine



a) (RS)-4-Methyl-4-p-tolyl-4,5-dihydro-oxazol-2-ylamine

In analogy to example 1, the title compound was obtained from DL-2-(4-methylphenyl)alanine. White solid.

10 MS (ISP): 191.3 ([M+H]⁺)

b) (S)-4-Methyl-4-p-tolyl-4,5-dihydro-oxazol-2-ylamine


(RS)-4-Methyl-4-p-tolyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 15:85) to give (S)-4-methyl-4-p-tolyl-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Off-white solid.

15

MS (ISP): 191.3 ([M+H]⁺)

Example 162

(S)-4-[2-(4-Chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine



20 a) (S)-4-(2,2-Dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester

To a stirred, cooled (0°C) solution of (R)-4-formyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (4.30 g; CAS 95715-87-0 and triphenylphosphine (9.15 g) in dichloromethane (100 ml) was added portionwise carbon tetrabromide (6.94 g). The mixture was stirred at 0 °C for 20 min and then at r.t. for 2 h. The mixture was

5 concentrated *in vacuo* to ca 20 ml, then diluted with hexane (100 ml) and concentrated *in vacuo* to half-volume. The residue was stirred at 0 °C for 15 min, then the mixture was filtered and the filtrate was concentrated *in vacuo* to afford (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (6.18 g, 92%) as a colourless oil. MS (EI): 330.9 ([⁸¹Br}M-C₄H₈]⁺), 328.9 ([⁸¹Br⁷⁹Br}M-C₄H₈]⁺), 326.9 ([⁷⁹Br}M-C₄H₈]⁺).

10

b) (S)-4-[(Z)-2-Bromo-2-(4-chloro-phenyl)-vinyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester

To a stirred solution of (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (3.6 g) in dioxane (48 ml) were added 4-chlorophenylboronic acid (1.75 g), tris(dibenzylideneacetone)dipalladium (0) (290 mg), tris(2-furyl)phosphine (326 mg) and aqueous sodium carbonate solution (18.7 ml, 1 M solution). The mixture was stirred at 50 °C for 90 min. The mixture was diluted with ethyl acetate and washed with saturated brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue

15 was purified by column chromatography (SiO₂; gradient: heptane/EtOAc) to give (S)-4-(benzothiazole-2-sulfonylmethyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (1.77 g, 45%) as a light yellow oil. MS (ISP): 420.0 ([³⁷Cl⁸¹Br}M+H]⁺), 418.0 ([³⁷Cl⁷⁹Br, ³⁵Cl⁸¹Br }M+H]⁺), 416.0 ([³⁵Cl⁷⁹Cl}M+H]⁺).

20

c) (S)-4-[(E)-2-(4-Chloro-phenyl)-but-1-enyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester

To a stirred solution of (S)-4-[(Z)-2-bromo-2-(4-chloro-phenyl)-vinyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (1.04 g) in THF (8 ml) were added bis(tri-tert-butylphosphine)dipalladium (0) (64 mg) and diethylzinc (4.99 ml, 1.1 M solution in toluene). The mixture was stirred at r.t. for 90 min then was diluted with ethyl acetate and washed with saturated brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified by column chromatography (SiO₂; gradient: heptane/EtOAc) to give (S)-4-[(E)-2-(4-chloro-phenyl)-but-1-enyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (824 mg, 90%) as a colourless oil. MS (ISP): 368.5 ([³⁷Cl}M+H]⁺),

30

35 366.5 ([³⁵Cl}M+H]⁺).

d) (E)-(S)-2-Amino-4-(4-chloro-phenyl)-hex-3-en-1-ol

To a stirred solution of (S)-4-[(E)-2-(4-chloro-phenyl)-but-1-enyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (820 mg) at r.t. in dioxane (8 ml) was added
 5 4 M HCl solution in dioxane (11.2 ml). The mixture was stirred at 35 °C for 3.5 h. The mixture was then diluted with ethyl acetate and made basic by addition of 2 N aq sodium hydroxide solution. The phases were separated and the organic phase was washed with saturated brine, dried over sodium sulphate and concentrated *in vacuo* to give (E)-(S)-2-amino-4-(4-chloro-phenyl)-hex-3-en-1-ol (524 mg, quant.) as a yellow oil. MS (ISP):
 10 228.2 ([³⁷Cl]M+H)⁺, 226.2 ([³⁵Cl]M+H)⁺.

e) (S)-2-Amino-4-(4-chloro-phenyl)-hexan-1-ol

To a stirred solution of (E)-(S)-2-amino-4-(4-chloro-phenyl)-hex-3-en-1-ol (0.52 g) at r.t. in ethanol (30 ml) under an argon atmosphere was added 5 % Pt/C (180 mg). The
 15 mixture was stirred at r.t. under a hydrogen atmosphere for 16 hrs. The catalyst was filtered off and the filtrate was concentrated *in vacuo*. The residue was purified by column chromatography (SiO₂; gradient: heptane/EtOAc) to give (S)-2-amino-4-(4-chloro-phenyl)-hexan-1-ol (mainly one epimer) (0.157 g, 30%) as colourless oil. MS (ISP): 230.3 ([³⁷Cl]M+H)⁺, 228.2 ([³⁵Cl]M+H)⁺.


20

f) (S)-4-[2-(4-Chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine

In analogy to example 1b (S)-2-amino-4-(4-chloro-phenyl)-hexan-1-ol was reacted with cyanogen bromide to give (S)-4-[2-(4-chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine (mainly one epimer). Colourless oil. MS (ISP): 255.2 ([³⁷Cl]M+H)⁺, 253.2
 25 ([³⁵Cl]M+H)⁺.

Example 163

(S)-4-(2-Phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine



a) (S)-4-((Z)-2-Bromo-2-phenyl-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester
 30

In analogy to example 162b (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester was reacted with phenylboronic acid to give (S)-4-((Z)-2-bromo-2-phenyl-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester. Light yellow crystalline solid.

5

b) (S)-2,2-Dimethyl-4-((E)-2-phenyl-but-1-enyl)-oxazolidine-3-carboxylic acid tert-butyl ester

In analogy to example 162c (S)-4-((Z)-2-bromo-2-phenyl-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester was reacted with diethylzinc to give (S)-2,2-dimethyl-4-((E)-2-phenyl-but-1-enyl)-oxazolidine-3-carboxylic acid tert-butyl ester. Colourless oil. MS (ISP): 332.3 ($[M+H]^+$).

10

c) (E)-(S)-2-Amino-4-phenyl-hex-3-en-1-ol

In analogy to example 162d (S)-2,2-dimethyl-4-((E)-2-phenyl-but-1-enyl)-oxazolidine-3-carboxylic acid tert-butyl ester was reacted with hydrogen chloride to give (E)-(S)-2-amino-4-phenyl-hex-3-en-1-ol. Yellow crystalline solid.

15

d) (S)-2-Amino-4-phenyl-hexan-1-ol

To a stirred solution of (E)-(S)-2-amino-4-phenyl-hex-3-en-1-ol (1.0 g) at r.t. in methanol (50 ml) under an argon atmosphere was added 10% Pd/C (278 mg). The mixture was stirred at r.t. under a hydrogen atmosphere for 30 min. The catalyst was filtered off and the filtrate was concentrated *in vacuo*. The residue was purified by column chromatography (SiO₂; gradient: dichloromethane/methanol) to give (S)-2-amino-4-phenyl-hexan-1-ol (mainly one epimer) (0.81 g, 80%) as a colourless oil. MS (ISP): 194.4 ($[M+H]^+$).

25

e) (S)-4-(2-Phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine

In analogy to example 1b (S)-2-amino-4-phenyl-hexan-1-ol was reacted with cyanogen bromide to give (S)-4-(2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine (mainly one epimer). White crystalline solid. MS (ISP): 219.4 ($[M+H]^+$).


30

In analogy to example 163 were prepared:

Example 164

(R)-4-[2-(4-Trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine

- 106 -




From (R)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 4-(trifluoromethyl)phenyl boronic acid and dimethylzinc. Mainly one epimer. Colourless oil. MS (ISP): 273.3 ($[M+H]^+$).

5

Example 165

(S)-4-[2-(4-Trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine




From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 4-(trifluoromethyl)phenyl boronic acid and dimethylzinc. Mainly one epimer. Colourless oil. MS (ISP): 273.3 ($[M+H]^+$).

10

Example 166

(S)-4-(3,4-Difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine



15

a) (RS)-4-(3,4-Difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

In analogy to example 1, the title compound was obtained from DL-3,4-difluorophenylglycine. Off-white solid.


MS (ISP): 199.3 ($[M+H]^+$)

b) (S)-4-(3,4-Difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(3,4-Difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine was separated by chiral
5 HPLC (Chiralpak AD, EtOH/heptane 15:85) to give (S)-4-(3,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Off-white solid.
MS (ISP): 199.1 ($[M+H]^+$)

Example 167

(R)-4-(2,3-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine



10

a) (RS)-4-(2,3-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine

In analogy to example 1, the title compound was obtained from DL-amino-(2,3-dichloro-phenyl)-acetic acid. Light yellow solid.

MS (ISP): 231.1 ($[M+H]^+$)

15


b) (R)-4-(2,3-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(2,3-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine was separated by chiral
HPLC (Chiralpak AD, EtOH/heptane 1:9) to give (R)-4-(2,3-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. White solid.

20 MS (ISP): 231.1 ($[M+H]^+$)

Example 168


(S)-4-(2,3-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine



(RS)-4-(2,3-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine was separated by chiral
25 HPLC (Chiralpak AD, EtOH/heptane 1:9) to give (S)-4-(2,3-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. White solid.
MS (ISP): 231.3 ($[M+H]^+$)

Example 169

(S)-4-(4-Chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine




In analogy to example 1, the title compound was obtained from (S)-4-chlorophenyl
5 glycine. Light yellow solid.

MS (ISP): 197.3 ($[M+H]^+$)

Example 170

(S)-4-(3,4,5-Trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine



10 a) (RS)-4-(3,4,5-Trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

In analogy to example 1, the title compound was obtained from 3,4,5-trifluoro-DL-phenylglycine. Light yellow solid.

MS (ISP): 217.4 ($[M+H]^+$)

15 b) (S)-4-(3,4,5-Trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(3,4,5-Trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 15:85) to give (S)-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Colorless viscous oil.


MS (ISP): 217.3 ($[M+H]^+$)

20

Example 171

(R)-4-(3-Chloro-4-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

- 109 -



a) (RS)-4-(3-Chloro-4-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

In analogy to example 1, the title compound was obtained from 3-chloro-4-fluoro-DL-phenylglycine. Light yellow waxy solid.

MS (ISP): 215.1 ($[M+H]^+$)


b) (R)-4-(3-Chloro-4-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(3-Chloro-4-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 15:85) to give (R)-4-(3-chloro-4-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. White solid.

MS (ISP): 215.4 ($[M+H]^+$)

Example 172

(R)-4-(3-Chloro-4-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(3-Chloro-4-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 15:85) to give (S)-4-(3-chloro-4-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. White solid.

MS (ISP): 215.1 ($[M+H]^+$)

Example 173

(R)-4-(4-Chloro-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

- 110 -



a) (RS)-4-(4-Chloro-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

In analogy to example 1, the title compound was obtained from 4-chloro-3-fluoro-DL-phenylglycine. Yellow waxy solid.

5 MS (ISP): 215.1 ($[M+H]^+$)


b) (R)-4-(4-Chloro-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(4-Chloro-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine was separated by
10 chiral HPLC (Chiralpak AD, EtOH/heptane 15:85) to give (R)-4-(4-chloro-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. Off-white solid.

MS (ISP): 215.1 ($[M+H]^+$)

Example 174

(S)-4-(4-Chloro-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine



15


(RS)-4-(4-Chloro-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine was separated by
chiral HPLC (Chiralpak AD, EtOH/heptane 15:85) to give (S)-4-(4-chloro-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Off-white solid.

MS (ISP): 215.3 ($[M+H]^+$)

20

Example 175

(R)-4-(3,5-Difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine



a) ((RS)-4-(3,5-Difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

In analogy to example 1, the title compound was obtained from 3,5-difluoro-DL-phenylglycine. Yellow solid.

MS (ISP): 199.1 ($[M+H]^+$)

5


b) (R)-4-(3,5-Difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(3,5-Difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 15:85) to give (R)-4-(3,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. Light yellow solid.

10 MS (ISP): 199.1 ($[M+H]^+$)

Example 176

(S)-4-(3,5-Difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(3,5-Difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 15:85) to give (S)-4-(3,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. White solid.

15

MS (ISP): 199.3 ($[M+H]^+$)

Example 177

(R)-4-(3-Chloro-5-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine



20

a) (RS)-4-(3-Chloro-5-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

In analogy to example 1, the title compound was obtained from 3-chloro-5-fluoro-DL-phenylglycine. Waxy yellow solid.

MS (ISP): 215.3 ($[M+H]^+$)

25


b) (R)-4-(3-Chloro-5-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(3-Chloro-5-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 15:85) to give (R)-4-(3-chloro-5-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. Light yellow solid.
MS (ISP): 215.3 ($[M+H]^+$)

5

Example 178

(S)-4-(3-Chloro-5-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(3-Chloro-5-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 15:85) to give (S)-4-(3-chloro-5-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Light yellow solid.
MS (ISP): 215.1 ($[M+H]^+$)

10

Example 179

(R)-4-(2-Chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

15 a) (RS)-4-(2-Chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

In analogy to example 147, the title compound was obtained starting from 2'-chloro-acetophenone. White solid.

MS (ISP): 211.1 ($[M+H]^+$)

20 b) (R)-4-(2-Chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(2-Chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 1:9) to give (R)-4-(2-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. White solid.


MS (ISP): 211.1 ($[M+H]^+$)

25

Example 180

(S)-4-(2-Chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

- 113 -




(RS)-4-(2-Chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 1:9) to give (S)-4-(2-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. White solid.

5 MS (ISP): 211.1 ($[M+H]^+$)

In analogy to example 165, except that the order of the hydrogenation and deprotection steps was reversed, was prepared:

Example 181

(S)-4-[2-(4-Trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine




10

From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 4-(trifluoromethyl)phenyl boronic acid and dimethylzinc. Mainly one epimer, which is different from the major epimer produced in example 165. Colourless amorphous solid. MS (ISP): 273.4 ($[M+H]^+$).

15 In analogy to example 164, except that the order of the hydrogenation and deprotection steps was reversed, was prepared:

Example 182

(R)-4-[2-(4-Trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine




From (R)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 4-(trifluoromethyl)phenyl boronic acid and dimethylzinc. Mainly one epimer, which is different from the major epimer produced in example 164. Colourless oil. MS (ISP): 273.1 ($[M+H]^+$).

- 5 In analogy to example 184, except that the order of the hydrogenation and deprotection steps was reversed, was prepared:

Example 183

(S)-4-[2-(4-Trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine




- 10 From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 4-(trifluoromethyl)phenyl boronic acid and diethylzinc. Mainly one epimer, which is different from the major epimer produced in example 184. Colourless oil. MS (ISP): 287.1 ($[M+H]^+$).

In analogy to example 163 was prepared:

15

Example 184

(S)-4-[2-(4-Trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine




- From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 4-(trifluoromethyl)phenyl boronic acid and diethylzinc. Mainly one epimer. Colourless oil. MS (ISP): 287.1 ($[M+H]^+$).
- 20

Example 185

(RS)-4-(3-Chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine

- 115 -



a) (RS)-2-Amino-2-(3-chloro-phenyl)-ethanol

To a stirred solution of lithium borohydride in THF (10.5 ml, 2 M solution) under an argon atmosphere was added dropwise chlorotrimethylsilane (5.34 ml). The resulting suspension was cooled to 0 °C and amino-(3-chlorophenyl)-acetic acid (2.0 g) was added portionwise. The ice bath was removed and stirring at r.t. was then continued for 16 h. The mixture was quenched by dropwise addition of methanol (15 ml) and then concentrated in vacuo. The residue was suspended in ethyl acetate and washed with 2 N aq NaOH. The phases were separated and the aqueous phase was extracted with ethyl acetate. The combined organic phases were dried over sodium sulphate and concentrated in vacuo to afford (RS)-2-amino-2-(3-chloro-phenyl)-ethanol (1.84 g, quant.) as a yellow viscous oil. MS (ISP): 174.2 ([³⁷Cl]M+H)⁺, 172.2 ([³⁵Cl]M+H)⁺.


b) (RS)-4-(3-Chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine

In analogy to example 1.b (RS)-2-amino-2-(3-chloro-phenyl)-ethanol was converted to (RS)-4-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine by treatment with cyanogen bromide and potassium carbonate. White solid. MS (ISP): 199.0 ([³⁷Cl]M+H)⁺, 197.0 ([³⁵Cl]M+H)⁺.

In analogy to example 185 and starting from the respective amino acid or amino acid derivative was prepared:

Example 186


(RS)- 4-(3-Bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine



From (RS)-2-amino-2-(3-bromophenyl)-acetic acid. White solid. MS (ISP): 243.2 ([⁸¹Br]M+H)⁺, 241.1 ([⁷⁹Br]M+H)⁺.

Example 187

(S)-4-(2,5-Difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine



a) (RS)-4-(2,5-Difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

In analogy to example 147, the title compound was obtained starting from 2',3',6'-trifluoroacetophenone (one of the ortho fluorine atoms gets lost during the lithium aluminium hydride reduction). White solid.

MS (ISP): 213.3 ($[M+H]^+$)

b) (S)-4-(2,5-Difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine


(RS)-4-(2,5-Difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 1:9) to give (S)-4-(2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. White solid.

MS (ISP): 213.3 ($[M+H]^+$)

In analogy to example 186 and starting from the respective amino acid or amino acid derivative were prepared:

Example 188

(RS)- 4-(3-Fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




From (RS)-2-amino-2-(3-fluorophenyl)-acetic acid. White solid.

MS (ISP): 181.1 ($[M+H]^+$).

Example 189

(RS)- 4-(3,5-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine




From (RS)-2-amino-2-(3,5-dichlorophenyl)-acetic acid. White solid.

MS (ISP): 235.1 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 233.1 ($[\{^{37}\text{Cl}^{35}\text{Cl}\}\text{M}+\text{H}]^+$), 231.2 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$).

Example 190


(+)-(S)-4-(5-Chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine



(RS)-4-(5-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 19) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 10:90) to yield (+)-(S)-4-(5-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 217.1 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 215.1 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$)).

Examples 191 & 192

(-)-(R)-4-(3-Chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine & (+)-(S)-4-(3-Chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine



(RS)-4-(3-Chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 185) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 15:85) to yield (-)-(R)-4-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (light yellow solid; MS (ISP): 199.0

($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 197.0 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$)) and (+)-(S)-4-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (light yellow solid; MS (ISP): 199.0 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 197.0


($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$)).

In analogy to example 163 were prepared:

Example 193

(S)-4-[2-(3-Trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine

- 118 -




From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 3-(trifluoromethyl)phenyl boronic acid and dimethylzinc. Mainly one epimer. Colourless oil. MS (ISP): 273.3 ($[M+H]^+$).

5

Example 194

(S)-4-[2-(3-Trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine




From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 3-(trifluoromethyl)phenyl boronic acid and diethylzinc. Mainly one epimer. Colourless oil. MS (ISP): 287.1 ($[M+H]^+$).

10

Example 195

(R)-4-Phenylsulfanylmethyl-4,5-dihydro-oxazol-2-ylamine



15

a) (R)-2-Amino-3-phenylsulfanyl-propionic acid methyl ester hydrochloride

To a solution of S-phenyl-L-cysteine (5.0 g, 25.4 mmol) in methanol (50 ml) was added acetylchloride (2.7 ml, 38 mmol) and the mixture was refluxed overnight. The solvent was evaporated and the residue was recrystallised from ethyl acetate / methanol (3:1) to yield a white solid (3.81 g, 61%). MS (ISP): 211.9 ($[M+H]^+$).

20

b) (R)-2-Amino-3-phenylsulfanyl-propan-1-ol


To a stirred suspension of (R)-2-amino-3-phenylsulfanyl-propionic acid methyl ester hydrochloride (0.50 g, 2.0 mmol) in tetrahydrofuran (10 ml) under an argon atmosphere
5 was added slowly lithium aluminum hydride (0.153 g, 4.0 mmol) and the mixture was stirred overnight at room temperature. For work-up water (1.5 ml) and 2N sodium hydroxide solution (0.5 ml) were added and the mixture was stirred for 30 min. After filtration the solvent was evaporated and the residue was purified by column chromatography (column: Isolute® Flash-NH₂ from Separtis; eluent: heptane/EtOAc= 1:1
10 to yield a light yellow oil, (0.095 g, 26 %); MS (ISP): 183.9 ((M+H)⁺).

c) (R)-4-Phenylsulfanylmethyl-4,5-dihydro-oxazol-2-ylamine

To a stirred mixture of (R)-2-amino-3-phenylsulfanyl-propan-1-ol (0.09 g, 0.49 mmol) and K₂CO₃ (0.081 g, 0.59 mmol) in THF (3 ml) under an argon atmosphere was added a
15 solution of cyanogen bromide (0.062 g, 0.59 mmol) in THF (1 ml). The mixture was stirred overnight, then ethyl acetate and water were added. The aqueous phase was back-extracted with EtOAc. The combined organics were dried over MgSO₄, filtered and concentrated. The crude product was purified by column chromatography (column: Isolute® Flash-NH₂ from Separtis; eluent: EtOAc/MeOH= 95:5) to yield a light yellow
20 solid, (0.026 g, 26 %); MS (ISP): 209.1 ((M+H)⁺).

Example 196

(R)-4-(2-Fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine



25 a) (RS)-4-(2-Fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

In analogy to example 147, the title compound was obtained starting from 2'-fluoro-acetophenone. Viscous colorless oil.

MS (ISP): 195.1 ([M+H]⁺)

30 b) (R)-4-(2-Fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine


(RS)-4-(2-Fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 1:9) to give (R)-4-(2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. White solid.

MS (ISP): 195.1 ($[M+H]^+$)

5

Example 197

(S)-4-(2-Fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(2-Fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 1:9) to give (S)-4-(2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Off-white solid.

MS (ISP): 195.1 ($[M+H]^+$)

Example 198

(+)-(S)-4-(3-Bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine




15

(RS)-4-(3-Bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 186) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 15:85) to yield (+)-(S)-4-(3-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 243.2 ($[^{81}\text{Br}M+H]^+$), 241.1 ($[^{79}\text{Br}M+H]^+$)).

20

Example 199

(+)-(S)-4-(3-Fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(3-Fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 188) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 15:85) to yield (+)-(S)-4-(3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 181.1 ($[M+H]^+$)).

25

Examples 200 & 201


(-)-(R)-4-(3,5-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine & (+)-(S)-4-(3,5-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine



(RS)-4-(3,5-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 189) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 15:85) to yield (-)-(R)-4-(3,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 235.1 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 233.1 ($[\{^{37}\text{Cl}^{35}\text{Cl}\}\text{M}+\text{H}]^+$), 231.2 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$) and (+)-(S)-4-(3,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 235.1 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 233.1 ($[\{^{37}\text{Cl}^{35}\text{Cl}\}\text{M}+\text{H}]^+$), 231.2 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$)). In analogy to example 163 were prepared:

Example 202


(S)-4-[2-(3,5-Difluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine



From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 3,5-difluorophenyl boronic acid and dimethylzinc. Mainly one epimer. Colourless oil. MS (ISP): 241.4 ($[\text{M}+\text{H}]^+$).

Example 203

(S)-4-[2-(3,5-Difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine




From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 3,5-difluorophenyl boronic acid and diethylzinc. Mainly one epimer. Colourless oil. MS (ISP): 255.3 ($[M+H]^+$).

5

Example 204

(S)-4-(2,6-Difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine



a) (RS)-4-(2,6-Difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine


In analogy to example 147, the title compound was obtained starting from 2',6'-
10 difluoroacetophenone. White solid.
MS (ISP): 213.3 ($[M+H]^+$)

b) (S)-4-(2,6-Difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(2,6-Difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine was separated by
15 chiral HPLC (Chiralpak AD, EtOH/heptane 1:9) to give (S)-4-(2,6-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. White solid.
MS (ISP): 213.3 ($[M+H]^+$)

Example 205

(R)-4-(2,6-Difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine




20

(RS)-4-(2,6-Difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine was separated by
chiral HPLC (Chiralpak AD, EtOH/heptane 1:9) to give (R)-4-(2,6-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. White solid.
MS (ISP): 213.3 ($[M+H]^+$)

25

Example 206

(S)-4-(2,4-Difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine



a) (RS)-(2-Amino-2-(2,4-difluoro-phenyl))-propionic acid hydrochloride

In analogy to example 147.a und 147.b, the title compound was obtained starting from 2',4'-difluoroacetophenone. White solid.

5 MS

b) (RS)-2-Amino-2-(2,4-difluoro-phenyl)-propan-1-ol

To a stirred 2 M LiBH₄ solution (16.22 ml) at r.t. in THF under an argon atmosphere was added chlorotrimethylsilane (5.47 ml) over 2 min. The white suspension was cooled to
 10 0°C and (RS)-(2-amino-2-(2,4-difluoro-phenyl))-propionic acid hydrochloride (2.57g) was added portionwise over 5 min. The ice bath was removed and the compact off-white suspension was stirred at r.t. for 20 h. The mixture was cooled again to 0°C and treated carefully with methanol (15 ml). The mixture was stirred at r.t. for 30 min, filtered and the cake was washed with MeOH. The filtrate was concentrated. The crude product was
 15 purified by column chromatography (silica gel; gradient: CH₂Cl₂ -> CH₂Cl₂/MeOH 9:1) to give (RS)-2-amino-2-(2,4-difluoro-phenyl)-propan-1-ol (1.47 g, 73%) as colorless viscous oil.

MS (ISP): 188.3 ([M+H]⁺)

20 c) (RS)-4-(2,4-Difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

In analogy to example 1.b (RS)-2-amino-2-(2,4-difluoro-phenyl)-propan-1-ol was converted to the title compound. White solid.

MS (ISP): 213.3 ([M+H]⁺)


25 d) (S)-4-(2,4-Difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(2,4-Difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 1:9) to give (S)-4-(2,4-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. White solid.

MS (ISP): 213.1 ([M+H]⁺)

30

Example 207

(R)-4-Benzenesulfonylmethyl-4,5-dihydro-oxazol-2-ylaminea) (R)-3-Benzenesulfonyl-2-tert-butoxycarbonylamino-propionic acid methyl ester

To a stirred suspension of (R)-2-amino-3-phenylsulfanyl-propionic acid methyl ester
 5 hydrochloride (1.0 g, 4.0 mmol, Example 195a) in 1 M bicarbonate solution (10 ml) was
 added a solution of di-tert.-butyl dicarbonate (0.969 g, 4.4 mmol) in dioxane (10 ml) and
 the mixture was stirred at room temperature overnight. The solvents were evaporated and
 the residue was partitioned between water and ethyl acetate. The combined organic layers
 were dried (MgSO₄) and filtered and cooled to 0 °C. Then meta-chloroperbenzoic acid
 10 (1.38 g, 10 mmol) was added slowly at 0 °C and the mixture was stirred for an additional
 4 hours at room temperature. For work-up saturated sodium sulfite solution (6 ml) and
 saturated sodium bicarbonate solution (6 ml) were added. After stirring the mixture for
 additional 30 min it was extracted three times with ethyl acetate. The combined organic
 layers were dried (MgSO₄), filtered and evaporated. The residue was purified by column
 15 chromatography (SiO₂, heptane/EtOAc= 1:1) to yield a white solid, (1.068 g, 78 %); MS
 (ISP): 344.0 ((M+H)⁺); 244.0 ((M+H-BOC)⁺).

b) ((R)-2-Benzenesulfonyl-1-hydroxymethyl-ethyl)-carbamic acid tert-butyl ester

To a solution of lithium borohydride in tetrahydrofuran (2M, 1.14 ml, 2.28 mmol) was
 20 added slowly at 0 °C a solution of (R)-3-benzenesulfonyl-2-tert-butoxycarbonylamino-
 propionic acid methyl ester (0.52 g, 1.51 mmol) in tetrahydrofuran (3 ml). After stirring
 at room temperature for 2.5 hours methanol was added (0.5 ml). The mixture was
 partitioned between ethyl acetate and saturated ammoniumchloride solution. The
 combined organic layers were dried (MgSO₄), filtered and evaporated. The residue was
 25 purified by column chromatography (SiO₂, heptane/EtOAc= 1:1 to yield a white solid,
 (0.292 g, 61 %); MS (ISP): 316.0 ((M+H)⁺); 216.1 ((M+H-BOC)⁺).

c) (R)-4-Benzenesulfonylmethyl-4,5-dihydro-oxazol-2-ylamine

((R)-2-Benzenesulfonyl-1-hydroxymethyl-ethyl)-carbamic acid tert-butyl ester (0.29 g,
 30 0.92 mmol) was dissolved in ethanol (2 ml), hydrochloric acid in ethanol (5M, 5 ml) was


added and the mixture was stirred at 60 °C for 3 hours. The solvent was evaporated and the residue was taken up in tetrahydrofuran (5 ml). K₂CO₃ (0.326 g, 2.36 mmol) and cyanogen bromide (0.136 g, 1.29 mmol) were added. The mixture was stirred overnight and afterwards partitioned between ethyl acetate and water. The combined organic layers
5 were dried (MgSO₄), filtered and evaporated. The residue was purified by column chromatography (SiO₂, EtOAc/MeOH= 95:5 to yield a white solid, (0.062 g, 28 %); MS (ISP): 241.1 ((M+H)⁺).

In analogy to example 163 were prepared:

10

Example 208


(S)-4-[3-Methyl-2-(3-trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine



From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 3-(trifluoromethyl)phenyl boronic acid and
15 diisopropylzinc. Mainly one epimer. Colourless oil. MS (ISP): 301.5 ([M+H]⁺).

Example 209

(S)-4-[2-(3,5-Difluoro-phenyl)-3-methyl-butyl]-4,5-dihydro-oxazol-2-ylamine




20 From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 3,5-difluorophenyl boronic acid and diisopropylzinc. Mainly one epimer. Colourless oil. MS (ISP): 269.5 ([M+H]⁺).

Example 210

25

(S)-4-[2-(4-Fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine

- 126 -




From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 4-fluorophenyl boronic acid and diethylzinc. Mainly one epimer. Colourless oil. MS (ISP): 237.1 ($[M+H]^+$).

5

Example 211

(S)-4-[2-(3,4-Difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine




From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 3,4-difluorophenyl boronic acid and diethylzinc. Mainly one epimer. Colourless oil. MS (ISP): 255.4 ($[M+H]^+$).

10

Example 212

(S)-4-[2-(6-Trifluoromethyl-pyridin-2-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine



15

a) (S)-2,2-Dimethyl-4-(6-trifluoromethyl-pyridin-2-ylethynyl)-oxazolidine-3-carboxylic acid tert-butyl ester

To a solution of tert.-butyl (4S)-4-ethynyl-2,2-dimethyl-1,3-oxazolidine-3-carboxylate

(0.9 g, 4.0 mmol) in triethylamine (8 ml) were added 2-bromo-6-trifluoromethylpyridine (0.9 g, 4.0 mmol), copper(I) iodide (0.076 g, 0.4 mmol) and bis(triphenylphosphine)palladium(II) chloride (0.281 g, 0.4 mmol) and the mixture was stirred for 1 hour at room temperature. The solvent was evaporated, ether was added and the brown suspension was filtered through Celite. The filtrate was evaporated and purified by column chromatography (SiO₂, heptane/EtOAc= 1:1 to yield an orange solid, (1.0 g, 67.5 %); MS (ISP): 371.4 ((M+H)⁺).

10 b) (S)-2,2-Dimethyl-4-[2-(6-trifluoromethyl-pyridin-2-yl)-ethyl]-oxazolidine-3-carboxylic acid tert-butyl ester

To a solution of (S)-2,2-dimethyl-4-(6-trifluoromethyl-pyridin-2-ylethynyl)-oxazolidine-3-carboxylic acid tert-butyl ester (0.58 g, 1.56 mmol) in methanol (8 ml) were added ammonium formate (0.983 g, 15.6 mmol) and palladium on charcoal (10% Pd, 0.58 g). The mixture was refluxed for 1 hour. After cooling the solid was filtered off, the filtrate was evaporated and the residue was purified by column chromatography (SiO₂, heptane/EtOAc= 7:3 to yield a light colourless liquid, (0.538 g, 92 %); MS (ISP): 375.5 ((M+H)⁺).

20 c) (S)-2-Amino-4-(6-trifluoromethyl-pyridin-2-yl)-butan-1-ol

(S)-2,2-Dimethyl-4-[2-(6-trifluoromethyl-pyridin-2-yl)-ethyl]-oxazolidine-3-carboxylic acid tert-butyl ester (0.522 g, 1.39 mmol) was dissolved in ethanol (2.5 ml), hydrochloric acid in ethanol (5N, 2.5 ml) was added and the mixture was stirred at 60 °C for 2 hours. The solvent was evaporated and the residue was dissolved in dichloromethane. A solution of ammonia in methanol (2N, 2 ml) was added and the mixture was evaporated over Isolute[®] Flash-NH₂ silicagel. Chromatography (column: Isolute[®] Flash-NH₂ from Separatis; eluent: ethyl acetate/ MeOH = 90:10) yielded a colourless liquid, (0.237 g, 73 %); MS (ISP): 235.1 ((M+H)⁺).

30 d) (S)-4-[2-(6-Trifluoromethyl-pyridin-2-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine


To a stirred mixture of (S)-2-amino-4-(6-trifluoromethyl-pyridin-2-yl)-butan-1-ol (0.224 g, 0.96 mmol) and K₂CO₃ (0.198 g, 1.43 mmol) in THF (7 ml) under an argon atmosphere was added a solution of cyanogen bromide (0.152 g, 1.05 mmol) in THF (1 ml). The mixture was stirred for 18 hours, then water and ethyl acetate were added. The organic layer was washed with water, dried over MgSO₄ and evaporated over Isolute[®] Flash-NH₂ silicagel. Chromatography (column: Isolute[®] Flash-NH₂ from Separatis; eluent:

ethyl acetate/ MeOH = 90:10) yielded the title compound as off-white solid, (0.096 g, 39 %); MS (ISP): 260.0 ($(M+H)^+$).

In analogy to example 87 was prepared:

Example 213

5 (S)-4-(4-Fluoro-phoxymethyl)-4,5-dihydro-oxazol-2-ylamine




From tert-butyl (S)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylate and 4-fluorophenol. Colourless viscous oil.

MS (ISP): 211.1 ($[M+H]^+$).

10

Example 214

(R)-4-(2-Fluoro-4-trifluoromethyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine



a) (RS)-4-(2-Fluoro-4-trifluoromethyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

In analogy to example 206, the title compound was obtained starting from 2'-fluoro-4'-(trifluoromethyl)acetophenone. White solid.

15

MS (ISP): 263.3 ($[M+H]^+$)

b) (R)-4-(2-Fluoro-4-trifluoromethyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(2-Fluoro-4-trifluoromethyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine


20 was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 5:95) to give (R)-4-(2-fluoro-4-trifluoromethyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. Colorless viscous oil.

MS (ISP): 263.0 ($[M+H]^+$)

Example 215

25 (S)-4-(2-Fluoro-4-trifluoromethyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

- 129 -



(RS)-4-(2-Fluoro-4-trifluoromethyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 5:95) to give (S)-4-(2-fluoro-4-trifluoromethyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (+)-


5 Enantiomer. Colorless viscous oil.

MS (ISP): 263.0 ($[M+H]^+$)

In analogy to example 87 was prepared:

Example 216

10 (S)-4-(4-Chloro-phenoxy-methyl)-4,5-dihydro-oxazol-2-ylamine




From tert-butyl (S)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylate and 4-chlorophenol. White solid.

MS (ISP): 229.3 ($[^{37}\text{Cl}]M+H^+$), 227.1 ($[^{35}\text{Cl}]M+H^+$).

15 In analogy to example 163 was prepared:

Example 217

(S)-4-[2-(2-Fluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine




From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 2-fluorophenyl boronic acid and dimethylzinc. Mainly one epimer. White crystalline solid. MS (ISP): 223.3 ($[M+H]^+$).

5

Example 218

(R)-4-Methyl-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine



a) ((RS)-4-Methyl-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

In analogy to example 206, the title compound was obtained starting from 2'-fluoro-4'-(trifluoromethyl)acetophenone. Viscous colorless oil.

10

MS (ISP): 245.1 ($[M+H]^+$)

b) (R)-4-Methyl-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-Methyl-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine was

15


separated by chiral HPLC (Chiralpak AD, EtOH/heptane 5:95) to give (R)-4-methyl-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. Colorless viscous oil.

MS (ISP): 245.1 ($[M+H]^+$)

Example 219

20

(S)-4-Methyl-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine



(RS)-4-Methyl-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine was

separated by chiral HPLC (Chiralpak AD, EtOH/heptane 5:95) to give (S)-4-methyl-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Colorless

25


viscous oil.

MS (ISP): 245.1 ($[M+H]^+$)

- 131 -

Example 220


(S)-4-[2-(2-Methyl-pyridin-4-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine



The title compound, MS (ISP): 206.1 ($(M+H)^+$) was obtained in comparable yield
 5 analogous to the procedure described for Example 212 using 4-bromo-2-methylpyridine
 instead of 2-bromo-6-trifluoromethyl)pyridine in step a).

Example 221

(S)-4-[2-(3,4-Dichloro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine



10

a) (E)-(S)-2-Amino-4-phenyl-hex-3-en-1-ol

In analogy to example 162a-d (R)-4-formyl-2,2-dimethyl-oxazolidine-3-carboxylic acid
 tert-butyl ester was treated sequentially with triphenylphosphine/carbon tetrabromide,
 3,4-dichlorophenylboronic acid, dimethyl zinc and hydrogen chloride to give (E)-(S)-2-
 15 amino-4-phenyl-hex-3-en-1-ol. Yellow oil.

b) (S)-2-Amino-4-(3,4-dichloro-phenyl)-pentan-1-ol

To a stirred solution of (E)-(S)-2-amino-4-phenyl-hex-3-en-1-ol (390 mg) at r.t. in THF
 (50 ml) under an argon atmosphere were added 10% Pd/C (280 mg) and zinc bromide
 20 (36 mg). The mixture was stirred at r.t. under a hydrogen atmosphere for 16. The catalyst
 was filtered off and the filtrate was concentrated *in vacuo*. The residue was purified by
 column chromatography (SiO₂; gradient: dichloromethane/methanol) to give (S)-2-
 amino-4-(3,4-dichloro-phenyl)-pentan-1-ol (mainly one epimer) (69 mg, 18%) as a
 colourless oil. MS (ISP): 252.2 ($[^{37}\text{Cl}]M+H^+$), 250.2 ($[^{37}\text{Cl}^{35}\text{Cl}]M+H^+$), 248.1
 25 ($[^{35}\text{Cl}]M+H^+$).


c) (S)-4-[2-(3,4-Dichloro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine

In analogy to example 1b (S)-2-amino-4-(3,4-dichloro-phenyl)-pentan-1-ol was reacted with cyanogen bromide to give (S)-4-[2-(3,4-dichloro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine (mainly one epimer). Colourless oil. MS (ISP): 277.1 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 275.0 ($[\{^{37}\text{Cl}^{35}\text{Cl}\}\text{M}+\text{H}]^+$), 273.1 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$).

In analogy to example 221 was prepared:

Example 222

10 (S)-4-[2-(3,4-Dichloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine




From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 3,4-dichlorophenyl boronic acid and diethylzinc.

Mainly one epimer. Colourless oil. MS (ISP): 291.1 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 289.0 ($[\{^{37}\text{Cl}^{35}\text{Cl}\}\text{M}+\text{H}]^+$), 287.1 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$).

In analogy to example 163 was prepared:

Example 223

(S)-4-[2-(2-Fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine




20

From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 2-fluorophenyl boronic acid and diethylzinc. Mainly one epimer. Colourless oil. MS (ISP): 237.1 ($[\text{M}+\text{H}]^+$).

25

Example 224

(RS)- 4-(4-Fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine



a) (RS)-Amino-(4-fluoro-2-trifluoromethyl-phenyl)-acetonitrile

To a stirred solution of 4-fluoro-2-(trifluoromethyl)benzaldehyde (5.0 g) in methanol (20 ml) were added sequentially ammonia solution (28.9 ml, 7 M solution in methanol) and tetraisopropyl orthotitanate (9.0 ml) and the resulting mixture was stirred at r.t. for 1 h. Trimethylsilylcyanide (3.3 ml) was then added dropwise and stirring continued at r.t. overnight. The reaction mixture was poured onto ice-water (400 ml) and the mixture was then extracted twice with ethyl acetate. The combined organic phases were washed with brine and then dried over sodium sulphate and concentrated *in vacuo* to afford (RS)-amino-(4-fluoro-2-trifluoromethyl-phenyl)-acetonitrile (4.48 g, 81%) as an orange viscous oil. MS (ISP): 219.1 ($[M+H]^+$).

b) (RS)-2-Amino-2-(4-fluoro-2-trifluoromethyl-phenyl)-acetamide hydrochloride

A solution of (RS)-amino-(4-fluoro-2-trifluoromethyl-phenyl)-acetonitrile (4.47 g) in formic acid (15 ml) saturated with hydrogen chloride was stirred at room temperature for 90 min. The mixture was then concentrated *in vacuo* and the residue was resuspended in acetone whereby white crystals formed. The crystals were collected by filtration, washed with acetone and dried *in vacuo* to afford (RS)-2-amino-2-(4-fluoro-2-trifluoromethyl-phenyl)-acetamide hydrochloride (1.40 g, 25%) as a white solid. MS (ISP): 273.1 ($[M+H]^+$).

c) (RS)-Amino-(4-fluoro-2-trifluoromethyl-phenyl)-acetic acid

2-amino-2-(4-fluoro-2-trifluoromethyl-phenyl)-acetamide hydrochloride (1.39 g) was suspended in 5 N aq hydrochloric acid (15 ml) and the mixture was heated at reflux for 3 h. The mixture was then concentrated *in vacuo*, and the residue was resuspended in isopropanol and concentrated *in vacuo* again. The residue was taken up in water and neutralised by dropwise addition of 1 N aq NaOH, whereby white crystals slowly formed. The crystals were collected by filtration and dried *in vacuo* at 50 °C to afford (RS)-amino-(4-fluoro-2-trifluoromethyl-phenyl)-acetic acid (0.75 g, 62%) as a white solid. MS (ISP): 237.9 ($[M+H]^+$).

d) (RS)-2-Amino-2-(4-fluoro-2-trifluoromethyl-phenyl)-ethanol

In analogy to example 185.a (RS)-amino-(4-fluoro-2-trifluoromethyl-phenyl)-acetic acid was converted to (RS)- 2-amino-2-(4-fluoro-2-trifluoromethyl-phenyl)-ethanol by treatment with lithium borohydride and chlorotrimethylsilane. Light yellow oil. MS

5 (ISP): 224.3 ($[M+H]^+$).


e) (RS)-4-(4-Fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

In analogy to example 1.b (RS)-2-amino-2-(4-fluoro-2-trifluoromethyl-phenyl)-ethanol was converted to (RS)-4-(4-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine by treatment with cyanogen bromide and potassium carbonate. White solid. MS (ISP): 249.1 ($[M+H]^+$).

In analogy to example 224 and starting from the respective aldehyde were prepared:

Example 225

15 (RS)-4-(5-Chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




From 5-chloro-2-(trifluoromethyl)benzaldehyde. Off-white solid.

MS (ISP): 267.1 ($[^{37}\text{Cl}]M+H^+$), 265.0 ($[^{35}\text{Cl}]M+H^+$).

20

Example 226

(RS)-4-(4-Chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine



From 4-chloro-2-(trifluoromethyl)benzaldehyde. White solid.


MS (ISP): 267.1 ($[^{37}\text{Cl}]M+H^+$), 265.0 ($[^{35}\text{Cl}]M+H^+$).

25

Example 227

(RS)-4-Methyl-4-(2,3,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

- 135 -




In analogy to example 206, the title compound was obtained starting from 2,3,5-trifluoroacetophenone. White solid.

MS (ISP): 231.1 ($[M+H]^+$)

5

Example 228

(S)-4-[2-(2-Chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine



a) (2S,5R)-2-[2-(2-Chloro-phenyl)-ethyl]-5-isopropyl-3,6-dimethoxy-2-methyl-2,5-dihydro-pyrazine

- 10 A solution of (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-5-methylpyrazine (1.0 g, 5.0 mmol) in tetrahydrofuran (23 ml) was cooled to -70 °C, then tert.butyllithium (1.7 M in pentane, 3.26 ml, 5.55 mmol) was added and the mixture was stirred for 1 hour. A solution of 1-(2-bromo-ethyl)-2-chlorobenzene (1.44 g, 6.56 mmol) in tetrahydrofuran (10 ml) was added slowly and the mixture was stirred overnight at -70 °C. At room
- 15 temperature saturated ammonium chloride solution was added and the mixture was extracted three times with ether. The combined organic layers were dried ($MgSO_4$), filtered and evaporated. The residue was purified by column chromatography (SiO_2 , heptane/EtOAc= 1:1 to yield an orange solid, (1.22 g, 72 %); MS (ISP): 337.1; 339.1 ($(M+H)^+$).

20

b) (S)-2-Amino-4-(2-chloro-phenyl)-2-methyl-butyric acid methyl ester

- To a solution of (2S,5R)-2-[2-(2-chloro-phenyl)-ethyl]-5-isopropyl-3,6-dimethoxy-2-methyl-2,5-dihydro-pyrazine (1.22 g, 3.62 mmol) in acetonitrile (12 ml) were added water (4 ml) and trifluoroacetic acid (2 ml). The mixture was stirred overnight at 40 °C.
- 25 Saturated ammonium chloride solution was added and the mixture was extracted with dichloromethane three times. The combined organic layers were dried ($MgSO_4$), filtered

and evaporated. The residue was purified by column chromatography (SiO₂, EtOAc/MeOH= 95:5 to yield a colorless oil, (0.46 g, 52 %); MS (ISP): 242.1; 244.1 ((M+H)⁺).

5 c) (S)-2-Amino-4-(2-chloro-phenyl)-2-methyl-butan-1-ol

To a suspension of lithium aluminum hydride (0.072 g, 1.9 mmol) in tetrahydrofuran (10 ml) was added a solution of (S)-2-amino-4-(2-chloro-phenyl)-2-methyl-butyric acid methyl ester (0.23 g, 0.95 mmol) in tetrahydrofuran (3 ml) and the mixture was stirred for 2 hours. Sodium sulphate solution (2M, 0.3 ml) was added and the mixture was
10 filtered through Celite. The solvent was evaporated and the residue was purified by chromatography (column: Isolute® Flash-NH₂ from Separtis; eluent: ethyl acetate/ MeOH = 95:5) to yield a colourless oil, (0.190 g, 93 %); MS (ISP): 214.0; 216.0 ((M+H)⁺).

d) (S)-4-[2-(2-Chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine


15 To a stirred mixture of (S)-2-amino-4-(2-chloro-phenyl)-2-methyl-butan-1-ol (0.190 g, 0.89 mmol) and K₂CO₃ (0.155 g, 1.12 mmol) in THF (10 ml) under an argon atmosphere was added a solution of cyanogen bromide (0.119 g, 1.12 mmol) in THF (1 ml). The mixture was stirred for 18 hours, then water and ethyl acetate were added. The organic layer was washed with water, dried over MgSO₄ and evaporated over Isolute® Flash-NH₂
20 silica gel. Chromatography (column: Isolute® Flash-NH₂ from Separtis; eluent: ethyl acetate/ MeOH = 90:10) yielded the title compound as off-white solid, (0.070 g, 33 %); MS (ISP): 239.2; 241.2 ((M+H)⁺).

In analogy to example 224 and starting from the respective aldehyde was prepared:

25

Example 229

(RS)-4-(4-Methoxy-2-(trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine



From 4-methoxy-2-(trifluoromethyl)benzaldehyde. White solid.


MS (ISP): 261.1 ([M+H]⁺).

30

Example 230

(R)-4-(4-Bromo-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

- 137 -



a) (RS)-4-(4-Bromo-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

In analogy to example 147, the title compound was obtained starting from 4-bromoacetophenone. White solid.

5 MS (ISP): 255.1 ($[M+H]^+$)

b) (R)-4-(4-Bromo-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine


(RS)-4-(4-Bromo-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 20:80) to give (R)-4-(4-bromo-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. White solid.

10

MS (ISP): 255.1 ($[M+H]^+$)

Example 231

(S)-4-(4-Bromo-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine




15 (RS)-4-(4-Bromo-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 20:80) to give (S)-4-(4-bromo-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. White solid.

MS (ISP): 255.2 ($[M+H]^+$)

Example 232

20 (S)-4-[2-(3-Chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine



a) (R)-4-(Benzothiazol-2-ylsulfanyl-methyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid
tert-butyl ester

In analogy to example 83a. from (R)-4-hydroxymethyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester. Yellow viscous oil.

5

b) (R)-4-(Benzothiazole-2-sulfonylmethyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid
tert-butyl ester

In analogy to example 83b. from (R)-4-(benzothiazol-2-ylsulfanyl-methyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester. Off-white solid. MS (ISP): 413.3

10 ([M+H]⁺).

c) (S)-4-[(E)-2-(3-Chloro-phenyl)-vinyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid
tert-butyl ester

In analogy to example 83c. from (R)-4-(benzothiazole-2-sulfonylmethyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester and 3-chloro-benzaldehyde. Off-white

15 solid. MS (ISP): 340.2 ([³⁷Cl]M+H)⁺, 338.2 ([³⁵Cl]M+H)⁺.

d) (E)-(S)-2-Amino-4-(3-chloro-phenyl)-but-3-en-1-ol

In analogy to example 83e. from (S)-4-[(E)-2-(3-chloro-phenyl)-vinyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester. Off-white solid.

20

e) (S)-2-Amino-4-(3-chloro-phenyl)-butan-1-ol

To a stirred solution of (E)-(S)-2-amino-4-(3-chloro-phenyl)-but-3-en-1-ol (155 mg) at r.t. in ethanol (5 ml) under an argon atmosphere was added 5 % Pt/C (16 mg). The mixture was stirred at r.t. under a hydrogen atmosphere for 20 hrs. The catalyst was

25 filtered off and the filtrate was concentrated to give (S)-2-amino-4-(3-chloro-phenyl)-butan-1-ol (102 mg, 65%) as light yellow oil. MS (ISP): 202.2 ([³⁷Cl]M+H)⁺, 200.2 ([³⁵Cl]M+H)⁺.

f) (S)-4-[2-(3-Chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine

30 In analogy to example 1b (S)-2-amino-4-(3-chloro-phenyl)-butan-1-ol was reacted with cyanogen bromide to give (S)-4-[2-(3-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine. Light yellow viscous oil. MS (ISP): 227.2 ([³⁷Cl]M+H)⁺, 225.1 ([³⁵Cl]M+H)⁺.


In analogy to example 224 and starting from the respective aldehyde were prepared:

35

- 139 -

Example 233

(RS)-4-(3-Chloro-2-fluoro-6-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




From 3-chloro-2-fluoro-6-(trifluoromethyl)benzaldehyde. White solid.

5 MS (ISP): 284.9 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 283.1 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$).

Example 234

(RS)-4-(4,5-Dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




10 From 4,5-dichloro-2-(trifluoromethyl)benzaldehyde. Orange solid.

MS (ISP): 303.0 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 301.0 ($[\{^{37}\text{Cl}^{35}\text{Cl}\}\text{M}+\text{H}]^+$), 299.0 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$).

In analogy to example 185 and starting from the respective amino acid or amino acid derivative was prepared:

15 Example 235

(RS)-4-(2,4-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine



From amino-(2,4-dichloro-phenyl)-acetic acid. White solid.


MS (ISP): 235.1 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 233.1 ($[\{^{37}\text{Cl}^{35}\text{Cl}\}\text{M}+\text{H}]^+$), 231.2 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$).

20

Example 236

(S)-4-(4-Chloro-3-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

- 140 -



a) (RS)-4-(4-Chloro-3-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

In analogy to example 206, the title compound was obtained starting from 4-bromoacetophenone. White solid.

5 MS (ISP): 229.4 ($[M+H]^+$)

b) (S)-4-(4-Chloro-3-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(4-Chloro-3-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 5:95) to give (S)-4-(4-chloro-3-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Off-white solid.


MS (ISP): 229.1 ($[M+H]^+$)

In analogy to example 185 and starting from the respective amino acid or amino acid derivative was prepared:

15

Example 237

(RS)-4-(2-Bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine




From amino-(2-bromo-phenyl)-acetic acid. White solid.

MS (ISP): 243.1 ($[^{81}\text{Br}]\text{M}+H]^+$), 241.1 ($[^{79}\text{Br}]\text{M}+H]^+$).

20

Examples 238 & 239

(+)-(S)-4-(4-Chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine & (-)-(R)-4-(4-Chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(4-Chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 226) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 5:95) to yield (+)-(S)-4-(4-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 267.1 ($[^{37}\text{Cl}]\text{M}+\text{H}^+$), 265.0 ($[^{35}\text{Cl}]\text{M}+\text{H}^+$)) and (-)-(R)-4-(4-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 267.1 ($[^{37}\text{Cl}]\text{M}+\text{H}^+$), 265.0 ($[^{35}\text{Cl}]\text{M}+\text{H}^+$)).

10

Examples 240 & 241

(+)-(S)-4-(4-Methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine & (-)-(R)-4-(4-Methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(4-Methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 229) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 5:95) to yield (+)-(S)-4-(4-methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (colourless gum; MS (ISP): 261.1 ($[\text{M}+\text{H}]^+$)) and (-)-(R)-4-(4-methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (colourless gum; MS (ISP): 261.1 ($[\text{M}+\text{H}]^+$)).

20

Examples 242 & 243


(+)-(S)-4-(4,5-Dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine & (-)-(R)-4-(4,5-Dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine



(RS)-4-(4,5-Dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example
 5 234) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 5:95) to yield (+)-
 (S)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (white
 solid; MS (ISP): 303.0 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 301.0 ($[\{^{37}\text{Cl}^{35}\text{Cl}\}\text{M}+\text{H}]^+$), 299.0
 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$)) and (-)-(R)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-
 oxazol-2-ylamine (white solid; MS (ISP): 303.0 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 301.0
 10 ($[\{^{37}\text{Cl}^{35}\text{Cl}\}\text{M}+\text{H}]^+$), 299.0 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$)).

Example 244


(S)-4-[2-(4-Chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine



15 The title compound, MS (ISP): 239.1; 241.2 ($(\text{M}+\text{H})^+$) was obtained in comparable yield
 analogous to the procedure described for Example 228 using 1-(2-bromo-ethyl)-4-
 chlorobenzene instead of 1-(2-bromo-ethyl)-2-chlorobenzene in step a).

Example 245

20 (S)-4-Methyl-4-[2-(3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




The title compound, MS (ISP): 273.0 ($(M+H)^+$) was obtained in comparable yield analogous to the procedure described for Example 228 using 1-(2-iodo-ethyl)-3-trifluoromethyl-benzene instead of 1-(2-bromo-ethyl)-2-chlorobenzene in step a).

5

Example 246

(S)-4-[2-(3-Chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine




The title compound, MS (ISP): 239.1; 241.2 ($(M+H)^+$) was obtained in comparable yield analogous to the procedure described for Example 228 using 1-(2-bromo-ethyl)-3-chlorobenzene instead of 1-(2-bromo-ethyl)-2-chlorobenzene in step a).

10

Examples 247 & 248

(-)-(R)-4-(4-Fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine & (+)-(S)-4-(4-Fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine



15

(RS)-4-(4-Fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 224) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 5:95) to yield (-)-(R)-4-(4-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (colourless oil; MS (ISP): 249.1 ($[M+H]^+$) and (+)-(S)-4-(4-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (colourless oil; MS (ISP): 249.1 ($[M+H]^+$)).


20

In analogy to example 224 and starting from the respective aldehyde were prepared:

Example 249

(RS)-4-(5-Fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

- 144 -




From 5-fluoro-2-(trifluoromethyl)benzaldehyde. Light yellow solid.

MS (ISP): 249.1 ($[M+H]^+$).

Example 250

5 (RS)-4-(5-Fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




From 5-fluoro-2-methyl-benzaldehyde. White solid.

MS (ISP): 195.1 ($[M+H]^+$).

Example 251

10 (RS)-4-Methyl-4-(2,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




In analogy to example 206, the title compound was obtained starting from 2,4,5-trifluoroacetophenone. Viscous colorless oil.

MS (ISP): 231.3 ($[M+H]^+$)

15

Example 252

(RS)-4-(4-Bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine



a) (RS)-2-Amino-2-(4-bromo-3-fluoro-phenyl)-ethanol

In analogy to example 224a-d 4-bromo-3-fluorobenzaldehyde was treated sequentially
20 with ammonia/tetraisopropyl orthotitanate/trimethylsilyl cyanide, hydrogen chloride in


formic acid, hydrochloric acid, and lithium borohydride/chlorotrimethylsilane to give (RS)-2-amino-2-(4-bromo-3-fluoro-phenyl)-ethanol. Yellow viscous oil. MS (ISP): 236.1 ($[\{^{81}\text{Br}\}\text{M}+\text{H}]^+$), 234.1 ($[\{^{79}\text{Br}\}\text{M}+\text{H}]^+$).

5 b) (RS)-4-(4-Bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

To a stirred, cooled (0 °C) solution of (RS)-2-amino-2-(4-bromo-3-fluoro-phenyl)-ethanol (3.26 g) and sodium acetate (2.22 g) in methanol (25 ml) was added dropwise a solution of cyanogen bromide (1.52 g) in methanol (10 ml) over 10 min. The mixture was then allowed to warm to at r.t. and stirring continued for 16 h. The mixture was
 10 concentrated *in vacuo* and the residue was resuspended in water and made basic by addition of 1 M aq sodium hydroxide solution. The mixture was then extracted twice with dichloromethane and the combined organic phases were dried over sodium sulphate and concentrated *in vacuo*. The residue was triturated in dichloromethane and the resultant crystals washed with ether to give (RS)-4-(4-bromo-3-fluoro-phenyl)-4,5-
 15 dihydro-oxazol-2-ylamine (1.09 g, 30%) as a white solid. MS (ISP): 261.0 ($[\{^{81}\text{Br}\}\text{M}+\text{H}]^+$), 258.9 ($[\{^{79}\text{Br}\}\text{M}+\text{H}]^+$).

Example 253


(-)-(S)-4-(3-Chloro-2-fluoro-6-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine



20 (RS)-4-(3-Chloro-2-fluoro-6-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 233) was separated by chiral HPLC (Chiralpak AD, iPrOH/heptane = 5:95) to yield (-)-(S)-4-(3-chloro-2-fluoro-6-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 284.9 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 283.1 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$).

Example 254

25 (S)-4-Methyl-4-(4-trifluoromethoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine



a) (RS)-4-Methyl-4-(4-trifluoromethoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine

In analogy to example 147, the title compound was obtained starting from 4'-(trifluoromethoxy)acetophenone. Viscous colorless oil.


MS (ISP): 261.0 ($[M+H]^+$)

- 5 b) (S)-4-Methyl-4-(4-trifluoromethoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine
((RS)-4-Methyl-4-(4-trifluoromethoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 10:90) to give (S)-4-methyl-4-(4-trifluoromethoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Viscous colorless oil.

10 MS (ISP): 261.0 ($[M+H]^+$)

Example 255


(S)-4-[2-(4-Fluoro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine



- The title compound, MS (ISP): 223.3 ($[M+H]^+$) was obtained in comparable yield
15 analogous to the procedure described for Example 228 using 1-(2-bromo-ethyl)-4-fluorobenzene instead of 1-(2-bromo-ethyl)-2-chlorobenzene in step a).

Example 256


(S)-4-[2-(4-Chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine



- 20 The title compound, MS (ISP): 225.3; 227.2 ($[M+H]^+$) was obtained in comparable yield
analogous to the procedure described for Example 228 using (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-pyrazine instead of (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-5-methylpyrazine and 1-(2-bromo-ethyl)-4-chloro-benzene instead of 1-(2-bromo-ethyl)-2-chlorobenzene in step a).
25

Example 257

(S)-4-[1-(4-Chloro-phenyl)-cyclopropylmethyl]-4,5-dihydro-oxazol-2-ylamine



a) 1-Chloro-4-(1-iodomethyl-cyclopropyl)-benzene

- 5 To a stirred solution of triphenylphosphine (3.45 g, 13 mmol) and imidazole (0.90 g, 13 mmol) in dichloromethane (25 ml) under an argon atmosphere was added slowly iodine (3.33 g, 13 mmol) and [1-(4-chlorophenyl)-cyclopropyl]-methanol (2.00 g, 11 mmol). The mixture was stirred for 2 hours at room temperature, then dichloromethane (75 ml) was added and mixture was extracted with saturated sodium thiosulfate solution (100 ml)
- 10 and hydrochloric acid (1N, 50 ml). The organic layer was dried over MgSO_4 and evaporated. The residue was suspended in ether and filtered to remove insoluble triphenylphosphine oxide. The ether was evaporated and the residue was purified by column chromatography (SiO_2 , heptane/EtOAc= 9:1) to yield a light yellow oil, (2.30 g, 72 %); MS (EI): 292.0 (M^+).


15

b) (S)-4-[1-(4-Chloro-phenyl)-cyclopropylmethyl]-4,5-dihydro-oxazol-2-ylamine

- The title compound, MS (ISP): 251.1; 253.1 ($(\text{M}+\text{H})^+$) was obtained in comparable yield analogous to the procedure described for Example 228 using (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-pyrazine instead of (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-
- 20 isopropyl-5-methylpyrazine and 1-chloro-4-(1-iodomethyl-cyclopropyl)-benzene instead of 1-(2-bromo-ethyl)-2-chlorobenzene in step a).

Example 258

(S)-4-[2-(3,4-Difluoro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine




25

The title compound, MS (ISP): 241.1 ($(M+H)^+$) was obtained in comparable yield analogous to the procedure described for Example 228 using 1-(2-iodo-ethyl)-3,4-difluorobenzene instead of 1-(2-bromo-ethyl)-2-chlorobenzene in step a).

5

Example 259

(+)-(S)-4-(5-Fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-(S)-4-(5-Fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 249) was separated by chiral HPLC (Chiralpak AD, iPrOH/heptane = 5:95) to yield (+)-
10 (S)-4-(5-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 249.1 ($[M+H]^+$).

In analogy to example 252 and starting from the respective aldehyde was prepared:

15

Example 260

(RS)-4-(2,5-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine




From 2,5-dichlorobenzaldehyde. White solid. MS (ISP): 235.0 ($[^{37}\text{Cl}]M+H^+$), 233.0 ($[^{37}\text{Cl}^{35}\text{Cl}]M+H^+$), 231.1 ($[^{35}\text{Cl}]M+H^+$).

20

Example 261

(RS)-4-(2-Chloro-4,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine




In analogy to example 206, the title compound was obtained starting from 2-chloro-4,5-difluoroacetophenone. White solid.

MS (ISP): 247.1 ($[M+H]^+$)

Example 262

(RS)-4-(3,4-Difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine




- 5 In analogy to example 206, the title compound was obtained starting from 3,4-difluoroacetophenone. White solid.

MS (ISP): 213.3 ($[M+H]^+$)

Example 263

(RS)-4-(4-Chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine




10

- In analogy to example 206, the title compound was obtained starting from 4-chloro-3-methylacetophenone. White solid.

MS (ISP): 225.1 ($[M+H]^+$)

Examples 264 & 265


- 15 (-)-(R)-4-(2-Bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine & (+)-(S)-4-(2-Bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine



- (RS)-4-(2-Bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 237) was separated by chiral HPLC (Chiralpak AD, iPrOH/heptane = 5:95) to yield (-)-(R)-4-(2-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 243.1 ($[^{81}\text{Br}]M+H^+$), 241.1 ($[^{79}\text{Br}]M+H^+$) and (+)-(S)-4-(2-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 243.1 ($[^{81}\text{Br}]M+H^+$), 241.1 ($[^{79}\text{Br}]M+H^+$)).
- 20

Example 266

(S)-4-(3-Chloro-5-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine



a) (RS)-4-(3-Chloro-5-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

- 5 In analogy to example 206, the title compound was obtained starting from 3'-chloro-5'-fluoroacetophenone. White solid.


MS (ISP): 229.1 ([M+H]⁺)

b) (S)-4-(3-Chloro-5-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

- 10 (RS)-4-(3-Chloro-5-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 15:850) to give (S)-4-(3-chloro-5-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. White solid.
MS (ISP): 229.1 ([M+H]⁺)

Example 267

- 15 (S)-4-[2-(2-Chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




- The title compound, MS (ISP): 225.1; 227.1 ((M+H)⁺) was obtained in comparable yield analogous to the procedure described for Example 228 using (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-pyrazine instead of (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-5-methylpyrazine and 1-(2-bromo-ethyl)-2-chloro-benzene instead of 1-(2-bromo-ethyl)-2-chlorobenzene in step a).
- 20

Example 268

(RS)-4-(4-Chloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine

- 151 -



a) (RS)-2-Amino-2-(4-chloro-phenyl)-butyronitrile

A solution of 4'-chloropropiophenone (5 g) in MeOH (20 ml) was treated under an argon atmosphere and at r.t. with 7M NH₃ in MeOH (33.9 ml). Then, tetraisopropyl orthotitanate (10.54 ml) was added dropwise. The reaction mixture was stirred for 1 hr at r.t.. Then, trimethylsilyl cyanide (3.72 ml) was added and stirring was continued at r.t. overnight. The reaction mixture was poured in ice and extracted with EtOAc. The organic layer was dried over MgSO₄, filtered and concentrated. The crude (RS)-2-amino-2-(4-chloro-phenyl)-butyronitrile (4.95 g) was used in the next reaction step without further purification.

b) (RS)-2-Amino-2-(4-chloro-phenyl)-butyric acid hydrochloride

A solution of (RS)-2-amino-2-(4-chloro-phenyl)-butyronitrile (4.9 g) in 5 HCl (30 ml) was refluxed overnight, then cooled to r.t. and washed with EtOAc. The aqueous layer was concentrated. The crude (RS)-2-amino-2-(4-chloro-phenyl)-butyric acid hydrochloride (3.0 g) was used in the next reaction step without further purification.


c) (RS)-4-(4-Chloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine

In analogy to example 206.b and c (RS)-2-amino-2-(4-chloro-phenyl)-butyric acid hydrochloride was converted to the title compound. White solid.

MS (ISP): 225.1 ([M+H]⁺)

Example 269

(RS)-4-Methyl-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




In analogy to example 206, the title compound was obtained starting from 2,3,4-trifluoroacetophenone. Off-white solid.

MS (ISP): 231.1 ($[M+H]^+$)

Example 270

(S)-4-(5-Chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine



5 a) (S)-4-(5-Chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

In analogy to example 206, the title compound was obtained starting from 5'-chloro-2'-fluoroacetophenone. White solid.

MS (ISP): 229.3 ($[M+H]^+$)

10 b) (RS)-4-(5-Chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine


(RS)-4-(5-Chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 5:95) to give (S)-4-(5-chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. White solid.

MS (ISP): 229.1 ($[M+H]^+$)

15

Example 271

(RS)-4-Methyl-4-(4-chloro-2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine



20 a) (RS)-4-(4-Chloro-2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

In analogy to example 147.a, but stirring the reaction mixture overnight instead of 3 hrs, the title compound was obtained starting from 4-chloro-2,5 -difluoro-acetophenone. Off-white solid.

MS (ISP): 247.1 ($[M+H]^+$)

25 b) (RS)-4-(4-Chloro-2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

The title compound was obtained in analogy to example 206.b and 206.c. Off-white solid.


MS (ISP): 247.1 ($[M+H]^+$)

In analogy to example 252 and starting from the respective aldehyde was prepared:

- 153 -

Example 272


(RS)-4-(5-Chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine



From 5-chloro-2-methylbenzaldehyde. White solid. MS (ISP): 213.1 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$),
 5 211.1 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$).

Example 273


(RS)-4-Methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine



The title compound was obtained in analogy to example 268 starting from 3',4',5'-
 10 trifluoro-acetophenone. White solid.
 MS (ISP): 231.3 ($[\text{M}+\text{H}]^+$)

Example 274


(RS)-4-(4-Chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine



15 The title compound was obtained in analogy to example 268 starting from 4-chloro-2-fluoro-5-methyl-acetophenone. White solid.
 MS (ISP): 243.1 ($[\text{M}+\text{H}]^+$)

Example 275

(S)-4-[1-(4-Chloro-phenyl)-cyclobutylmethyl]-4,5-dihydro-oxazol-2-ylamine



20

a) 1-Chloro-4-(1-iodomethyl-cyclobutyl)-benzene


To a stirred solution of triphenylphosphine (4.91 g, 18.7 mmol) and imidazole (1.28 g, 18.7 mmol) in dichloromethane (40 ml) under an argon atmosphere was added slowly iodine (4.75 g, 18.7 mmol) and [1-(4-chlorophenyl)-cyclopropyl]-methanol (3.07 g, 15.6 mmol). The mixture was stirred for 2 hours at room temperature, then dichloromethane (100 ml) was added and mixture was extracted with saturated sodium thiosulfate solution (100 ml) and hydrochloric acid (1 N, 50 ml). The organic layer was dried over MgSO_4 and evaporated. The residue was suspended in ether and filtered to remove insoluble triphenylphosphine oxide. The ether was evaporated and the residue was purified by column chromatography (SiO_2 , heptane/EtOAc= 9:1) to yield a colourless oil, (2.50 g, 52 %); MS (EI): 306.0 (M^+); 179.0 ($(\text{M}-\text{I})^+$).

b) (S)-4-[1-(4-Chloro-phenyl)-cyclobutylmethyl]-4,5-dihydro-oxazol-2-ylamine

The title compound, MS (ISP): 265.0; 267.1 ($(\text{M}+\text{H})^+$) was obtained in comparable yield analogous to the procedure described for Example 228 using (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-pyrazine instead of (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-5-methylpyrazine and 1-chloro-4-(1-iodomethyl-cyclobutyl)-benzene instead of 1-(2-bromo-ethyl)-2-chlorobenzene in step a).

Example 276

(R)-4-(3-Chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine



a) (R)-4-(3-Chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

In analogy to example 206, the title compound was obtained starting from 3-chloro-4-fluoro-acetophenone. Viscous colorless oil.

MS (ISP): 229.4 ($[\text{M}+\text{H}]^+$)

b) ((R)-4-(3-Chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine


(RS)-4-(3-Chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 1:9) to give (R)-4-(3-chloro-4-

fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. Off-white solid.

MS (ISP): 229.1 ($[M+H]^+$)

Example 277

5 (R)-4-(3-Chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(3-Chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 1:9) to give (S)-4-(3-chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. Off-white solid.

MS (ISP): 229.1 ($[M+H]^+$)

Examples 278 & 279

(-)-(R)-4-(5-Fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine & (+)-(S)-4-(5-Fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(5-Fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 250) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 10:90) to yield (-)-(R)-4-(5-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 195.1 ($[M+H]^+$) and (+)-(S)-4-(5-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 195.1 ($[M+H]^+$)).

Example 280

(R)-4-(4-Chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

- 156 -




(RS)-4-(4-Chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine (example 263) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 1:9) to give (R)-4-(4-chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer.

5 White solid.

MS (ISP): 225.1 ($[M+H]^+$)

Example 281

(S)-4-(4-Chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine



10 (RS)-4-(4-Chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine (example 263) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 1:9) to give (S)-4-(4-chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer.


White solid.

MS (ISP): 225.3 ($[M+H]^+$)

15

Example 282

(R)-4-(3,4-Difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine



(RS)-4-(3,4-Difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine (example 262) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 1:9) to give (R)-4-(3,4-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (-)-Enantiomer. White solid.


20

MS (ISP): 213.1 ($[M+H]^+$)

- 157 -

Example 283

(S)-4-(3,4-Difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine



(RS)-4-(3,4-Difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine (example 262)
5 was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 1:9) to give (S)-4-(3,4-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine. (+)-Enantiomer. White solid.


MS (ISP): 213.3 ($[M+H]^+$)

In analogy to example 87 were prepared:

10

Example 284


(S)-4-(3,4-Dichloro-phenoxy-methyl)-4,5-dihydro-oxazol-2-ylamine



From tert-butyl (S)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylate and 3,4-dichlorophenol. White solid. MS (ISP): 265.0 ($[^{37}\text{Cl}]M+H^+$), 263.0
15 ($[^{37}\text{Cl}^{35}\text{Cl}]M+H^+$), 261.0 ($[^{35}\text{Cl}]M+H^+$).

Example 285

(S)-4-(3,5-Dichloro-phenoxy-methyl)-4,5-dihydro-oxazol-2-ylamine




20

From tert-butyl (S)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylate and 3,5-dichlorophenol. Colourless oil. MS (ISP): 265.1 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 263.1 ($[\{^{37}\text{Cl}^{35}\text{Cl}\}\text{M}+\text{H}]^+$), 261.1 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$).

5

Example 286

(S)-4-(3-Trifluoromethyl-phenoxy-methyl)-4,5-dihydro-oxazol-2-ylamine




From tert-butyl (S)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylate and 3-(trifluoromethyl)phenol. Colourless oil. MS (ISP): 261.0 ($[\text{M}+\text{H}]^+$).

10 In analogy to example 162 was prepared:

Example 287

(S)-4-[2-(3-Chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine




15 From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 3-chlorophenyl boronic acid and diethylzinc. Mainly one epimer. Colourless oil. MS (ISP): 255.3 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 253.3 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$).

Example 288

20


(S)-4-(3-Phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine



The title compound, MS (ISP): 205.1 ($(M+H)^+$) was obtained in comparable yield analogous to the procedure described for Example 228 using (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-pyrazine instead of (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-5-methylpyrazine and (3-bromo-propyl)-benzene instead of 1-(2-bromo-ethyl)-2-chlorobenzene in step a).

Example 289

(S)-4-(4-Chloro-2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(4-Chloro-2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine (example 271) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 5:95) to give the title compound. (+)-Enantiomer. White solid.
MS (ISP): 247.1 ($[M+H]^+$)

In analogy to example 252 and starting from the respective aldehyde were prepared:

Example 290


(RS)-4-(2-Fluoro-6-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine



From 2-fluoro-6-trifluoromethyl-benzaldehyde. White solid. MS (ISP): 248.9 ($[M+H]^+$).

Example 291


(RS)-4-(4-Bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine



From 4-bromo-2-chloro-benzaldehyde. White solid. MS (ISP): 278.9 ($[^{81}\text{Br}^{37}\text{Cl}]M+H^+$), 276.9 ($[^{81}\text{Br}^{35}\text{Cl}$ or $^{79}\text{Br}^{37}\text{Cl}]M+H^+$), 274.9 ($[^{79}\text{Br}^{35}\text{Cl}]M+H^+$).

Example 292

(S)-4-((S)-2-Phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine



a) ((R)-1-Iodomethyl-propyl)-benzene

- 5 To a solution of triphenylphosphine (15.4 g, 59 mmol) and imidazole (3.99 g, 59 mmol) in dichloromethane (150 ml) at room temperature was added portionwise iodine (14.9 g, 50 mmol) at such a rate that the temperature of the reaction mixture did not rise above 30 °C. To the mixture was then added a solution of (R)-2-phenyl-butan-1-ol (7.34 g, 41 mmol, CAS 16460-75-6) in dichloromethane (50 ml) and the mixture was then stirred at
- 10 room temperature overnight. The mixture was then concentrated *in vacuo* and the residue was resuspended in ether and the resulting crystals collected by filtration. The filtrate was concentrated *in vacuo* and the residue was triturated in heptane. The resulting crystals were removed by filtration and the filtrate was concentrated *in vacuo*. The residue was purified by column chromatography (SiO₂, heptane/EtOAc) to yield a colourless oil,
- 15 (6.38 g, 60 %).

b) (2R,5S)-2-Isopropyl-3,6-dimethoxy-5-((S)-2-phenyl-butyl)-2,5-dihydro-pyrazine

- A solution of (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-5-methylpyrazine (4.25 g, 23.1 mmol) in tetrahydrofuran (30 ml) was cooled to -78 °C, then n-butyllithium (1.6 M
- 20 in hexane, 15.1 ml, 24.2 mmol) was added and the mixture was stirred for 1 hour. A solution of ((R)-1-iodomethyl-propyl)-benzene (6.30 g, 24.2 mmol) in tetrahydrofuran (30 ml) was added dropwise over 30 min and the mixture was stirred overnight while being allowed to warm slowly from -70 °C to room temperature. The reaction was quenched by addition of saturated aqueous ammonium chloride solution and the
- 25 mixture was extracted with ether. The organic layer was separated, washed with saturated brine, then dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by column chromatography (SiO₂, heptane/EtOAc) to yield a light yellow oil (4.69 g, 64%); MS (ISP): 317.0 ([M+H]⁺).

- 30 c) (2S,4S)-2-Amino-4-phenyl-hexanoic acid methyl ester

To a solution of trifluoroacetic acid (3.4 ml) in water (440 ml) was added dropwise over 15 min a solution of (2R,5S)-2-isopropyl-3,6-dimethoxy-5-((S)-2-phenyl-butyl)-2,5-dihydro-pyrazine (4.69 g, 14.8 mmol) in acetonitrile (75 ml). The mixture was stirred overnight at room temperature then made basic by addition of saturated aqueous sodium carbonate solution and the mixture was extracted with ethyl acetate. The phases were separated and the organic phase was washed sequentially with water and with saturated brine, then dried over Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by column chromatography (SiO₂, EtOAc/heptane) to yield a yellow oil (2.78 g, 85 %); MS (ISP): 222.1 ([M+H]⁺).

10

d) (2S,4S)-2-Amino-4-phenyl-hexan-1-ol

To a suspension of lithium aluminum hydride (121 mg, 3.18 mmol) in tetrahydrofuran (8 ml) was added a solution of (2S,4S)-2-amino-4-phenyl-hexanoic acid methyl ester (320 mg, 1.45 mmol) in tetrahydrofuran (10 ml) and the mixture was stirred for 16 hours. The reaction was quenched by dropwise addition of ethyl acetate, then acidified to pH 5 by addition of hydrochloric acid and then made basic by addition of saturated aqueous sodium bicarbonate solution. The mixture was taken up in ethyl acetate/tetrahydrofuran (1:1), the phases were separated and the organic phase was washed sequentially with water and with saturated brine. The organic phase was then dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by chromatography (column: Isolute[®] Flash-NH₂ from Separtis; eluent: dichloromethane/MeOH) to yield a yellow oil, (116 mg, 42 %); MS (ISP): 194.4 ([M+H]⁺).

15

20

25

e) (S)-4-((S)-2-Phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine

To a stirred, cooled (0 °C) solution of (2S,4S)-2-amino-4-phenyl-hexan-1-ol (270 mg, 1.40 mmol) and sodium acetate (229 mg, 2.70 mmol) in methanol (20 ml) was added dropwise a solution of cyanogen bromide (180 mg, 1.68 mmol) in methanol (2 ml) over 10 min. The mixture was then allowed to warm to r.t. and stirring was continued for 16 h. The mixture was concentrated *in vacuo* and the residue was taken up in ethyl acetate and washed sequentially with saturated aqueous sodium bicarbonate solution and with saturated brine. The organic phase was dried over sodium sulphate and concentrated *in vacuo*. The residue was purified by chromatography (column: Isolute[®] Flash-NH₂ from Separtis; eluent: heptane/EtOAc/MeOH) to yield a light yellow solid. MS (ISP): 219.3 ([M+H]⁺).


30

35

- 162 -

Example 293


(S)-4-((R)-2-Phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine



The title compound, MS (ISP): 219.4 ($(M+H)^+$) was obtained in comparable yield
 5 analogous to the procedure described for Example 292 starting from (S)-2-phenyl-butan-
 1-ol (CAS 33442-47-6). Colourless oil. MS (ISP): 219.4 ($[M+H]^+$).

Example 294

(RS)-4-(2,4-Dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine



10


The title compound was obtained in analogy to example 268 starting from 2',4'-dichloro-
 acetophenone. Off-white viscous oil.

MS (ISP): 245.3 ($[M+H]^+$)

15

Examples 295 & 296

(-)-(R)-4-(2,4-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine & (+)-(S)-4-(2,4-
 Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(2,4-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 235) was
 20 separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 5:95) to yield (-)-(R)-4-(2,4-
 dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 235.0
 ($[^{37}\text{Cl}]M+H^+$), 233.0 ($[^{37}\text{Cl}^{35}\text{Cl}]M+H^+$), 231.1 ($[^{35}\text{Cl}]M+H^+$)) and (+)-(S)-4-(2,4-
 dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 235.0
 ($[^{37}\text{Cl}]M+H^+$), 233.0 ($[^{37}\text{Cl}^{35}\text{Cl}]M+H^+$), 231.1 ($[^{35}\text{Cl}]M+H^+$)).

25

Examples 297 & 298


(-)-(R)-4-(2,5-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine & (+)-(S)-4-(2,5-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine



- 5 (RS)-4-(2,5-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 260) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 5:95) to yield (-)-(R)-4-(2,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 235.0 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 233.0 ($[\{^{37}\text{Cl}^{35}\text{Cl}\}\text{M}+\text{H}]^+$), 231.1 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$)) and (+)-(S)-4-(2,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 235.0 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 233.0 ($[\{^{37}\text{Cl}^{35}\text{Cl}\}\text{M}+\text{H}]^+$), 231.1 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$)).
- 10

Example 299

(RS)-4-(2,5-Dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine




- 15 The title compound was obtained in analogy to example 271 starting from 2',5'-dichloro-acetophenone. Off-white viscous oil.
MS (ISP): 245.3 ($[\text{M}+\text{H}]^+$)

Examples 300 & 301

(-)-(R)-4-(2,3,4-Trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine & (+)-(S)-4-(2,3,4-Trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

20



(RS)-4-(2,3,4-Trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 17) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 5:95) to yield (-)-(R)-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 217.3


($[M+H]^+$) and (+)-(S)-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 217.3 ($[M+H]^+$)).

In analogy to example 252 and starting from the respective aldehyde was prepared:

5

Example 302

(RS)-4-(4-Bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




From 4-bromo-2-trifluoromethyl-benzaldehyde. White solid. MS (ISP): 311.0 ($[^{81}\text{Br}]M+H^+$), 309.1 ($[^{79}\text{Br}]M+H^+$).

10

Example 303

(S)-4-[2-(2-chloro-6-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




The title compound, MS (ISP): 243.0; 245.1 ($[M+H]^+$) was obtained in comparable yield analogous to the procedure described for Example 228 using (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-pyrazine instead of (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-5-methylpyrazine and 2-chloro-6-fluoro-1-(2-iodo-ethyl)-benzene instead of 1-(2-bromo-ethyl)-2-chlorobenzene in step a).

20

Example 304

(S)-4-[2-(2,4-dichloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine




The title compound, MS (ISP): 273.1; 275.0 ($[M+H]^+$) was obtained in comparable yield analogous to the procedure described for Example 228 using 2,4-dichloro-1-(2-iodo-ethyl)-benzene instead of 1-(2-bromo-ethyl)-2-chlorobenzene in step a).

5

Example 305

(R)-4-Methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-Methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 273) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 1:9) to give the title

10 compound. (-)-Enantiomer. White solid.

MS (ISP): 231.1 ($[M+H]^+$)

Example 306

(S)-4-Methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




15 (RS)-4-Methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 273) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 1:9) to give the title compound. (+)-Enantiomer. White solid.

MS (ISP): 231.1 ($[M+H]^+$)

Example 307

20 (R)-4-(4-Chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(4-Chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine (example 274) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 5:95) to give the title compound. (-)-Enantiomer. Waxy white solid.

25 MS (ISP): 243.3 ($[M+H]^+$)

Example 308

(S)-4-(4-Chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(4-Chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine (example 274) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 5:95) to give the title compound. (+)-Enantiomer. Waxy white solid.

MS (ISP): 243.3 ($[M+H]^+$)

Example 309

(RS)-4-(4-Methoxy-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine




The title compound was obtained in analogy to example 271 starting from 4-methoxyacetophenone. White solid.

MS (ISP): 206.9 ($[M+H]^+$)

In analogy to example 87 was prepared:

Example 310


(S)-4-(4-Bromo-phenoxy-methyl)-4,5-dihydro-oxazol-2-ylamine



From tert-butyl (S)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylate and 4-bromophenol. White solid. MS (ISP): 273.1 ($[^{37}\text{Cl}]M+H^+$), 271.1 ($[^{35}\text{Cl}]M+H^+$).

Example 311

(RS)-4-(3-Chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine




The title compound was obtained in analogy to example 268 starting from 3-chloro-2-fluoro-acetophenone. White solid.

MS (ISP): 229.1 ($[M+H]^+$)

Example 312

5 (R)-4-(4-Chloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(4-Chloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine (example 268) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 5:95) to give the title compound. (-)-Enantiomer. White solid.

10 MS (ISP): 225.1 ($[M+H]^+$)

Example 313

(S)-4-(4-Chloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine




15 (RS)-4-(4-Chloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine (example 268) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 5:95) to give the title compound. (+)-Enantiomer. White solid.

MS (ISP): 225.1 ($[M+H]^+$)

Example 314

(+)-(S)-4-(5-Chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




20

(RS)-4-(5-Chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 272) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 5:95) to yield (+)-(S)-4-(5-chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 213.1 ($[^{37}\text{Cl}]M+H^+$), 211.1 ($[^{35}\text{Cl}]M+H^+$)).

25

Examples 315 & 316


(-)-(R)-4-(4-Bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine & (+)-(S)-4-(4-Bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine



(RS)-4-(4-Bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 291) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 5:95) to yield (-)-(R)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 278.9 ($[\{^{81}\text{Br}^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 276.9 ($[\{^{81}\text{Br}^{35}\text{Cl}\text{ or }^{79}\text{Br}^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 274.9 ($[\{^{79}\text{Br}^{35}\text{Cl}\}\text{M}+\text{H}]^+$) and (+)-(S)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 278.9 ($[\{^{81}\text{Br}^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 276.9 ($[\{^{81}\text{Br}^{35}\text{Cl}\text{ or }^{79}\text{Br}^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 274.9 ($[\{^{79}\text{Br}^{35}\text{Cl}\}\text{M}+\text{H}]^+$)).

Example 317


(-)-(S)-4-(2-Fluoro-6-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine



(RS)-4-(2-Fluoro-6-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 290) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 5:95) to yield (-)-(S)-4-(2-fluoro-6-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 248.9 ($[\text{M}+\text{H}]^+$)).

Example 318

(RS)-4-(2-Chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine



The title compound was obtained in analogy to example 206 starting from 2-chloro-4-fluoro-acetophenone. Off-white solid.


MS (ISP): 229.1 ($[\text{M}+\text{H}]^+$)

In analogy to example 87 was prepared:

Example 319

- 169 -

(S)-4-p-Tolyloxymethyl-4,5-dihydro-oxazol-2-ylamine




From tert-butyl (S)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylate and 4-methyl-phenol. White solid. MS (ISP): 207.3 ($[M+H]^+$).

5

Examples 320 & 321


(-)-(R)-4-(4-Bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine & (+)-(S)-4-(4-Bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine



- 10 (RS)-4-(4-Bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 252) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 20:80) to yield (-)-(R)-4-(4-bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 261.0 ($[^{81}\text{Br}]M+H^+$), 258.9 ($[^{79}\text{Br}]M+H^+$)) and (+)-(S)-4-(4-bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 261.0 ($[^{81}\text{Br}]M+H^+$), 258.9 ($[^{79}\text{Br}]M+H^+$)).
- 15

Example 322


(S)-4-[2-(2-Bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine



- The title compound, MS (ISP): 191.3 ($[M-\text{Br}+H]^+$); 269.1; 271.1 ($[M+H]^+$) was obtained in comparable yield analogous to the procedure described for Example 228 using (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-pyrazine instead of (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-5-methylpyrazine and 2-bromo-1-(2-iodo-ethyl)-benzene instead of 1-(2-bromo-ethyl)-2-chlorobenzene in step a).
- 20

Example 323

(R)-4-Benzylsulfanylmethyl-4,5-dihydro-oxazol-2-ylamine




- 5 The title compound, MS (ISP): 223.2 ($[M+H]^+$) was obtained in comparable yield analogous to the procedure described for Example 195 using S-benzyl-L-cysteine instead of S-phenyl-L-cysteine in step a).

In analogy to example 87 was prepared:

Example 324

10 (S)-4-(4-Chloro-2-fluorophenoxymethyl)-4,5-dihydro-oxazol-2-ylamine




From tert-butyl (S)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylate and 4-chloro-2-fluorophenol. White solid. MS (ISP): 247.2 ($[^{37}\text{Cl}]M+H^+$), 245.2 ($[^{35}\text{Cl}]M+H^+$).

15

Example 325

((S)-4-Cyclohexyl-4,5-dihydro-oxazol-2-ylamine



The title compound was obtained in analogy to example 1.b starting from (S)-2-amino-2-cyclohexyl-ethanol. White solid.


- 20 MS (ISP): 169.1 ($[M+H]^+$)

In analogy to example 252 and starting from the respective aldehyde was prepared:

Example 326

(RS)-4-(4-Bromo-3-chlorophenyl)-4,5-dihydro-oxazol-2-ylamine

- 171 -




From 4-bromo-3-chloro-benzaldehyde. White solid. MS (ISP): 278.9

($[\{^{81}\text{Br}^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 277.0 ($[\{^{81}\text{Br}^{35}\text{Cl}\}\text{M}+\text{H}]^+$ or $[\{^{79}\text{Br}^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 274.9 ($[\{^{79}\text{Br}^{35}\text{Cl}\}\text{M}+\text{H}]^+$).


5

Example 327

(RS)-4-(3,4-Dichloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine



a) (S)-4-(3,4-Dichloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine



10 In analogy to example 206, the title compound was obtained starting from 3,4-dichloropropiophenone. White solid.

b) (R)-4-(3,4-Dichloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine


15 (S)-4-(3,4-Dichloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 1:9) to give the title compound. (-)-Enantiomer. Off-white solid.

MS (ISP): 259.0 ($[\text{M}+\text{H}]^+$)

Example 328

20 (S)-4-(3,4-Dichloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine

- 172 -




(RS)-4-(3,4-Dichloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, EtOH/heptane 1:9) to give the title compound. (+)-Enantiomer. Off-white solid.

5 MS (ISP): 258.8 ($[M+H]^+$)

Examples 329 & 330


(-)-(R)-4-(4-Bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine & (+)-(S)-4-(4-Bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine



10 (RS)-4-(4-Bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 326) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 20:80) to yield (-)-(R)-4-(4-bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 278.9 ($[^{81}\text{Br}^{37}\text{Cl}]M+H^+$), 277.0 ($[^{81}\text{Br}^{35}\text{Cl}$ or $^{79}\text{Br}^{37}\text{Cl}]M+H^+$), 274.9 ($[^{79}\text{Br}^{35}\text{Cl}]M+H^+$)) and (+)-(S)-4-(4-bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid;
15 MS (ISP): 278.9 ($[^{81}\text{Br}^{37}\text{Cl}]M+H^+$), 277.0 ($[^{81}\text{Br}^{35}\text{Cl}$ or $^{79}\text{Br}^{37}\text{Cl}]M+H^+$), 274.9 ($[^{79}\text{Br}^{35}\text{Cl}]M+H^+$)).

Example 331


(RS)-4-(2,3-Dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine



20 The title compound was obtained in analogy to example 271 starting from 2,3-dichloro-acetophenone. White solid.
MS (ISP): 245.3 ($[M+H]^+$)

Example 332

(S)-4-(2-Cyclohexyl-ethyl)-4,5-dihydro-oxazol-2-ylamine




The title compound was obtained in analogy to example 1 starting from (+)-ethyl-(S)-2-amino-4-cyclohexylbutyrate. Off-white solid.

5 MS (ISP): 197.1 ($[M+H]^+$)

Example 333

(S)-4-[2-(2,5-Dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine




The title compound, MS (ISP): 258.9; 261.0 ($[M+H]^+$) was obtained in comparable yield
 10 analogous to the procedure described for Example 228 using (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-pyrazine instead of (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-5-methylpyrazine and 1-(2-bromo-ethyl)-2,5-dichloro-benzene instead of 1-(2-bromo-ethyl)-2-chlorobenzene in step a).

In analogy to example 163 were prepared:

15

Example 334


(S)-4-[2-(2,4-Difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine



From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl
 20 ester by sequential treatment with 2,4-difluorophenyl boronic acid and diethylzinc.
 Mainly one epimer. Colourless oil. MS (ISP): 255.1 ($[M+H]^+$).

Example 335


(S)-4-[2-(2,3,4-Trifluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine



- 5 From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 2,3,4-trifluorophenyl boronic acid and diethylzinc. Mainly one epimer. Colourless oil. MS (ISP): 273.1 ($[M+H]^+$).

Example 336

10 (S)-4-[2-(3,4,5-Trifluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine




From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 3,4,5-trifluorophenyl boronic acid and diethylzinc. Mainly one epimer. Colourless oil. MS (ISP): 273.1 ($[M+H]^+$).

- 15 In analogy to example 252 and starting from the respective aldehyde was prepared:

Example 337


(RS)-4-(4-Fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine



- 20 From 4-fluoro-2-methyl-benzaldehyde. White solid. MS (ISP): 195.1 ($[M+H]^+$)

Examples 338 & 339

(+)-(S)-4-(4-Bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine & (-)-(R)-4-(4-Bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




- 5 (RS)-4-(4-Bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 302) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 20:80) to yield (-)-(R)-4-(4-bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (colourless viscous oil; MS (ISP): 311.0 ($[^{81}\text{Br}]\text{M}+\text{H}^+$), 309.1 ($[^{79}\text{Br}]\text{M}+\text{H}^+$)) and (+)-(S)-4-(4-bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (colourless viscous oil; MS (ISP): 311.0 ($[^{81}\text{Br}]\text{M}+\text{H}^+$), 309.1 ($[^{79}\text{Br}]\text{M}+\text{H}^+$)).

In analogy to example 163 was prepared:

Example 340


(S)-4-[2-(3-Fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine



- 15 From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 3-fluorophenyl boronic acid and diethylzinc. Mainly one epimer. Colourless oil. MS (ISP): 237.3 ($[\text{M}+\text{H}]^+$).

Example 341

- 20 (+)-(S)-4-(5-Chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(5-Chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 225) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 20:80) to yield (-)-

(S)-4-(5-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (off-white solid; MS (ISP): 267.1 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 265.0 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$).

Example 342

5 (S)-4-(1-Phenyl-cyclopropylmethyl)-4,5-dihydro-oxazol-2-ylamine




The title compound, MS (ISP): 217.1 ($[\text{M}+\text{H}]^+$) was obtained in comparable yield analogous to the procedure described for Example 257 using (1-phenyl-cyclopropyl)-methanol instead of [1-(4-chlorophenyl)-cyclopropyl]-methanol in step a).

10 In analogy to example 87 was prepared:

Example 343

(S)-4-(3-Chloro-phenoxy-methyl)-4,5-dihydro-oxazol-2-ylamine




15

From tert-butyl (S)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylate and 3-chloro-phenol. Colourless oil. MS (ISP): 229.2 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 227.2 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$).

Example 344

20 (RS)-4-(4-Chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine



a) 4-Chloro-2-ethyl-benzaldehyde

The title compound was obtained starting from 4-chloro-2-fluoro-benzaldehyde by sequential treatment with N-butylamine/p-toluenesulphonic acid and ethylmagnesium chloride/manganese(II) chloride according to the procedures described in *Synthesis* 1999, 2138-2144 and WO 2007/085557. Yellow oil.

5


b) (RS)-4-(4-Chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

In analogy to example 252, the title compound was obtained starting from 4-chloro-2-ethyl-benzaldehyde. Light yellow solid. MS (ISP): 227.1 ($[^{37}\text{Cl}]\text{M}+\text{H}^+$), 225.1 ($[^{35}\text{Cl}]\text{M}+\text{H}^+$).

10

Examples 345

(-)-(R)-4-Methyl-4-(2,3,6-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine



a) (RS)-4-Methyl-4-(2,3,6-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

In analogy to example 206, the title compound was obtained starting from 1-(2,3,6-trifluoro-phenyl)-ethanone. White solid. MS (ISP): 231.3 ($[\text{M}+\text{H}]^+$)

15


a) (-)-(R)-4-Methyl-4-(2,3,6-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-Methyl-4-(2,3,6-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine was separated by chiral HPLC (Chiralpak AD, iPrOH/heptane = 5:95) to yield (-)-(R)-4-methyl-4-(2,3,6-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 231.1 ($[\text{M}+\text{H}]^+$).

20

Examples 346

(+)-(S)-4-Methyl-4-(2,3,6-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-Methyl-4-(2,3,6-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (Example 345.a) was separated by chiral HPLC (Chiralpak AD, iPrOH/heptane = 5:95) to yield (+)-(S)-4-methyl-4-(2,3,6-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 231.1 ($[\text{M}+\text{H}]^+$).

25

Examples 347 & 348

(-)-(R)-4-(4-Fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine & (+)-(S)-4-(4-Fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(4-Fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 337) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 10:90) to yield (-)-(R)-4-(4-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 195.1 ($[M+H]^+$) and (+)-(S)-4-(4-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 195.1 ($[M+H]^+$)).

In analogy to example 252 and starting from the respective aldehyde was prepared:

10

Example 349

(RS)-4-(4-Bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine




From 4-bromo-2-fluoro-benzaldehyde. White solid. MS (ISP): 261.0 ($[^{81}\text{Br}]M+H^+$), 258.9 ($[^{79}\text{Br}]M+H^+$).

15

In analogy to example 1 was prepared:

Example 350

(S)-4-Benzyloxymethyl-4,5-dihydro-oxazol-2-ylamine



From O-benzyl-L-serine methyl ester. Colourless oil. MS (ISP): 206.9 ($[M+H]^+$)

20


In analogy to example 252 and starting from the respective aldehyde was prepared:

Example 351

(RS)-4-(3-Chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

25


- 179 -



From 3-chloro-4-methyl-benzaldehyde. White solid. MS (ISP): 213.1 ($[^{37}\text{Cl}]\text{M}+\text{H}^+$), 211.0 ($[^{35}\text{Cl}]\text{M}+\text{H}^+$).

Example 352

5 (+)-(R)-4-(5-Chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(5-Chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 225) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 20:80) to yield (+)-(R)-4-(5-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (off-white
10 solid; MS (ISP): 267.1 ($[^{37}\text{Cl}]\text{M}+\text{H}^+$), 265.0 ($[^{35}\text{Cl}]\text{M}+\text{H}^+$).

In analogy to example 87 were prepared:

Example 353

(S)-4-(2,4-Difluoro-phenoxy-methyl)-4,5-dihydro-oxazol-2-ylamine




15 From tert-butyl (S)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylate and 2,4-difluorophenol. Colourless oil. MS (ISP): 229.2 ($[\text{M}+\text{H}]^+$).

Example 354

(S)-4-(2-Fluoro-phenoxy-methyl)-4,5-dihydro-oxazol-2-ylamine

- 180 -




From tert-butyl (S)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylate and 2,4-difluorophenol. Colourless oil. MS (ISP): 211.1 ($[M+H]^+$).

In analogy to example 162 were prepared:

5

Example 355

(S)-4-[2-(3-Chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine




From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 3-chloro-2-fluorophenyl boronic acid and diethylzinc.

10 Mainly one epimer. Colourless oil. MS (ISP): 273.2 ($[^{37}\text{Cl}]M+H^+$), 271.3 ($[^{35}\text{Cl}]M+H^+$).

Example 356

(S)-4-[2-(3-Chloro-4-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine




15 From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 3-chloro-4-fluorophenyl boronic acid and diethylzinc.

Mainly one epimer. Colourless oil. MS (ISP): 273.1 ($[^{37}\text{Cl}]M+H^+$), 271.1 ($[^{35}\text{Cl}]M+H^+$).

Example 357

20 (S)-4-[2-(3-Chloro-5-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine

- 181 -




From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 3-chloro-5-fluorophenyl boronic acid and diethylzinc. Mainly one epimer. Colourless oil. MS (ISP): 273.3 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 271.3

5 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$)).

Example 358

(S)-4-[2-(5-Chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine




From (S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester by sequential treatment with 5-chloro-2-fluorophenyl boronic acid and diethylzinc. Mainly one epimer. Colourless oil. MS (ISP): 273.1 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 271.1 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$)).

In analogy to example 344 was prepared:

Example 359

15 (RS)-4-(4-Chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine



Starting from 4-chloro-2-fluoro-benzaldehyde. White solid. MS (ISP): 239.1 ($[\{^{37}\text{Cl}\}\text{M}+\text{H}]^+$), 237.1 ($[\{^{35}\text{Cl}\}\text{M}+\text{H}]^+$)).


In analogy to example 1 were prepared:

20

Example 360

(S)-4-Cyclohexylmethyl-4,5-dihydro-oxazol-2-ylamine

- 182 -




From (S)-2-amino-3-cyclohexyl-propan-1-ol. White amorphous solid.

MS (ISP): 183.2 ($[M+H]^+$)

Example 361

5 (R)-4-(3-Phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine




From D-2-amino-5-phenyl-pentanoic acid. Light yellow amorphous solid.

MS (ISP): 205.3 ($[M+H]^+$)

Example 362

10 (S)-4-[(Benzyl-ethyl-amino)-methyl]-4,5-dihydro-oxazol-2-ylamine



a) (S)-4-(Benzylamino-methyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester

To a stirred solution of tert-butyl (R)-(-)-4-formyl-2,2-dimethyl-3-oxazolinecarboxylate
 15 (2.0 g) at r.t. in methanol (20 ml) under an argon atmosphere was added benzylamine
 (0.935 g) and the mixture was stirred overnight at 60 °C. Then at room temperature
 NaBH₄ (0.495 g) was added and the mixture was stirred for additional 4 h. This was taken
 up in dichloromethane and aqueous sodium bicarbonate solution. The aqueous phase
 was back extracted with dichloromethane. The combined organics were dried over
 20 MgSO₄, filtered and concentrated. The crude product was purified by column
 chromatography (column: Isolute® Flash-NH₂ from Separtis; eluent: heptane/ethyl
 acetate= 1:1) to give (S)-4-(benzylamino-methyl)-2,2-dimethyl-oxazolidine-3-carboxylic
 acid tert-butyl ester (1.72 g, 61 %) as colourless oil. MS (ISP): 321.1 ($[M+H]^+$)

b) (S)-4-[(Benzyl-ethyl-amino)-methyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester

To a stirred solution of (S)-4-(benzylamino-methyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (800 mg) at r.t. in methanol (10 ml) under an argon atmosphere were added acetaldehyde (0.70 ml), ZnCl₂ (1.36 g) and NaBH₃CN (0.47 g). The mixture was warmed to 50 °C and stirring at that temperature was continued for 17 h. The mixture was cooled to r.t. and partitioned between ammonium chloride solution and dichloromethane. The combined organic layers were dried over MgSO₄, filtered and concentrated. The residue was purified by column chromatography (column: Isolute® Flash-NH₂ from Separtis; eluent: heptane/ethyl acetate= 1:1) to give (S)-4-[(benzyl-ethyl-amino)-methyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (160 mg, 18 %) as colorless oil. MS (ISP): 293.5 ([M-tBu+H]⁺)


c) (S)-4-[(Benzyl-ethyl-amino)-methyl]-4,5-dihydro-oxazol-2-ylamine

To a stirred solution of (S)-4-(benzylamino-methyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (155 mg) in ethanol (2 ml) under an argon atmosphere was added HCl solution (5 M in ethanol; 2.0 ml). The mixture was stirred at 60 °C for 2 hours and concentrated. The residue was taken up in EtOAc and washed with 1N NaOH. The aqueous layer was back extracted with EtOAc. The combined organics were washed with brine, dried over MgSO₄ and concentrated. The residue was dissolved in methanol (2 ml) and sodium acetate (79 mg) was added. Under ice cooling cyanogen bromide (51 mg) was added and stirring was continued for 18 h. The mixture was directly adsorbed on silica gel and purified by column chromatography (Isolute® SPE flash NH₂ column, aminopropyl-functionalized silica; gradient: CH₂Cl₂ -> CH₂Cl₂/MeOH 9:1) to provide (R)-4-[(ethyl-phenyl-amino)-methyl]-4,5-dihydro-oxazol-2-ylamine (25 mg, 22 %) as colourless oil. MS (ISP): 234.3 ([M+H]⁺)

Examples 363 & 364

(-)-(R)-4-(4-Chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine & (+)-(S)-4-(4-Chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

- 184 -



(RS)-4-(4-Chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 344) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 10:90) to yield (-)-(R)-4-(4-chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 227.1


- 5 ([$\{^{37}\text{Cl}\}\text{M}+\text{H}\}^+$), 225.1 ([$\{^{35}\text{Cl}\}\text{M}+\text{H}\}^+$)) and (+)-(S)-4-(4-chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 227.1 ([$\{^{37}\text{Cl}\}\text{M}+\text{H}\}^+$), 225.1 ([$\{^{35}\text{Cl}\}\text{M}+\text{H}\}^+$)).

In analogy to example 252 and starting from the respective aldehyde was prepared:

10

Example 365

(RS)-4-(3-Fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




From 3-fluoro-2-methyl-benzaldehyde. Light yellow solid. MS (ISP): 195.3 ([$\text{M}+\text{H}\}^+$)).

15

Examples 366 & 367


(-)-(R)-4-(4-Bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine & (+)-(S)-4-(4-Bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine



- (RS)-4-(4-Bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 349) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 10:90) to yield (-)-(R)-4-(4-bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 261.0 ([$\{^{81}\text{Br}\}\text{M}+\text{H}\}^+$), 258.9 ([$\{^{79}\text{Br}\}\text{M}+\text{H}\}^+$)) and (+)-(S)-4-(4-bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 261.0 ([$\{^{81}\text{Br}\}\text{M}+\text{H}\}^+$), 258.9 ([$\{^{79}\text{Br}\}\text{M}+\text{H}\}^+$)).
- 20

Examples 368 & 369

(-)-(R)-4-(4-Chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine & (+)-(S)-4-(4-Chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




- 5 (RS)-4-(4-Chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 359) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 10:90) to yield (-)-(R)-4-(4-chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 239.1 ([^{37}Cl]M+H) $^{+}$), 237.1 ([^{35}Cl]M+H) $^{+}$) and (+)-(S)-4-(4-chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 239.1 ([^{37}Cl]M+H) $^{+}$),
 10 237.1 ([^{35}Cl]M+H) $^{+}$).

In analogy to example 87 was prepared:

Example 370

(R)-4-(4-Chloro-phenylsulfanylmethyl)-4,5-dihydro-oxazol-2-ylamine



15


From tert-butyl (S)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylate and 4-chloro-thiophenol. White crystals. MS (ISP): 245.2 ([^{37}Cl]M+H) $^{+}$), 243.2 ([^{35}Cl]M+H) $^{+}$).

In analogy to example 252 and starting from the respective aldehyde was prepared:

20

Example 371

(RS)-4-(3-Fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




From 3-fluoro-2-(trifluoromethyl)-benzaldehyde. Yellow solid. MS (ISP): 249.3 ($[M+H]^+$).

In analogy to example 332 was prepared:

5

Example 372

(R)-4-(2-Cyclohexyl-ethyl)-4,5-dihydro-oxazol-2-ylamine




Starting from (+)-ethyl-(S)-2-amino-4-cyclohexylbutyrate. White crystals. MS (ISP): 197.2 ($[M+H]^+$).

10

Examples 373 & 374

(-)-(R)-4-(3-Chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine & (+)-(S)-4-(3-Chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine




(RS)-4-(3-Chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (example 351) was separated by chiral HPLC (Chiralpak AD, EtOH/heptane = 20:80) to yield (-)-(R)-4-(3-chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 213.1 ($[^{37}\text{Cl}]M+H^+$), 211.0 ($[^{35}\text{Cl}]M+H^+$)) and (+)-(S)-4-(3-chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine (white solid; MS (ISP): 213.1 ($[^{37}\text{Cl}]M+H^+$), 211.0 ($[^{35}\text{Cl}]M+H^+$)).

20

Example 375

(S)-4-[2-(3-Chloro-phenyl)-5,5,5-trifluoro-pentyl]-4,5-dihydro-oxazol-2-ylamine



a) rac-2-(3-Chloro-phenyl)-5,5,5-trifluoro-pentanoic acid

To a stirred solution of m-chlorophenylacetic acid (2.38 g, 14 mmol) in tetrahydrofuran (85 ml) was added at -78 °C lithium diisopropylamide solution (31 ml 1M in THF, 31 mmol). After stirring the mixture for 20 min 1-iodo-3,3,3-trifluoropropane (4.38 g, 20 mmol) was added and the mixture was allowed to warm to room temperature overnight.

5 Water (5 ml) was added followed by 2N hydrochloric acid (10 ml). The reaction mixture was extracted twice with ethyl acetate. The combined organic layers were dried over MgSO₄ and evaporated and the residue was purified by column chromatography (SiO₂, heptane/EtOAc= 9:1) to yield a colourless oil, (1.75 g, 47 %); MS (EI): 264.9 (M⁺).

10 b) rac-2-(3-Chloro-phenyl)-5,5,5-trifluoro-pentan-1-ol

To a stirred solution of 2-(3-chloro-phenyl)-5,5,5-trifluoro-pentanoic acid (1.75 g, 7 mmol) in tetrahydrofuran (40 ml) under an argon atmosphere was added slowly lithium aluminum hydride (0.4 g, 11 mmol) and the mixture was stirred for 17 hours at room temperature. For work-up water (1.5 ml) and 2N sodium hydroxide solution (0.5 ml)

15 were added and the mixture was stirred for 30 min. After filtration the solvent was evaporated and the residue was purified by column chromatography (SiO₂, heptane/EtOAc= 1:1 to yield a colourless oil, (1.25 g, 75 %); MS (EI): 311.0 ((M+OAc)⁺).

c) rac-1-Chloro-3-(4,4,4-trifluoro-1-iodomethyl-butyl)-benzene

20 To a stirred solution of triphenylphosphine (1.56 g, 6.0 mmol) and imidazole (0.41 g, 6.0 mmol) in dichloromethane (16 ml) under an argon atmosphere was added slowly iodine (1.51 g, 6.0 mmol) and 2-(3-chloro-phenyl)-5,5,5-trifluoro-pentan-1-ol (1.26 g, 5.0 mmol). The mixture was stirred for 2 hours at room temperature, then dichloromethane (50 ml) was added and mixture was extracted with saturated sodium thiosulfate solution

25 (50 ml) and hydrochloric acid (1N, 25 ml). The organic layer was dried over MgSO₄ and evaporated. The residue was suspended in ether and filtered to remove insoluble triphenylphosphine oxide. The ether was evaporated and the residue was purified by column chromatography (SiO₂, heptane/EtOAc= 9:1) to yield a light yellow liquid, (1.73 g, 96 %); (EI): 235.0 ((M-I)⁺).

30

d) (S)-4-[2-(3-Chloro-phenyl)-5,5,5-trifluoro-pentyl]-4,5-dihydro-oxazol-2-ylamine

The title compound, MS (ISP): 321.1 ((M+H)⁺) was obtained in comparable yield analogous to the procedure described for Example 228 using (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-pyrazine instead of (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-


isopropyl-5-methylpyrazine and rac-1-chloro-3-(4,4,4-trifluoro-1-iodomethyl-butyl)-benzene instead of 1-(2-bromo-ethyl)-2-chlorobenzene in step a).

Analogously to Example 1 there were prepared:

5

Example 376

(R)-4-((R)-1-Benzoyloxy-ethyl)-4,5-dihydro-oxazol-2-ylamine




From O-Benzyl-L-threonine. White solid. MS (ISP): 221.4 ($[M+H]^+$).

10

Example 377

(S)-4-(4-Chloro-benzoyloxymethyl)-4,5-dihydro-oxazol-2-ylamine




From O-p-chlorobenzyl-L-serine. Light yellow oil. MS (ISP): 241.2; 243.3 ($[M+H]^+$).

15

Example 378

(R)-4-[(Dimethyl-phenyl-silanyl)-methyl]-4,5-dihydro-oxazol-2-ylamine



The title compound, MS (ISP): 158.2 ($[M-Ph+H]^+$), 235.1 ($[M+H]^+$) was obtained in comparable yield analogous to the procedure described for Example 228 using (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-pyrazine instead of (R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-5-methylpyrazine and chloromethyl dimethyl phenylsilane instead of 1-(2-bromo-ethyl)-2-chlorobenzene in step a).


Examples A - G

Additionally the following known compounds were prepared as TAARI ligands using procedures analogous to those describe above:

- A: (S)-4-Phenyl-4,5-dihydro-oxazol-2-ylamine (CAS 165035-65-4)
- 5 B: (R)-4-Phenyl-4,5-dihydro-oxazol-2-ylamine (CAS 165035-66-5)
- C: (S)-4-Benzyl-4,5-dihydro-oxazol-2-ylamine (CAS 856899-65-5)
- D: (RS)-4-Phenethyl-4,5-dihydro-oxazol-2-ylamine (CAS 103522-08-3)
- E: 4,4-Diphenyl-4,5-dihydro-oxazol-2-ylamine (CAS 132798-69-7)
- F: (RS)-4-Benzyloxymethyl-4,5-dihydro-oxazol-2-ylamine (CAS 103521-92-2)
- 10 G: (RS)-4-Cyclohexyl-4,5-dihydro-oxazol-2-ylamine (CAS 63204-74-0)

Claims

1. The use of a compound of formula



wherein

R¹ is hydrogen, deuterium, tritium, C₁₋₇-alkyl, C₁₋₇-alkoxy, C₁₋₇-alkyl substituted by halogen, C₁₋₇-alkoxy substituted by halogen, halogen, phenyl optionally substituted by halogen, or is phenyloxy, benzyl, benzyloxy, -COO-C₁₋₇-alkyl, -O-(CH₂)_o-O-C₁₋₇-alkyl, NH-C₃₋₆-cycloalkyl, C₃₋₆-cycloalkyl or tetrahydropyran-4-yloxy, wherein the substituents for n > 1 may be the same or different;

X is a bond, -CHR-, -CHRCHR'-, -OCH₂-, -CH₂OCHR-, -CH₂CH₂CH₂-, -SCH₂-, -S(O)₂CH₂-, -CH₂SCH₂-, -CH₂N(R)CH₂-, -C₃₋₆-cycloalkyl-CH₂- or SiRR'-CH₂-;

R/R' may be independently from each other hydrogen, C₁₋₇-alkyl or C₁₋₇-alkyl substituted by halogen;

R² is hydrogen, phenyl or C₁₋₇-alkyl;

Y is phenyl, naphthyl, thiophenyl, pyridinyl, C₃₋₆-cycloalkyl, 1,2,3,4-tetrahydro-naphthalen-2-yl, 2,3-dihydrobenzo[1,4]dioxin-6-yl or benzo[1,3]dioxol-5-yl;

n is 0, 1, 2 or 3;

o is 2 or 3;

or of a pharmaceutically suitable acid addition salt for the manufacture of medicaments for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases are anxiety disorders, bipolar disorder, psychotic disorders, neurological diseases, Parkinson's disease, neurodegenerative disorders,

Alzheimer's disease, epilepsy, migraine, and metabolic disorders, diabetes, diabetic complications, dyslipidemia, disorders of energy consumption and assimilation, and disorders and malfunction of body temperature homeostasis.

2. The use of a compound of formula I according to claim 1, wherein X is a bond.

3. The use of a compound of formula I according to claim 2, wherein Y is phenyl, substituted by one or more halogen atoms.

4. The use of a compound of formula I according to claim 3, wherein the compounds are

- (S)-4-(2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(4-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(2,3-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(3,4-dichlorophenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(3-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(5-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(4-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(3-bromo-2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(3,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(4-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(2,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(3-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(2,3,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(3,4-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(4-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(3,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(2,3-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(4-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(3-chloro-4-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

(S)-4-(4-chloro-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-5-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(5-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(3-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(3,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2,4-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(2,3,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-bromo-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-3-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(2,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(2-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-5-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(5-chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(4-chloro-2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(-)-(R)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine

(+)-(S)-4-(2,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2,5-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine
(-)-(R)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2-chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,4-dichloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine or
(S)-4-(4-bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine.

5. The use of a compound of formula I according to claim 2, wherein Y is phenyl substituted by CH₃, CF₃, OCH₃, OCF₃ or OCH₂-phenyl.

6. The use of a compound of formula I according to claim 5, which compounds are

(RS)-4-(2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-o-tolyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-trifluoromethoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-o-tolyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-benzyloxy-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-methyl-4-(4-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-methyl-4-p-tolyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-methyl-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

7. The use of a compound of formula I according to claim 2, wherein Y is phenyl substituted by phenyl, which is optionally substituted by halogen.
8. The use of a compound of formula I according to claim 7, which compounds are
(RS)-4-biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine
(S)-4-biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine or
(RS)-4-(4'-chloro-biphenyl-4-yl)-4,5-dihydro-oxazol-2-ylamine.
9. The use of a compound of formula I according to claim 2, wherein Y is phenyl substituted by OCH₃ or by halogen and CF₃, halogen and CH₃, halogen and C₃₋₆-cycloalkyl or by halogen and OCH₃.
10. The use of a compound of formula I according to claim 9, wherein the compounds are
(RS)-4-(3-chloro-4-methoxyphenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-4-methoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-fluoro-4-trifluoromethyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(5-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(-)-(R)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(5-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(5-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(5-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(5-chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(5-chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

- 195 -

(+)-(S)-4-(4-bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(5-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine.
(S)-4-(4-chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine or
(S)-4-(3-chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine.

11. The use of a compound of formula I according to claim 1, wherein X is CHR and Y is phenyl.

12. The use of a compound of formula I according to claim 11, which compounds are
(S)-4-(2-chloro-benzyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-trifluoromethyl-benzyl)-4,5-dihydro-oxazol-2-ylamine or
(RS)-4-(2-fluoro-5-methyl-benzyl)-4,5-dihydro-oxazol-2-ylamine

13. The use of a compound of formula I according to claim 1, wherein X is CHRCHR' and Y is phenyl.

14. The use of a compound of formula I according to claim 13, which compounds are
(R)-4-phenethyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-phenethyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-phenethyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-methyl-4-phenethyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-phenethyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-3-methoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
((S)-4-[2-(2,4-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine

- 196 -

- (S)-4-[2-(3,5-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-o-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-m-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-p-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(R)-4-[2-(3,4-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-2-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-4-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-3-methyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-3-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,3-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-(1-methyl-2-phenyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-difluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine

- 197 -

(S)-4-[2-(4-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-dichloro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-dichloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-((S)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-((R)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-6-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,4-dichloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,5-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-4-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-5-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine or
(S)-4-[2-(5-chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine.

15. The use of a compound of formula I according to claim 1, wherein X is OCH_2 and Y is phenyl.

16. The use of a compound of formula I according to claim 15, which compounds are

(S)-4-(4-fluoro-phenoxy-methyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-phenoxy-methyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,4-dichloro-phenoxy-methyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,5-dichloro-phenoxy-methyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-bromo-phenoxy-methyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-phenoxy-methyl)-4,5-dihydro-oxazol-2-ylamine

- 198 -

(S)-4-(2,4-difluoro-phenoxyethyl)-4,5-dihydro-oxazol-2-ylamine or
(S)-4-(2-fluoro-phenoxyethyl)-4,5-dihydro-oxazol-2-ylamine.

17. The use of a compound of formula I according to claim 1, wherein X is CH_2OCHR and Y is phenyl, wherein the compound is

(S)-4-benzyloxyethyl-4,5-dihydro-oxazol-2-ylamine.

18. The use of a compound of formula I according to claim 1, wherein X is $-(\text{CH}_2)_3-$ and Y is phenyl, wherein the compounds are

(S)-4-(3-phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine or

(R)-4-(3-phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine.

19. The use of a compound of formula I according to claim 1, wherein X is $-\text{SCH}_2-$, $-\text{S(O)}_2\text{CH}_2-$, or $-\text{CH}_2\text{SCH}_2-$ and Y is phenyl, wherein the compounds are

(R)-4-phenylsulfanylmethyl-4,5-dihydro-oxazol-2-ylamine

(R)-4-benzenesulfonylmethyl-4,5-dihydro-oxazol-2-ylamine

(R)-4-benzylsulfanylmethyl-4,5-dihydro-oxazol-2-ylamine or

(R)-4-(4-chloro-phenylsulfanylmethyl)-4,5-dihydro-oxazol-2-ylamine.

20. The use of a compound of formula I according to claim 1, wherein X is $-\text{CH}_2\text{N(R)CH}_2-$, C_{3-6} -cycloalkyl- CH_2- or $\text{SiRR}'-\text{CH}_2-$ and Y is phenyl, which compounds are

(S)-4-[1-(4-chloro-phenyl)-cyclopropylmethyl]-4,5-dihydro-oxazol-2-ylamine

(S)-4-[1-(4-chloro-phenyl)-cyclobutylmethyl]-4,5-dihydro-oxazol-2-ylamine

(S)-4-(1-phenyl-cyclopropylmethyl)-4,5-dihydro-oxazol-2-ylamine

(S)-4-[(benzyl-ethyl-amino)-methyl]-4,5-dihydro-oxazol-2-ylamine or

(R)-4-[(dimethyl-phenyl-silanyl)-methyl]-4,5-dihydro-oxazol-2-ylamine.

21. The use of a compound of formula I according to claim 1, wherein X is described in claim 1 and Y is naphthyl, pyridyl, cyclohexyl, 2,3-dihydrobenzo[1,4]dioxin or 1,2,3,4-tetrahydronaphthalen, which compounds are

(RS)-4-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine

(RS)-4-naphthalen-1-yl-4,5-dihydro-oxazol-2-ylamine

(R)-4-naphthalen-1-ylmethyl-4,5-dihydro-oxazol-2-ylamine


(S)-4-naphthalen-1-ylmethyl-4,5-dihydro-oxazol-2-ylamine

(S)-4-naphthalen-2-ylmethyl-4,5-dihydro-oxazol-2-ylamine

- 199 -

- (RS)-4-(1,2,3,4-tetrahydro-naphthalen-2-yl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine
 (S)-4-[2-(3-fluoro-pyridin-4-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
 (S)-4-[2-(6-trifluoromethyl-pyridin-2-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
 (S)-4-[2-(2-methyl-pyridin-4-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine or
 (S)-4-(2-cyclohexyl-ethyl)-4,5-dihydro-oxazol-2-ylamine.

22. A compound of formula I-A according to formula I in claim 1,



wherein

R^1 is halogen, for $n > 1$ the halogen atom may be the same or different;

R^2 is hydrogen, phenyl or C_{1-7} -alkyl;

n is 1, 2 or 3;

or a pharmaceutically suitable acid addition salt, with the exception of 4-(4-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine.

23. A compound of formula I-A according to claim 22, which compounds are

- (S)-4-(2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(4-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(2,3-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(3,4-dichlorophenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(3-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(5-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(3-bromo-2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(3,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(4-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(2,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(3-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine


- 200 -

(S)-4-(2,3,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,4-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2,3-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-4-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-5-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(5-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(3-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(3,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2,4-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(2,3,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-bromo-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-3-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(2,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(2-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-5-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(5-chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

-201-

(RS)-4-methyl-4-(4-chloro-2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(3-chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(4-chloro-2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
 (-)-(R)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (+)-(S)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (+)-(S)-4-(2,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(2,5-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
 (+)-(S)-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(3-chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(4-chloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine
 (-)-(R)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (+)-(S)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(2-chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
 (+)-(S)-4-(4-bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(4-bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (S)-4-(3,4-dichloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine
 (+)-(S)-4-(4-bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
 (RS)-4-(4-bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine or
 (S)-4-(4-bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine.

24. A compound of formula I-B according to formula I in claim 1,



R^1 is CH_3 , CF_3 , OCH_3 , OCF_3 or OCH_2 -phenyl;

R^2 is hydrogen, phenyl or C_{1-7} -alkyl;

n is 1, 2 or 3;

or a pharmaceutically suitable acid addition salt, with the exception of

4-(4-trifluoromethyl-phenyl)4,5-dihydro-oxazol-2-ylamine,


4-(4-methoxy-phenyl)4,5-dihydro-oxazol-2-ylamine and

4-(3,4-dimethoxy-phenyl)4,5-dihydro-oxazol-2-ylamine.

-202-

25. A compound of formula I-B according to claim 24, which compounds are
- (RS)-4-(2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - (RS)-4-o-tolyl-4,5-dihydro-oxazol-2-ylamine
 - (RS)-4-(4-trifluoromethoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - (RS)-4-(4-methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - (S)-4-o-tolyl-4,5-dihydro-oxazol-2-ylamine
 - (RS)-4-(4-benzyloxy-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - (S)-4-(2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - (S)-4-(4-methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - (S)-4-methyl-4-(4-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - (S)-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - (S)-4-methyl-4-p-tolyl-4,5-dihydro-oxazol-2-ylamine
 - (S)-4-methyl-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - (RS)-4-(4-methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
 - (+)-(S)-4-(4-methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

26. A compound of formula I-C according to formula I in claim 1,




wherein

R^2 is hydrogen, phenyl or C_{1-7} -alkyl;
or a pharmaceutically suitable acid addition salt.

27. A compound of formula I-C according to claim 26, which compounds are
- (RS)-4-biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine
 - (S)-4-biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine or
 - (RS)-4-(4'-chloro-biphenyl-4-yl)-4,5-dihydro-oxazol-2-ylamine.

28. A compound of formula I-D according to formula I in claim 1,



wherein

R¹ is halogen and CF₃, or halogen and CH₃, or halogen and C₃₋₆-cycloalkyl, or is halogen and OCH₃;

R² is hydrogen, phenyl or C₁₋₇-alkyl;

n is 2;

or a pharmaceutically suitable acid addition salt

29. A compound of formula I-D according to claim 28, wherein the compounds are

(RS)-4-(3-chloro-4-methoxyphenyl)-4,5-dihydro-oxazol-2-ylamine

(S)-4-(3-chloro-4-methoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine

(S)-4-(2-fluoro-4-trifluoromethyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(4-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(5-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(4-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(+)-(S)-4-(4-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(+)-(S)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(-)-(R)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(+)-(S)-4-(4-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(5-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(5-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(+)-(S)-4-(5-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(4-chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(5-chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(4-chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

(S)-4-(4-chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(4-bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(S)-4-(4-chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

(+)-(S)-4-(5-chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(4-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(+)-(S)-4-(4-bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(+)-(S)-4-(5-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(4-chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(+)-(S)-4-(4-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(3-chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(4-chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine.

(S)-4-(4-chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine


(RS)-4-(3-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(S)-4-(4-chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(3-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine or

(S)-4-(3-chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine.

30. A compound of formula I-E according to formula I in claim 1,



wherein

R¹ is halogen, CF₃ or CH₃,


R² is hydrogen, phenyl or C₁₋₇-alkyl;

R may be C₁₋₇-alkyl or C₁₋₇-alkyl substituted by halogen;

n is 1 or 2;

or a pharmaceutically suitable acid addition salt.

31. A compound of formula I-F according to formula I in claim 1,



wherein

R¹ is hydrogen, C₁₋₇-alkyl, C₁₋₇-alkoxy, C₁₋₇-alkyl substituted by halogen, C₁₋₇-alkoxy substituted by halogen or is halogen, wherein the substituents for n > 1 may be the same or different;

R/R' may be independently from each other hydrogen, C₁₋₇-alkyl or C₁₋₇-alkyl substituted by halogen,

R² is hydrogen, phenyl or C₁₋₇-alkyl;


n is 0, 1, 2 or 3;

or a pharmaceutically suitable acid addition salt, which compounds are

- (S)-4-[2-(4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(4-fluoro-3-methoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- ((S)-4-[2-(2,4-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(3,4-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(2-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(2-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(3-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(3,5-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(2-o-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(2-m-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(2-p-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(4-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (R)-4-[2-(3,4-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(3,4-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(4-chloro-2-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(3-fluoro-4-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(3,5-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(2-chloro-4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(4-fluoro-3-methyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-{2-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-ethyl}-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(3-bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(3-fluoro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(4-fluoro-3-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(2,3-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(3-chloro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(2-chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(1-methyl-2-phenyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-[2-(2-fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine

(S)-4-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-difluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-dichloro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-dichloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-((S)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-((R)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-6-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,4-dichloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,5-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-4-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-5-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine or
(S)-4-[2-(5-chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine.

32. A compound of formula I-H according to formula I in claim 1,



wherein

R¹ is halogen;

n is 0 or 1;

or a pharmaceutically suitable acid addition salt.

33. A compound of formula I in claim 1, wherein X is $-(CH_2)_3-$ and Y is phenyl.

34. A compound of formula I in claim 33, which compounds are

(S)-4-(3-Phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine or

(R)-4-(3-Phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine.

35. A compound of formula I in claim 1, wherein X is $-SCH_2-$, $-S(O)_2CH_2-$, $-CH_2S(O)_2CH_2-$ or $-CH_2SCH_2-$ and Y is phenyl.

36. A compound of formula I in claim 35, which compounds are

(R)-4-phenylsulfanylmethyl-4,5-dihydro-oxazol-2-ylamine

(R)-4-benzenesulfonylmethyl-4,5-dihydro-oxazol-2-ylamine

(R)-4-benzylsulfanylmethyl-4,5-dihydro-oxazol-2-ylamine or
(R)-4-(4-chloro-phenylsulfanylmethyl)-4,5-dihydro-oxazol-2-ylamine.

37. A compound of formula I in claim 1, wherein X is -CH₂N(R)CH₂-, C₃₋₆-cycloalkyl-CH₂- or SiRR'-CH₂- and Y is phenyl.

38. A compound of formula I in claim 37, which compounds are

(S)-4-[1-(4-chloro-phenyl)-cyclopropylmethyl]-4,5-dihydro-oxazol-2-ylamine

(S)-4-[1-(4-chloro-phenyl)-cyclobutylmethyl]-4,5-dihydro-oxazol-2-ylamine

(S)-4-(1-phenyl-cyclopropylmethyl)-4,5-dihydro-oxazol-2-ylamine

(S)-4-[(benzyl-ethyl-amino)-methyl]-4,5-dihydro-oxazol-2-ylamine or

(R)-4-[(dimethyl-phenyl-silanyl)-methyl]-4,5-dihydro-oxazol-2-ylamine.

39. A compound of formula I in claim 1, wherein X is described as in claim 1 and Y is naphthyl, pyridyl, cyclohexyl, 2,3-dihydrobenzo[1,4]dioxin or 1,2,3,4-tetrahydronaphthalen.

40. A compound of formula I in claim 39, which compounds are

(RS)-4-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-4,5-dihydro-oxazol-2-ylamine

(RS)-4-naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine

(RS)-4-naphthalen-1-yl-4,5-dihydro-oxazol-2-ylamine

(R)-4-naphthalen-1-ylmethyl-4,5-dihydro-oxazol-2-ylamine

(S)-4-naphthalen-1-ylmethyl-4,5-dihydro-oxazol-2-ylamine

(S)-4-naphthalen-2-ylmethyl-4,5-dihydro-oxazol-2-ylamine

(RS)-4-(1,2,3,4-tetrahydro-naphthalen-2-yl)-4,5-dihydro-oxazol-2-ylamine

(S)-4-naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine

(S)-4-[2-(3-fluoro-pyridin-4-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine

(S)-4-[2-(6-trifluoromethyl-pyridin-2-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine

(S)-4-[2-(2-methyl-pyridin-4-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine or

(S)-4-(2-cyclohexyl-ethyl)-4,5-dihydro-oxazol-2-ylamine.

41. A medicament containing one of the compounds according to claims 22 - 40

- (S)-4-(2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(4-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(2,3-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(3,4-dichlorophenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(3-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (RS)-4-(5-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(3-bromo-2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(2,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(3,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(4-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(2,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(3-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(2,3,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(3,4-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(4-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
- (S)-4-(3,4-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine

- 240 -

(S)-4-(2,3-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-4-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-5-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-chloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(5-chloro-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(3-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(3,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2,4-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(2,3,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-bromo-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-3-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(2,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(2-bromo-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-5-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(5-chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(4-chloro-2,5-difluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-2,5-difluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine

- 211 -

(RS)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2,4-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(-)-(R)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(2,4-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(2,5-dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2,5-dichloro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(2,3,4-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-methyl-4-(3,4,5-trifluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-chloro-2-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine
(-)-(R)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-bromo-2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2-chloro-4-fluoro-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-bromo-3-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3,4-dichloro-phenyl)-4-ethyl-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-bromo-3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-bromo-2-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-o-tolyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-trifluoromethoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-o-tolyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-benzyloxy-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-methoxy-3-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-methyl-4-(4-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-methyl-4-p-tolyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-methyl-4-(3-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-methoxy-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine
(S)-4-biphenyl-4-yl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4'-chloro-biphenyl-4-yl)-4,5-dihydro-oxazol-2-ylamine.

- 212 -

(RS)-4-(3-chloro-4-methoxyphenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-chloro-4-methoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-fluoro-4-trifluoromethyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(5-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(-)-(R)-4-(4,5-dichloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(5-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(5-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(5-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(5-chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-3-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-2-fluoro-5-methyl-phenyl)-4-methyl-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(5-chloro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-bromo-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(5-chloro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(+)-(S)-4-(4-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(4-chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-2-ethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(4-chloro-2-cyclopropyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(3-fluoro-2-trifluoromethyl-phenyl)-4,5-dihydro-oxazol-2-ylamine or
(S)-4-(3-chloro-4-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-3-methoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
((S)-4-[2-(2,4-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine

- 213 -

- (S)-4-[2-(3,4-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-difluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-o-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-m-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-p-tolyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(R)-4-[2-(3,4-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-2-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-4-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-4-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-3-methyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-3-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,3-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-4-trifluoromethoxy-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-3-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-(1-methyl-2-phenyl-ethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-(2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine

(S)-4-[2-(3-trifluoromethyl-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-trifluoromethyl-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-difluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,5-difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-difluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-dichloro-phenyl)-propyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3,4-dichloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-fluoro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(4-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-((S)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-((R)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-chloro-6-fluoro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,4-dichloro-phenyl)-ethyl]-4-methyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-bromo-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2,5-dichloro-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-4-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-chloro-5-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(5-chloro-2-fluoro-phenyl)-butyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-(3-Phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine
(R)-4-(3-Phenyl-propyl)-4,5-dihydro-oxazol-2-ylamine
(R)-4-phenylsulfanylmethyl-4,5-dihydro-oxazol-2-ylamine
(R)-4-benzenesulfonylmethyl-4,5-dihydro-oxazol-2-ylamine
(R)-4-benzylsulfanylmethyl-4,5-dihydro-oxazol-2-ylamine
(R)-4-(4-chloro-phenylsulfanylmethyl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-[1-(4-chloro-phenyl)-cyclopropylmethyl]-4,5-dihydro-oxazol-2-ylamine

(S)-4-[1-(4-chloro-phenyl)-cyclobutylmethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-(1-phenyl-cyclopropylmethyl)-4,5-dihydro-oxazol-2-ylamine
(R)-4-[(dimethyl-phenyl-silanyl)-methyl]-4,5-dihydro-oxazol-2-ylamine.
(RS)-4-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-4,5-dihydro-oxazol-2-ylamine
(RS)-4-naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-naphthalen-1-yl-4,5-dihydro-oxazol-2-ylamine
(R)-4-naphthalen-1-ylmethyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-naphthalen-1-ylmethyl-4,5-dihydro-oxazol-2-ylamine
(S)-4-naphthalen-2-ylmethyl-4,5-dihydro-oxazol-2-ylamine
(RS)-4-(1,2,3,4-tetrahydro-naphthalen-2-yl)-4,5-dihydro-oxazol-2-ylamine
(S)-4-naphthalen-2-yl-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(3-fluoro-pyridin-4-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(6-trifluoromethyl-pyridin-2-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine
(S)-4-[2-(2-methyl-pyridin-4-yl)-ethyl]-4,5-dihydro-oxazol-2-ylamine or
(S)-4-(2-cyclohexyl-ethyl)-4,5-dihydro-oxazol-2-ylamine.

and pharmaceutically acceptable excipients.

42. A medicament as claimed in claim 41 for the treatment of anxiety disorders, bipolar disorder, psychotic disorders, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, and metabolic disorders, diabetes, diabetic complications, dyslipidemia, disorders of energy consumption and assimilation, and disorders and malfunction of body temperature homeostasis.

43. A medicament according to claim 42 containing one or more compounds as claimed in claim 33 for the treatment of psychosis, Parkinson's disease and anxiety.
